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1.  SUMMARY 
 
Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia that results from 
inadequate insulin secretion in the face of insulin resistance. The efficiency of -cells to 
secrete sufficient amounts of insulin to maintain normoglycemia depends on -cell function 
and -cell mass. The endocrine pancreas has an exceptional capacity to adapt insulin output 
to an increased demand in conditions such as insulin resistance during obesity. However, in 
a subset of individuals at some point, this compensation fails and -cells do not secrete 
enough insulin anymore to cope with the metabolic demand, leading to the development of 
type 2 diabetes. This disease is therefore a result of relative insulin deficiency.  
Glucose has been identified as key fuel and regulator of -cell performance and survival. It is 
not only the major nutrient that induces insulin secretion, but it is implicated as stimulus for 
the expansion of -cell volume as a mechanisms of compensation, since it has been shown 
that glucose induces -cell proliferation in vitro. However, glucose can also negatively affect 
function and survival. Chronically elevated glucose levels decrease function and induce -
cell death in isolated islets. These findings have led to the establishment of the concept of 
glucotoxicity and have raised the interest in finding mechanisms and targets to protect from 
hyperglycemia-induced diabetes progression. 
It has been shown that obesity and type 2 diabetes are associated with low-grade 
inflammation indicating that immunological components are involved in the pathogenesis of 
this disease. The adipose tissue seems to be a major source of these inflammatory 
mediators. In obese individuals, adipocytes as well as infiltrating macrophages release 
increased amounts of non-esterified fatty acids, glycerol, hormones and pro-inflammatory 
cytokines that have been shown to play a crucial role in the development of insulin 
resistance. In addition to the occurrence of systemic sub-clinical inflammation, local 
inflammation in the pancretic islet has been identified as a major factor in the progressing 
deterioration of -cells in T2DM. The pro-inflammatory cytokine Interleukin-1 (IL-1) has 
been characterized as main active contributor. High glucose induces production and 
secretion of IL-1 by -cells themselves, which in turn partly mediates the adverse effects of 
glucose. Therefore, IL-1 constitutes an interesting target in the search for a therapy for type 
2 diabetes. A promising inhibitor of IL-1 is its natural antagonist Interleukin-1 Receptor 
Antagonist (IL-1Ra). IL-1Ra belongs to the IL-1 family and binds to IL-1 receptors but without 
inducing signal transduction, thereby antagonizing the inflammatory effects of IL-1 
competitively. Indeed, blocking experiments in vitro have shown that IL-1Ra counteracts IL-
1-induced -cell failure and death. Furthermore, a recent clinical trial demonstrated that IL-
1Ra treatment improves glycemic control in type 2 diabetic patients. One part of this work 
aimed to further characterize the protective mechanisms of IL-1Ra on -cells. Hence, we 
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investigated the ability of IL-1Ra to prevent diet-induced diabetes. Mice fed a high fat/ high 
sucrose diet (HFD) for 12 weeks developed impaired fasting glucose and hyperglycemia, 
which was prevented in animals from the HFD-group that were treated with IL-1Ra. 
Improvement was also observed during intraperitoneal glucose tolerance tests as IL-1Ra 
protected from impaired glucose clearance, which was a result of improved insulin secretion 
as well as insulin action. On the level of the -cell, we found that IL-1Ra protected from 
apoptosis and enhanced glucose-stimulated insulin secretion of isolated islets. In parallel, 
high fat feeding induced a decrease in insulin mRNA, which was prevented by IL-1Ra 
administration. As an underlying mechanism of decreased function, we identified the insulin 
transcription factor PDX-1 (pancreatic duodenum homeobox-1) whose localization shifted 
from the nucleus to the cytoplasm after 12 weeks of HFD. IL-1Ra-mediated protection from 
-cell failure was associated with PDX-1 remaining in the nucleus. We confirmed that the 
balance between glucose/ IL-1 and IL-1Ra also regulates PDX-1 localization in isolated 
human islets. Finally, we identified the JNK-pathway as possible link in the signal 
transduction between IL-1/ IL-1Ra and PDX-1. 
The second project of this work investigated the mechanisms of the loss of glucose-
stimulated insulin secretion induced by long-term hyperglycemia, the so-called glucose 
desensitization. We hypothesized that this process is controlled by the group of extracellular 
signal regulated kinases (ERK)-1/2. ERK1/2 are universal kinases that, in -cells, have been 
implicated to mediate short- as well as long-term effects of glucose. In the acute state, 
ERK1/2 induces insulin transcription and participates in the process of insulin secretion. In 
the long-term, ERK1/2-activity is involved in the adverse effects of chronic glucose 
incubations. We evaluated whether glucose desensitization after chronic hyperglycemia 
affects the responsiveness of ERK1/2 to a glucose challenge. We found that glucose-
induced ERK1/2 phosphorylation is diminished; correlating with abolished stimulated insulin 
secretion. Interestingly, both inhibition of insulin release and ERK1/2-activity can induce a 
state of ‘-cells rest’ despite prolonged exposure to elevated glucose concentrations. 
Inhibiting overstimulation sensitizes the islets for a following glucose stimulation resulting in 
increased insulin secretion as well as pERK1/2 upregulation. Hence, we confirmed a role of 
pERK1/2 in the deleterious effects of glucose on -cells but, at the same time, demonstrate a 
correlation between the ability for an acute stimulation of insulin secretion to an increase in 
pERK1/2 levels. 
In summary, in these studies both IL-1Ra- and ERK1/2-actions are analyzed related to 
glucose-mediated effects in -cells and are recognized as key-players determining the fate of 
-cells. Taken together, the results of this work identify possible novel therapeutic 
approaches by further characterizing the mechanisms underlying hyperglycemia-induced 
loss of -cell function and mass. 
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2. ZUSAMMENFASSUNG 
 
Der Typ 2 Diabetes Mellitus (T2DM) zeichnet sich durch chronische Hyperglykämie aus, die 
als Folge von mangelhafter Insulinsekretion in Kombination mit Insulinresistenz im Gewebe 
entsteht. Die Leistungsfähigkeit der -Zellen, genug Insulin abzugeben, um einen 
physiologischen Blutzuckerspiegel aufrecht zu erhalten, hängt sowohl von der 
Insulinproduktion und dem Sekretionspotential als auch von der Masse der -Zellen im 
Körper ab. Der endokrine Teil der Bauchspeicheldrüse hat eine enorme Kapazität, die 
Insulinabgabe an Bedingungen anzupassen, die einen erhöhten Bedarf hervorrufen, wie zum 
Beispiel an die erhöhte Insulinresistenz, die bei Fettleibigkeit entsteht. In einigen Fällen 
jedoch kann diese Kompensation versagen, sodass die -Zellen nicht mehr genug Insulin 
freisetzen um der Anforderung des Metabolismus zu entsprechen, was dann zur Entwicklung 
von Typ 2 Diabetes führt. Diese Krankheit ist demzufolge das Resultat eines 
Missverhältnisses zwischen Insulinangebot und Insulinbedarf. 
Glucose ist einer der Hauptfaktoren, der sowohl die Funktion der -Zellen als auch deren 
Überleben beeinflusst. Glucose ist nicht nur der wichtigste Nahrungsstoff, der zur 
gesteigerten Insulinabgabe führt, sondern ist auch an -Zellkompensationsmechanismen 
beteiligt. In vitro wurde gezeigt, dass Glucose -Zellproliferation auslösen kann. Im 
Gegensatz zu diesen Eigenschaften kann Glucose die -Zellen auch zerstören. Dauerhaft 
erhöhte Glucosekonzentrationen führen zu Minderleistung und Zelltod in isolierten Inseln. 
Diese Befunde werden unter dem Begriff ‚Glucotoxizität’ beschrieben und haben ein grosses 
Interesse daran geweckt, Mechanismen und Komponenten dieses Prozesses zu finden, um 
ein weiteres Fortschreiten des Diabetes aufgrund vorhandener Hyperglykämie zu verhindern. 
Es wurde gezeigt, dass sowohl Fettleibigkeit als auch T2DM mit Entzündungsmechanismen 
verbunden sind, was darauf hindeutet, dass die immunologische Komponente einen Teil der 
Pathogenese dieser Krankheit darstellt. Dabei scheint das Fettgewebe eine wichtige Quelle 
entzündlicher Faktoren zu sein. Die Adipozyten übergewichtiger Menschen sowie auch ins 
Fettgewebe infiltrierende Makrophagen geben verschiedene Stoffe in erhöhter Konzentration 
ab. Dazu gehören nicht-veresterte Fettsäuren, Glycerol, Hormone und pro-inflammatorische 
Zytokine, von welchen gezeigt wurde, dass sie zur Entwicklung der Insulinresistenz 
beitragen. Zusätzlich zur vorhandenen systemischen, sub-klinischen Entzündung spielen 
lokale Entzündungsherde in den Inseln der Bauchspeicheldrüse eine entscheidende Rolle im 
fortschreitenden Versagen und Zelltod der -Zellen in Patienten mit Typ 2 Diabetes. Das pro-
inflammatorische Zytokin Interleukin-1 (IL-1) ist dabei ein massgeblich aktiver Faktor. 
Erhöhte Glucosekonzentration regt die -Zellen an, selbst IL-1 zu produzieren und 
abzugeben, was dann wiederum zur Selbstzerstörung der -Zellen führt. Die entscheidende 
Rolle von IL-1 in der Pathogenese des Typ 2 Diabetes hat dieses Zytokin zu einem 
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interessanten Ziel in der Suche nach einer neuen Diabetestherapie gemacht. Ein 
vielversprechender, natürlich vorkommender Faktor, der die Aktivität des IL-1 blockiert, ist 
der Interleukin-1 Rezeptor Antagonist (IL-1Ra). IL-1Ra gehört zur gleichen Familie wie IL-1 
und bindet an den gleichen Rezeptor (Interleukin-1 Rezeptor, IL-1R), löst aber keine 
Signalkaskade aus. Daher ist IL-1Ra ein Konkurrent von IL-1, der Entzündungsreaktionen 
verhindert. Tatsächlich wurde in in vitro Experimenten gezeigt, dass die IL-1Ra-Zugabe zu 
isolierten Inseln IL-1 ausgelöstes -Zellversagen und Apoptose abblocken kann. 
Desweiteren hat eine klinische Studie nachgewiesen, dass IL-1Ra-Behandlung die 
Insulinproduktion in Typ 2 Diabetikern verbessert. Eines der Projekte dieser Arbeit hat sich 
damit befasst, die Mechanismen von IL-1Ra, die zum Schutz der -Zellen führen, weiter zu 
erforschen. Deshalb wurde die schützende Wirkung von IL-1Ra in einem Mausmodell 
genauer untersucht. In Mäusen löste eine 12-wöchige Nahrung mit hohem Anteil an Fett und 
Sucrose erhöhte Nüchternblutzuckerwerte sowie Hyperglykämien aus, eine Entwicklung, die 
durch tägliches Spritzen von IL-1Ra verhindert wurde. Verbesserungen wurde auch bei 
Glucosetoleranztests festgestellt, da IL-1Ra vor verzögertem Glucoseabbau im Blut schützte. 
Weitere Experimente zeigten, dass dies aus einer Kombination von verbesserter 
Insulinabgabe und Insulinwirkung hervorgerufen wurde. Auf der Ebene der -Zellen wurde 
festgestellt, dass IL-1Ra sowohl Zelltod durch Apoptose als auch verminderte glucose-
stimulierte Insulinsekretion verhinderte. Fett- und Sucrosereiche Nahrung führte zu 
erniedrigten Insulin mRNA-Konzentrationen, das ebenfalls durch IL-1Ra Behandlung 
vermieden wurde. Auf der Suche nach Mechanismen, die die -Zellfunktion regeln, wurde 
der Insulin Transkriptionsfaktor PDX-1 (Pancreatic Duodenum Homeobox-1) gefunden, 
dessen Lokalisation nach 12 Wochen Fett- und Sucrosereicher Nahrung vom Zellkern ins 
Zytoplasma wechselte. Der durch IL-1Ra vermittelte Schutz vor -Zellversagen war dabei mit 
dem Erhalt von nukleärem PDX-1 verbunden. Im letzen Teil dieses Projektes werden 
Hinweise geliefert, dass die Balance zwischen Glucose/ IL-1 und IL-1Ra auch in humanen 
Inseln die Lokalisation von PDX-1 bestimmt. Dabei wurde der c-Jun N-terminale Kinase 
(JNK)-Signalweg als Vermittler zwischen IL-1/ IL-1Ra und PDX-1 gefunden. 
Das zweite Projekt dieser Arbeit befasst sich mit den Konsequenzen des durch 
Hyperglykämien–ausgelösten Verlusts der glucosevermittelten Insulinsekretion, die 
sogenannte Glucose-Desensibilisierung. Unsere Arbeitshypothese war, dass durch 
extrazelluläre Signale regulierte Kinasen (ERK1/2) mit anhaltender Aktivierung einen Teil der 
negativen Einflüsse durch Glucose vermitteln. ERK1/2 sind universelle Kinasen, die in den -
Zellen sowohl kurz- als auch längerfristige Glucosesignale weiterleiten. Akut löst ERK1/2 die 
Transkription des Insulingens aus und nimmt auch am Prozess der Insulinsekretion teil. Wir 
untersuchten, ob Glucose-Desensibilisierung durch chronische Hyperglykämien die akute 
ERK1/2-Aktivierung beeinflusst. Unsere Resultate zeigen, dass -Zell-Desensibilisierung zu 
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einer abgeschwächten ERK1/2-Aktivierung führt. Dies geht einher mit einer verminderten 
Stimulation der Insulinsekretion. Interessanterweise kann sowohl die Blockade der 
Insulinabgabe als auch die Hemmung der ERK1/2-Aktivität eine Art Erholungsphase in -
Zellen auslösen, auch wenn eine erhöhte Glucose-Konzentration über längere Zeit 
vorhanden ist. Diese Verhinderung der Überstimmulierung führt dazu, dass die Inseln 
sensibel genug sind für eine folgende Glucose-Stimulation um sowohl Insulin zu sezernieren 
als auch ERK1/2 Proteine zu phosphorylieren. Somit haben wir bestätigt, dass ERK1/2 eine 
wichtige Rolle in den schädlichen Wirkungen der Glucose auf -Zellen spielen, zeigen aber 
gleichzeitig, dass deren Aktivierung als Antwort auf eine akut erhöhte Glucosekonzentration 
mit der Fähigkeit der Zellen, Insulin freizusetzen, verbunden ist. 
Zusammengefasst analysieren diese Studien sowohl IL-1Ra als auch ERK1/2 in Bezug auf 
deren Rolle in -Zellen als Vermittler von Glucoseeffekten. Dabei wurde festgestellt, dass 
beide Schlüsselfaktoren sind, die das Schicksal der -Zellen mitbestimmen. Damit 
identifiziert diese Arbeit das Potential möglicher neuer Therapieansätze, indem sie weitere 
Mechanismen des Hyperglykämie-induzierten Versagens und Verlusts von -Zellen aufklärt. 
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3.  INTRODUCTION 
3.1  The Pancreas 
 
The pancreas is a gland organ about 6 inches (15 cm) long that stretches across the back of 
the abdomen consisting of exocrine and endocrine tissue (Fig. 1). The exocrine cells, called 
acinar cells, produce pancreatic juice containing digestive enzymes. These enzymes are 
secreted into a network of ducts and released into the intestine where they digest 
carbohydrates, proteins and fats. The endocrine cells form tight clusters called ‘Islets of 
Langerhans’ and are scattered throughout the pancreas forming approximately 1% of the 
total mass of the pancreas. 
 
 
 
 
 Although the endocrine tissue is a small portion of the whole pancreas, its hormones 
which are secreted directly into the bloodstream regulate many important aspects of a body’s 
metabolism. The following cell types are present in the Islets of Langerhans: 
 -cells secreting insulin 
 -cells secreting glucagon 
 δ-cells secreting somatostatin 
 PP-cells containing pancreatic polypeptide 
These hormones have several anabolic and katabolic effects in order to keep blood glucose 
concentrations in a narrow range. Insulin is released in response to several stimuli, the main 
one being elevated blood glucose levels. It acts on muscle, adipose tissue and liver by 
promoting glucose uptake and inhibiting glycogenolysis, thus returning high circulating 
glucose concentrations to normal values. If blood glucose levels are low, e.g. after exercise 
or in-between meals, -cells produce glucagon who acts mainly on the liver. In response, 
Figure 1: The pancreas. (Picture adapted from (2)). 
The pancreas is located in the abdomen behind the stomach. The head of the pancreas is located on the right side of the 
abdomen, connected to the duodenum, the upper end of the small intestine. The narrow part of the pancreas, called the tail, 
extends to the left side of the body. 
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hepatic cells break down stored glycogen by a process called glycogenolysis. The resulting 
glucose is released into the bloodstream, preventing hypoglycemia. Somatostatin is an 
inhibitory peptide that regulates the endocrine system by suppressing the release of several 
gastrointestinal and pancreatic hormones. Pancreatic polypeptide is released after meal 
ingestion and suppresses food intake and gastric emptying as well as increases energy 
expenditure. Among many hormones which increase blood glucose levels, insulin is the only 
one which decreases blood glucose and regulates glucose homeostasis. Insulin is a peptide 
hormone that is synthesized as pro-insulin containing a B-, C- and A-chain (Fig. 2). 
Proteolytic cleavage removes the C-peptide and produces the mature insulin which consists 
of 51 amino acids of the B- and A-chain bound together by disulphide bonds. Insulin release 
from -cells is regulated by systemic glucose levels, the islet invading nervous system as 
well as hormones secreted by different organs such as intestine and adipose tissue. Upon 
entering -cells through the glucose transporter GLUT2, glucose undergoes glycolysis 
resulting in an increased ratio of ATP to ADP. This is followed by closure of ATP-controlled 
potassium (K+) channels which leads to depolarization of the cell membrane and opening of 
voltage-controlled calcium (Ca2+) channels. The raise in intracellular Ca2+-concentrations 
causes exocytosis of insulin-containing secretory vesicles. Insulin acts on different organs, 
including muscle, adipose tissue and liver. It promotes glucose uptake, glycogen and lipid 
synthesis, and it inhibits glycogenolysis, gluconeogenesis, lipolysis and proteinolysis. 
 
 
 
 
 
 
 
 
 
Figure 2: Pro-Insulin and Insulin. (Picture adapted from (1)).  
Insulin is a polypeptide hormone, whose maturation includes cleavage at two positions to release the C-peptide as well as 
forming of three disulphide bonds. Its amino acid sequence is conserved, as the insulin from pigs differs in only 1 amino acid 
from the one produced in humans. It was the first protein whose structure was completely determined by Frederick Sanger, 
for which he was awarded the Nobel Prize in Chemistry in 1958. 
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3.2  Diabetes: Incidence and Etiology 
 
Diabetes mellitus is a metabolic condition where the body fails to produce enough or properly 
use insulin to maintain blood glucose levels in the normal range. It is estimated that in 2006, 
171 million people worldwide suffered from diabetes, a number reaching epidemic 
proportions and reflecting that this disease is likely to be one of the most substantial threats 
to human health.  
Diabetes is a heterogeneous disease divided in several forms but all of them 
associated with high blood glucose concentrations (hyperglycemia). It is accompanied by 
macrovascular and microvascular complications which result in increased morbidity and 
mortality. As a consequence, diabetes may cause retinopathy leading to blindness, renal 
failure and neuropathy. It is also characterized by atherosclerotic damage which increases 
the risk for stroke, myocardial infarction and limb amputation due to poor wound healing.  
The major types of diabetes are called type 1 (former childhood-onset or insulin-dependent 
diabetes) and type 2 (former adult-onset or non-insulin dependent diabetes). 
 
 
3.3  Type 1 Diabetes Mellitus 
 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease resulting from specific 
destruction of pancreatic -cells. The main cause of -cell loss is considered to be 
autoimmune-mediated, with a minority of cases being idiopathic with no detectable immune 
markers. It has two phases: a moderate to long-term symptomless phase of insulitis when a 
mixed population of leucocytes invades the islets, and overt diabetes when most -cells are 
killed off leading to absolute insulin deficiency and hyperglycemia. The incidence of type 1 
diabetes is rapidly increasing in almost all populations and shows a trend towards earlier 
onset. Susceptibility for the disease is determined by environmental, genetic and 
immunological factors (6). Studies with monozygotic twin pairs revealed a concordance rate 
of T1DM of 30-50%, suggesting that at least 50% of the etiology are not due to genetic 
factors. Despite much research, it is not possible to pinpoint one particular environmental 
agent as causal factor and investigations focus on three groups of risk determinants: viral 
infections (e.g Coxsackie-B virus), early infant diet (e.g exposure to cow-milk) and toxins (e.g 
nitrosamines). Genetic studies have shown that this is a polygenic disease involving one 
major locus, the HLA class II region, as well as a number of non-HLA loci. The function of the 
genes of the HLA locus in terms of immune response is known, such as antigen presentation 
to T-cells, but the specific contribution to the pathogenesis is still under investigation. One of 
the non-HLA suscpetibility genes so far identified is the IDDM2-locus with a variable number 
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of tandem repeats 5’ of the insulin gene and genome-wide association studies continue to 
identify other susceptibility variants (7). Even though B-cells, macrophages and dendritic 
cells have important pathogenetic functions, type 1 diabetes is considered to be a T-cell 
mediated disease. T-cells have been found to respond to several autoantigens including 
peptides derived from insulin and glutamic acid decarboxylase (GAD). The initial step in the 
development of T1DM is thought to be macrophages and/ or dendritic cells presenting -cell 
autoantigens to CD4+ T-helper cells on MHC class II molecules. Activated macrophages and 
CD4+ T-cells release cytokines including interleukin (IL) -1, tumor necrosis factor (TNF) - 
and interferon (IFN) -γ. These attract and activate CD8+ T-cells in the inflammed islets which 
destroy -cells by different mechanisms such as release of granzymes and perforin as well 
as by Fas - Fas-Ligand interactions (8). Even though massive specific -cell destruction has 
been shown to be the hallmark of T1DM, underlying causes and mechanisms of -cell death 
vary and affected individuals have heterogenous clinical parameters. Therefore, diabetes 
could be a set of related disorders with possible differences in initiating antigens, primary 
effector cell types and induction of -cell death (9).  
 
 
3.4  Type 2 Diabetes Mellitus 
 
In type 2 diabetes mellitus (T2DM), pancreatic -cells fail to produce enough insulin to meet 
the body’s metabolic demand (10; 11). The disease is considered to result from the 
occurrence of increased insulin resistance together with decreased -cell function and mass 
(4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Relationship between insulin sensitivity and insulin release. (Picture adapted from Kahn et al. 2006, (4)). 
The relationship between insulin sensitivity and insulin release is hyperbolic. Hypothetical regions delineating normal glucose 
tolerance (NGT, green), impaired glucose tolerance (IGT, yellow) and type 2 diabetes mellitus (T2DM, red) are shown. In 
response to changes in insulin sensitivity, insulin release increases or decreases reciprocally to maintain NGT, ‘moving up or 
down’ the curve. In individuals who are at high risk of developing type 2 diabetes, the progression from NGT to T2DM 
transitions through IGT and results in ‘falling of the curve’.  
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Type 2 diabetes accounts for as much as 95% of diabetes cases (12) and modern lifestyle, 
with abundant nutrients and reduced physical activity, has led to a dramatic rise in the 
incidence of this obesity-associated condition. The overall risk and the rate of progression of 
type 2 diabetes is determined by genetic and environmental factors. T2DM is a polygenic 
condition, as various polymorphisms have been found within genes regulating islet function, 
insulin action and muscle, hepatic and adipocyte metabolism. Each variation adds risk and 
contributes to the genetic predisposition. In addition, susceptibility is also influenced by 
factors such as overnutrition (13), low birth weight (14), former gestational diabetes (15), a 
history of polycystic ovary syndrome (16) and being a first-degree relative of individuals with 
T2DM (17). Studies with some of these groups at high risk to develop type 2 diabetes have 
demonstrated that there is a whole spectrum of abnormalities, with some having reductions 
in insulin sensitivity, others having defects in -cell function and most having abnormalities in 
both. Interestingly, these subjects show reduced -cell function at a time when fasting 
plasma glucose concentration is still well within the normal range (18).  
Progression to diabetes has been proposed to have five stages (19): Stage 1 is 
compensation where insulin secretion increases to maintain normoglycemia (~ 4.5 mM, 
fasting state) in the face of insulin resistance. The mechanisms are not fully understood, but 
both expansion of -cell mass (20; 21) and enhanced -cell function are implicated (22; 23). 
Stage 2 occurs when glucose levels rise to 5 – 6.5 mM, a stable state of -cell adaptation 
that can last for years but is already accompanied by loss of -cell mass and acute glucose-
stimulated insulin secretion (24). Stage 3 is an unstable, transient stage where, due to early 
decompensation, glucose levels rise over a relatively short period of time to overt diabetes of 
stage 4. In most cases, this stage lasts a lifetime for patients with type 2 diabetes, as they 
typically have enough insulin secretion left rather than progressing to ketoacidosis. In 
contrast, rapid progressive autoimmune destruction of -cells in type 1 diabetes can lead to 
stage 5, where the marked loss of -cells is so severe that people become ketotic and truly 
dependent on insulin for survival.  
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As described above, two processes on the level of -cells have been implicated in the 
development of diabetes: -cell secretory failure and loss of -cell mass. 
-cell secretory failure: Insulin secretion from patients with type 2 diabetes show a 
prominent loss of acute glucose-stimulated insulin secretion with a completely diminished 
first (24) and only partially preserved second phase (25). However, insulin response to 
nonglucose secretagogues, such as arginine, remains largely intact (26). T2DM is also 
associated with impaired ultradian and diurnal (meal-related) oscillatory patterns and with 
perturbed rapid pulsatile insulin secretion. All of these pulsatile defects are implicated in 
diminished insulin action and are considered to be an early marker for T2DM (27-31). In 
addition, a defective conversion of pro-insulin to insulin leads to elevated pro-insulin to insulin 
ratio where pro-insulin only has 10% of the activity of mature insulin. Together, the defective 
insulin secretion and insulin deficiency compromise the ability of -cells to compensate for 
the increased demand due to insulin resistance which leads to hyperglycemia. 
Decreased -cell mass: -cell mass is plastic and adjustements in -cell growth and 
survival maintain a balance between insulin supply and demand. For example, during 
pregnancy, -cell mass increases in adaptation to changes in metabolic homeostasis. In rats, 
-cell population can almost double and proliferation coincides with an increase in placental 
lactogen and in prolactin and growth hormone receptors (32).  
Figure 4:Development of type 2 diabetes. (Picture adapted from Prentki et al., 2006, (3)). 
T2DM develops in response to overnutrition and lack of physical activity in individuals that have underlying genetic and 
acquired predispositions to both insulin resistance and -cell dysfunction. Over time, islet -cell compensation for the 
insulin resistance fails, resulting in a progressive decline in -cell function. As a consequence, subjects progress from NGT 
to IGT and finally to established T2DM. -cell function continues to worsen such that subjects progress from needing 
changes in diet and excersie to requiring oral hypoglycaemic agents or even insulin to achieve adequate glycaemic control. 
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More importantly, -cell mass adapts to an increased metabolic load caused by obesity and 
the inherent insulin resistance and therefore plays a crucial role in compensation. However, 
in a subset of individuals (~ 30%), this adaptation fails and type 2 diabetes develops. A study 
investigating human pancreata from autopsy revealed a 40% loss of -cell mass in subjects 
with impaired fasting glucose (IFG) and a 63% loss in patients with T2DM compared to 
weight matched controls, respectively. Lean diabetic patients had loss of 41% of -cell 
volume compared with lean controls. Furthermore, the decreased -cell mass was found to 
be associated with increased -cell apoptosis. The fact that loss of -cell volume was evident 
in individuals with IFG suggests that this decrease is not only confined to late-stage T2DM 
(33). Many mechanisms could trigger the increase in -cell apoptosis that occurs during the 
pathogenesis of T2DM. Among them are the development of endoplasmatic reticulum (ER) 
stress, oxidative stress, chronic hyperglycemia, dyslipidemia, and systemically and locally 
increased levels of cytokines.  
 
 
3.5  Glucotoxicity and Cytokines as Mediators of -Cell Secretory 
Failure and Apoptosis 
 
Glucose is a key physiological regulator of -cell function and survival whose outcome 
depends on concentration and duration of exposure. Studies on isolated islets from different 
species revealed that short-term exposure to elevated glucose concentrations induces insulin 
secretion as well as proliferation. However, prolonged increased glucose levels decreases 
function and moreover, lead to -cell apoptosis (34-41). These findings imply a crucial role of 
hyperglyemica in the progression of diabetes. It suggests a detrimental effect of even only 
slightly elevated circulating glucose levels in individuals before the onset of overt diabetes. 
Furthermore, in type 2 diabetic patients on diet and/ or oral hypoglycemic agents, fasting 
glucose and HbA1c levels might be within the normal range, but post-prandial concentrations 
of glucose are often abnormal which could have continuing adverse effects on -cells.  
Chronic exposure to hyperglycemia and its consequences on -cell function and 
survival have been described with three different terms (42-46): Glucose desensitization is 
defined as a temporary physiological state of cellular refractoriness to glucose stimulation 
induced by repeated or prolonged exposure to high glucose concentrations, which is 
reversed upon restoration of euglycemia. This process involves an intrinsic and reversible 
alteration in stimulus-secretion coupling. -cell exhaustion describes a physical depletion of 
insulin stores following prolonged, chronic stimulation with glucose or other secretagogues. 
Insulin secretion is not possible, even if the -cell would become resensitized to glucose. 
Glucose toxicity of the islets refers to nonphysiological and potentially irreversible cellular 
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damage caused by chronic exposure to supraphysiological glucose concentrations. It is 
characterized by defective insulin gene expression (47). So far, several mechanisms and 
pathways of -cell biology are being investigated in terms of finding triggers of 
hyperglycemia-induced -cell apoptosis and dysfunction. 
One such trigger might be increased endoplasmatic reticulum (ER)-stress (48). In -
cells, the ER is highly developed due to heavy engagement in insulin secretion. Insulin 
resistance in peripheral tissue induced by obesity and physical inactivity leads to a chronic 
challenge to the capacity of -cells and alterations in ER-function resulting from overload of 
proteins or accumulation of folding-incompetent proteins have been implicated in -cell death 
and dysfunction (49; 50). An intrinsic program called unfolded protein response (UPR) 
adapts the ER to this stress situation, but finally induces apoptosis if this mechanism fails to 
clear the pertubation and ER-stress persists. (51). A mutation in the insulin gene leading to 
misfolded proteins has been shown to lead to -cell death and diabetes in the Akita mouse 
(52) supporting a causative connection between ER-stress and diabetes. In addition, 
mediators of ER-stress have been found to be increased in pancreatic sections of type 2 
diabetic subjects (53) and exposure to increased glucose levels induced ER-stress markers 
in islets from type 2 diabetes patients but not in non-diabetic controls (54).  
Overstimulation by hyperglycemia might also result in chronic increases in 
cytoplasmatic [Ca2+]. Chronically increased [Ca2+] stands in contrast to the normal short-term 
rise in response to glucose metabolism that leads to fusion of insulin-containing vesicles to 
the cell membrane. These abnormalities in Ca2+-influx result in aberrations in insulin 
oscillation and persist even after normalization of glucose levels, triggering apoptosis and 
therefore participating in the deterioration of -cells (55).  
Signaling networks activated by death receptors are not only involved in -cell 
destruction in T1DM but are also detectable in islets from T2DM patients. Particularly, Fas-
FasL interactions have been shown to play a role. Fas (also known as CD95) is a receptor of 
the TNF-superfamily that contains an intracellular death domain (DD) responsible for 
transduction of apoptotic signals. The pathway is activated by FasLigand (FasL) which leads 
to recruitment and proteolytic cleavage of caspase-8 through the DD, triggering the 
downstream cascade (56). -cells have been shown to express Fas in response to cytokines 
(57-60) as well as to chronically elevated glucose (40). In addition, its expression is 
upregulated in type 2 diabetes islets, all of which renders -cells susceptible to apoptosis by 
interaction with FasL on T-cells or neighbouring -cells. Despite its role as inducer of 
apoptosis, Fas has also been implicated in proliferative signals in T-cells (61) and -cells 
(62). The determinant whether activation of Fas leads to apoptosis or proliferation seems to 
be FLICE-inhibitory protein (FLIP). FLIP structurally resembles caspase-8 but lacks its 
proteolytic activity (63). In human islets, FLIP is constitutively expressed but decreased in 
Introduction  15 
pancreatic tissue from T2DM patients and as well as after prolonged exposure of isolated 
islets to high glucose levels. Overexpression of FLIP protects -cells from glucose-induced 
apoptosis and counteracts a glucose-induced decrease in proliferation and acute insulin 
secretion (62). Therefore, the Fas-FLIP system seems to be a key regulator of -cells and 
might in part explain the dual role of glucose on -cell turnover and function.  
As described above, diminished insulin expression as a result of irreversible cellular 
damage is a characteristic of glucotoxicity (47). It has been shown in vitro and in vivo that 
loss of insulin production is accompanied by decreased expression and DNA binding activity 
of pancreas duodenum homeobox-1 (PDX-1) (64-66). The fact that treatment with 
antioxidants such as N-acetylcysteine improved glycemic control by preserving expression of 
PDX-1 and insulin suggests that glucotoxicity is in part explained by chronic oxidative stress 
(67-69). Already in 1987, it was proposed that metabolising excess glucose present during 
hyperglycemia can generate reactive oxygen species (ROS) in -cells such as hydrogen 
peroxide or superoxide (70; 71). Uncoupling of oxidative phosphorylation by activation of 
uncoupling protein-2 (UCP2) decreases ROS-production but also reduces ATP synthesis 
and therefore results in impaired insulin secretion. In addition, -cells only have limited 
defense against excess ROS-production compared to other tissue due to relatively small 
amounts of antioxidant enzymes such as catalase and glutathione peroxidase (72-74), 
rendering them at high risk for ROS-induced damage. Tanaka et al. (75) showed that high 
glucose concentrations indeed increased intracellular peroxide levels in the -cell line HIT-
T15 and in isolated human islets and that this increase was dependent on glucose 
metabolism. Several in vitro and in vivo studies so far observed a protective effect of 
antioxidative drugs on -cells in the presence of chronically elevated glucose levels (43; 76-
79). In addition, various reports on elevated markers of oxidative stress in the plasma and 
urine of type 2 diabetic patients provide clinical evidence that these mechanisms may 
contribute to -cell dysfunction and death (80-84).  
Over the last decade, an hypothesis of an immune origin of type 2 diabetes has been 
postulated with inflammatory mediators as a common link between type 1 and type 2 
diabetes. Environmental factors such as high-caloric diet and insufficient exercise have been 
proposed to be major contributors to the pathogenesis of T2DM and also have a direct 
impact on levels of systemic immune mediators. These mediators are considered to be 
responsible for the effects of these environmental factors on insulin resistance and -cell 
failure, forming an essential step in gluco- and lipotoxicity. Sub-clinical, low-grade 
inflammation has been observed in patients with type 2 diabetes and abnormalities of several 
systemic indicators of inflammation have been reported. These are hypothesized to not only 
represent markers of metabolic aberrations in T2DM, but may also contribute to -
dysfunction and death. Increased levels of acute phase proteins (e.g C-Reactive Protein 
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(CRP)), systemic cytokines (e.g IL-6, TNF-) and factors of blood and endothelial cell 
activation (e.g ICAM-1, PAI-1, leucocyte count) have been found in diabetic patients. 
However, the extent of the observed immune activations is far lower as compared to those 
seen in acute infections. Since low-grade inflammation precedes type 2 diabetes by many 
years and is already present in subjects with IGT at the same levels as in individuals with 
overt diabetes, it is considered to be a contributor rather than a consequence of the disease 
(85). In addition, prospective studies have reported modest increases many years before the 
diagnosis of T2DM and importantly, even at a stage when most individuals were not 
expected to have IGT or IFG yet (86-91). Furthermore, there is evidence that not single 
cytokines seem to be important but rather that the pattern of circulating inflammatory 
mediators modify the risk for future type 2 diabetes. Spranger et al (90) found a significant 
interaction between IL-1 and IL-6, as only the combination of detectable levels of IL-1 and 
elevated IL-6 resulted in an increased risk to develop T2DM, whereas undetectable IL-1 
and elevated IL-6 did not. The findings that alterations in cytokine levels modulate the risk for 
T2DM are supported by genetic studies which continue to identify associations between 
variants of immune genes and the risk to develop the disease. These alleles are found in 
several loci such as the HLA loci and the TNF-, IL-6, CRP and the plasminogen activator 
inhibitor-1 (PAI-1) genes (92-95) which encode key modulators for an immune response and 
partly determine the susceptibility for diabetes. Several animal models also provide a link 
between those inflammatory genes and type 2 diabetes, as disruption or overexpression had 
a major effect on the risk to develop diabetes in response to a high fat diet (96; 97).  
One major question is whether, and if so, how are immune mediators involved in -
cell failure. Maedler et al. (98) provided evidence that interleukin-1 (IL-1) might partly be 
responsible for -cell damage. In vitro exposure of islets from nondiabetic organ donors to 
prolonged elevated glucose levels resulted in increased RNA and protein levels as well as 
secretion of IL-1 into the supernatant, and -cells themselves were found to be the islet 
cellular source of glucose-induced IL-1. Long-term glucose or IL-1 treatment of islets 
resulted in Fas upregulation and NF-B activation, followed by impaired insulin secretion and 
DNA fragmentation. These detrimental effects could be partly inhibited by adding Interleukin-
1 receptor antagonist (IL-1Ra, a naturally occurring antagonist of IL-1) or PDTC (NF-B-
inhibitor) to the culture medium. The importance of IL-1 in vivo was confirmed by detection 
of this cytokine in pancreatic sections of diabetic psammomys obesus as well as sections of 
type 2 diabetic patients, but not in non-diabetic controls, respectively. These findings 
implicate an hyperglycemia-induced inflammatory process in the pathogenesis of type 2 
diabetes and identify IL-1 as mediator of glucose-induced adverse effects. 
IL-1 is a prototypic pro-inflammatory cytokine that affects almost every cell type and 
often acts in concert with other cytokines such as TNF-. There are two forms of IL-1 with 
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often indistinguishable activities, IL-1 and IL-1. The 3rd member of the family is IL-1Ra, 
which is structurally similar but lacks the agonistic activity. There are two surface binding 
proteins for all three cytokines, the IL-1 type I receptor (IL-1RI) and the IL-1 type II receptor 
(IL-1RII).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When IL-1 binds to the surface IL-1RI, the IL-1R accessory protein (IL-1RAcP) is able to 
dock and form a complex that triggers the intracellular downstream signal. Binding of IL-1 to 
IL-1RII does not transduce any signal since this receptor lacks the cytosolic domain, which 
makes it a “decoy” receptor. IL-1 and IL-1Ra may also bind to soluble extracellular domains 
of both receptors found in the circulation and in extracellular fluids after proteolytic cleavage, 
which function as natural “buffers”. IL-1Ra has an amino acid homology of 26% to IL-1 and 
binds with almost the same affinity to IL-1RI. However, since it lacks a second binding 
domain and does not recruit IL-1RAcP, binding does not result in signal transduction. 
Therefore, IL-1Ra is unique in cytokine biology as it represents a naturally occurring 
antagonist to IL-1. Hence, IL-1 activity is tightly regulated not only on the level of synthesis 
and secretion, but also through surface decoy receptors, soluble receptors and an antagonist 
(reviewed in (5; 99)). 
The ability of IL-1Ra to inhibit IL-1 activity has been used in different clinical 
applications to reduce disease severity. Especially, chronic inflammatory syndromes with 
IL-1Ra IL-1ß 
IL-1RAcP IL-1RI 
IL-1RII 
No signal 
No signal 
High affinity binding 
Signal transduction 
Figure 5: The IL-1 system. (Picture adapted from Dinarello et al., 1997, (5)). 
Following binding of IL-1 to IL-1RI, there is a structural change of this receptor, allowing the formation of a complex with 
IL-1RAcP which results in signal transduction. Lacking the second binding domain, IL-1Ra binds to IL-1RI but does not 
result in a structural change of the receptor. Since it does not recruit IL-1RAcP, there is no signal transduction and no 
biological response. IL-1RII lacks a cytosolic segment, hence binding of IL-1 does not lead to signaling. Therefore, IL-1RII 
as well as the soluble forms of the receptors (not shown) act as ‘decoy’ receptors or a’ sink’. 
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increased levels of IL-1 respond to IL-1Ra treatment, for example systemic onset juvenile 
idiopathic arthritis ((100), commentary in (101)). IL-1Ra is induced by many of the stimuli that 
induce IL-1 in the same cell, such as immune cells, hepatocytes and adipocytes. As with IL-
1, IL-1Ra has been shown to be expressed by -cells, and in contrast to IL-1, its levels are 
decreased in pancreatic sections from type 2 diabetic patients (102). This is in line with a 
study showing that patients with type 2 diabetes have significantly lower plasma levels of IL-
1Ra than non-diabetic patients (103). In vitro, addition of IL-1Ra to the culture medium or 
adenoviral overexpression (Ad-IL-1Ra) prevents glucose- and IL-1-induced -cell 
dysfunction and apoptosis (98; 104; 105), whereas depletion of IL-1Ra with small interfering 
RNAs (siIL-1Ra) results in impaired function, caspase-3 activation and DNA fragmentation. 
Infecting islets with Ad-IL-1Ra before transplantation into streptozotocin-(STZ)-rats increases 
-cell replication and mass in the islet grafts and lowered apoptosis compared to uninfected 
islets. These beneficial effects led to an improved metabolic outcome, accelerated recovery 
of normoglycemia and reduced the amount of islets needed to consistently achieve 
normoglycemia (106). IL-1 has been postulated to contribute to the non-specific 
inflammation at the grafted site that damages transplanted islets even in the absence of 
rejection or autoimmune attack (107). Furthermore, IL-1 gene expression is increased over 
4-fold in islets 24 hours after isolation and 45-fold in islets 1 day after transplantation (106). 
As a consequence, IL-1Ra might be an useful strategy to increase survival of transplanted 
islets and reduce the islet number required to reach normoglycemia.  
The importance of a balance between IL-1 and IL-1Ra has been demonstrated in 
vitro and in vivo in several studies and is considered to be an important factor influencing the 
course, susceptibility to and severity of many diseases (108). In a healthy population, the 
ratio of plasma IL-1 to IL-1Ra is close to 1 with minimal variations (109). However, 
expression of these cytokines are influenced by gene polymorphisms and associations 
between allele variants and clinical outcome of various disorders have been found, including 
nephropathy in diabetes (110). The human IL-1Ra gene (IL1RN) has a variable number 
tandem repeat (VNTR) within intron 2 and so far, six alleles have been identified 
representing of 1 to 6 copies of a 86bp sequence (111), with the 4-repeat (IL1RN*1) and 2-
repeat (IL1RN*2) variants being the most common ones, constituting 95% of all cases. The 
number of the repeats may have functional significance because it contains possible 
transcription factor binding sites (112). In the IL-1 gene, there are at least two biallelic base 
exchange polymorphisms, one at position –511 (in the promoter region) and one at position 
+3953 (within exon 5). Certain combinations of these polymorphisms have been shown to be 
significantly associated with T2DM (113). Also, healthy carriers of IL1RN*2 had higher levels 
of serum IL-1Ra than healthy non-carriers (745 vs 627 pg/ml). However, it has been shown 
that the enhancing effect of allele 2 on IL-1Ra plasma levels is influenced by the IL-1-
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variant present (114). It has also been demonstrated in vitro that the balance of IL1- to IL-
1Ra is crucial for -cell survival and function (115). Even though IL-1 has detrimental effects 
on islets at doses of 2-5 ng/ml, a lower concentration of 0.2 ng/ml induces proliferation. 
However, the presence of endogenous IL-1Ra is required for this effect since repressing it 
using siIL-1Ra was again deleterious to -cells. Since IL-1Ra does not have a signaling 
function itself, it is believed that the effect on -cells is a result of the overall ratio of IL-1 to 
IL-1Ra. 
A recent clinical trial has investigated IL-1 as a therapeutic target whose inhibition 
may preserve -cell mass and function (116). Type 2 diabetic patients received daily 
subcutaneous injections of 100 mg of a recombinant human IL-1Ra for 13 weeks. The IL-
1Ra-group showed improved glycemia due to improved -cell secretory function, which was 
apparent as enhanced C-peptide secretion and reduced ratio of pro-insulin to insulin, 
compared to the placebo-group. In addition, IL-1Ra treatment also decreased systemic IL-6 
and CRP, both markers of systemic inflammation. This study emphasizes IL-1 as a possible 
target and identifies the potential of IL-1Ra in treatment of type 2 diabetes. Part of the 
present study aimed to further characterize the role of IL-1 and IL-1Ra in the development 
of T2DM and investigate its ability to prevent diet-induced diabetes as well as find underlying 
mechanisms. 
 
 
3.6  Obesity and Diabetes 
 
The increased prevalence of obesity has focused attention on a world-wide problem, 
especially as obesity among children shows an equally marked increase (117). Obesity is 
associated with an array of additional health problems, including increased risk of insulin 
resistance, type 2 diabetes, hypertension, stroke, fatty liver disease and atherosclerosis as 
well as neurodegeneration, airway disease and some cancers (118). Environmental factors 
are largely responsible for the modern day epidemic of obesity. Increased caloric availability 
and fat consumption in the setting of decreased physical activity lead to overnutrition, 
increased nutrient storage and obesity. Between 60% and 90% of cases of type 2 diabetes 
now appear to be related to obesity (119). In addition to energy storage and metabolic 
homeostasis, the adipose tissue is considered to be an endocrine and paracrine organ, as it 
modulates a body’s metabolism be releasing non-esterified fatty acids (NEFAs), glycerol, 
hormones and pro-inflammatory cytokines (120). The secretion of many of these products is 
increased in obesity and type 2 diabetes, linking metabolic diseases to inflammatory 
processes. An abundance of evidence has emerged demonstrating a relationship between 
metabolism and the immune system. From an evolutionary point of view, survival depends 
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on the ability to fight pathogens as well as to withstand starvation. Metabolic and immune 
systems are therefore among the most basic requirements that are also highly conserved. It 
is not surprising that metabolic and immune pathways have evolved which are closely linked 
and interdependent and are regulated through common key mediators and signalling 
systems. In addition, it is noteworthy that the adipose tissue has an architectural organization 
in which the metabolic cells (adipocytes) are in close proximity to immune cells 
(macrophages) and therefore constitutes a key site for the interaction of adipocytes and the 
immune system. It has been proposed that the current lifestyle of metabolic overload 
disturbes the fine balance between those two systems leading to an association between 
metabolic diseases, such as obesity and type 2 diabetes, and chronic inflammation (118). 
The finding that the pro-inflammatory cytokine TNF- is overexpressed in the adipose tissue 
of obese mice provided the first molecular link between obesity, diabetes and inflammation 
(121). Furthermore, TNF- expression is also increased in adipose and muscle tissue of 
obese humans (122-124). Moreover, various other inflammatory mediators and cytokines are 
upregulated in experimental mouse models of obesity and in humans, such as IL-6, Leptin 
and Resistin (125). The observation that the systemic levels of many of these molecules 
strongly correlate with body mass index (BMI), fat mass and/ or waist circumference (126) 
has led to the assumption that they originate from adipocytes directly. However, recent 
studies have revealed that adipose tissue infiltrating macrophages are a major source of 
inflammatory mediators (127; 128) and account for most of TNF- and IL-6 expression. 
Macrophage infiltration has been described in obese conditions in both mice and humans 
and is thought to occur in response to chemotactic signals secreted by expanding adipocytes 
(125). Since pro-inflammatory gene expression in macrophages occur before systemic 
insulin is increased (sign of existing insulin resistance), studies especially focus on the role of 
chronic inflammation in promoting insulin resistance associated with obesity. Insulin 
resistance is an impairment of insulin action through interference of the insulin signaling 
pathway. Insulin signaling is initiated by binding to insulin- and IGF-receptors. The receptor 
tyrosine kinases then phosphorylate intracellular substrates that dock to these receptors. 
Among a large number of substrates, six belong to the family of insulin receptor substrate 
(IRS) proteins. Tyrosine phosphorylation of IRS is a crucial step in insulin action that is often 
defective in cases of insulin resistance. Inflammatory mediators as well as chronic 
hyperglycemia can also lead to serin/threonine phosphorylation of IRS which results in 
subsequent proteosomal degradation (129; 130). These IRS-modifying enzymes not only 
modulate insulin receptor signaling, they are also partly implicated in promoting further 
inflammatory processes, for example by activating NF-κB (131). Among them, the c-Jun N-
terminal kinase (JNK) has been proposed to be central in mediating insulin resistance. JNK 
can be induced upon exposure to cytokines such as TNF- (125) and to free fatty acids. In 
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obesity, JNK activity is upregulated in adipose and liver tissue (132). Furthermore, the 
absence of JNK1 results in decreased adiposity, significantly improved insulin sensitivity and 
enhanced insulin receptor signaling capacity, supporting the concept that the development of 
insulin resistance and T2DM involves immunological components. Taken together, obesity 
promotes both chronic low-grade inflammation and insulin resistance and evidence suggests 
that type 2 diabetes is an inflammatory disease with inflammation as a primary cause rather 
than a consequence (125).  
Despite the strong evidence pointing to obesity as major cause of insulin resistance, 
the fact that BMI and insulin sensitivity in healthy subjects do not have a linear correlation 
points to the presence of other factors contributing to insulin resistance. Indeed, it has been 
found that insulin sensitivity can be influenced by genetics (133), age (134; 135), acute 
exercise (136), physical fitness (137), dietary nutrients (138), medications (139) and body fat 
distribution (140-145) with central accumulation being the critical determinant of reduced 
insulin sensitivity (18).  
However, not all obese, insulin-resistant individuals develop diabetes. As described 
above, -cells are markedly plastic in their ability to regulate insulin release to maintain 
normoglycemia, both through increased secretory capacity (can be 4- to 5-fold enhanced) 
and increased -cell mass (can be increased up to 50%) (33; 146). In healthy individuals, this 
response of a proportionate and reciprocal alteration in insulin output results in glucose 
tolerance remaining normal (Fig. 3). Therefore, the two parameters of -cell function and 
insulin sensitivity must always be assessed relative to each other, as although insulin 
response may be identical in two individuals, if insulin sensitivity is not the same, then 
glucose tolerance will also differ (18).  
As described above (see 3.5), part of this work aimed to investigate the ability of the 
IL-1-antagonist IL-1Ra to prevent diabetes progression. In addition to the involvement of the 
IL-1/ IL-1Ra system in modulating glucose-induced -cell survival and function, IL-1Ra has 
several important implications in obesity. Besides liver and spleen, the white adipose tissue 
has been identified as major source of IL-1Ra even in the basal state, with a further increase 
in obese conditions in mice and humans (147). Serum IL-1Ra concentrations are elevated 
6.5-fold in obese individuals and are positively correlated with leptin levels and to a even 
higher extent with lean body mass (LBM) and insulin resistance index (IRI) compared to age- 
and sex-matched lean controls (148). Leptin is a cytokine mainly produced by adipocytes 
(‘adipocytokine’) that functions as a satiety signal regulating both appetite and weight in 
rodents and humans (149). Its action on the hypothalamus suppresses food intake and 
stimulates energy expenditure, therefore playing a major role in the control of body fat stores. 
A hallmark of most cases of obesity is leptin resistance rather than deficiency. There are 
several findings suggesting that leptin acts through IL-1 / IL-1RI signaling and that IL-1Ra 
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may contribute to central leptin resistance in morbid obesity (150). IL-1 has been implicated 
in mediating leptin-induced reduced food intake, as leptin fails to suppress food intake in IL-
1RI-/- mice. Also, IL-1Ra has been shown to counteract leptin-induced reduced food intake, 
supporting the involvement of the IL-1/ IL-1Ra network in regulating energy homeostasis. In 
addition, IL-1Ra-/- mice have a lean phenotype (151) in parallel to an increased food intake 
relative to their body weight (152) which could result from increased energy expenditure and 
from a six-fold reduction in circulating leptin concentrations.  
A part of this work further investigated the role of IL-1Ra in preventing T2DM in an animal 
model of obesity and elucidate the importance of adipo-insular interactions mediated by 
adipocyte-derived factors.  
 
 
3.7  Signaling Pathways and their Role in -Cell Function 
 
The mammalian insulin gene is exclusively expressed in -cells of the endocrine pancreas. It 
encodes a highly conserved single chain precursor pre-proinsulin (here referred to as insulin 
gene for simplicity), whose processing produces mature insulin consisting of two polypeptide 
chains joined by disulphide bonds. In most species, insulin exists as single gene, whereas in 
mice and rats, two non-allelic insulin genes are present. The human gene is homologous to 
the rodent insulin II, both contain three exons and two introns, while rodent insulin I lacks the 
second intron. Tissue specificity and correct initiation of transcription together with 
physiological regulation are controlled by 5’ flanking regions within ∼400 bp from the 
transcription start site that contain cis-acting regulatory elements (153). Precise regulation of 
transcription is achieved by the interaction of sequence motifs in the promoter with a number 
of ubiquitous and islet specific transcription factors. This provides a mechanism for 
combinatorial control whose outcome not only depends on the specific combinations but also 
on the concentrations of the factors. It results in the formation of complexes that not only can 
exert positive or negative regulation but can also integrate multiple regulatory inputs into one 
single output, therefore translating different physiological stimuli into the respective state of 
insulin gene transcription (153). Amongst the regulatory sequences, E, A and C elements are 
major determinants. 
E boxes bind proteins of the basis helix-loop-helix family (bHLH) which form 
heterodimers between ubiquitous and cell-restricted members (154). In -cells, the 
ubiquitous E47 binds to NeuroD/BETA2, that also plays a role in islet development. A boxes 
contain a conserved sequence that binds factors belonging to the homeodomain-containing 
family, of which PDX-1 (pancreatic duodenum homeobox factor-1) is the most important 
(155; 156). It functions in the early commitment of the primitive gut to pancreatic fate and in 
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the maturation of -cells (157) and is a major transactivator of the insulin gene as well as of 
glucosetransporter-2 (Glut2) and glucokinase (GK). The C1 element has been shown to bind 
RIPE3b1, which has recently been identified as the bZIP (basic leucine zipper) protein MafA 
(158). It has been shown that there are cooperative interactions between these proteins that 
also involves participation of coactivators such as p300/CBP histone acetyltransferases 
leading to appropriate transcriptional regulation. Of these factors associated with glucose-
regulated insulin gene transcription, PDX-1 is the most studied. Glucose promotes the DNA-
binding activity (159) as well as transactivation potency of PDX-1 (160). However, there are 
controversial studies on the signal transduction mechanisms leading to PDX-1 mediated 
insulin transcription (reviewed in (161)). There is evidence that glucose stimulates 
modification and translocation of a cytoplasmic, 31 kDa to the nuclear, 46 kDa form. Even 
though this process requires phosphorylation, the change in molecular mass suggests an 
involvment of other post-translational modifications such as sumoylation (162). In addition, 
several kinases were proposed to phosphorylate PDX-1, including p38 mitogen-activated 
protein kinase, phosphatidylinositol-3 kinase (PI3-K) and extracellular signal-regulated 
kinases (ERK) -1/2. Despite these controversial findings, the importance of PDX-1 in 
mediating glucose responsiveness has been underscored by several studies (153). For 
example, Leibowitz et al. (163) demonstrated that isolated islets from diabetic psammomys 
obesus, which do not respond to elevated glucose, are devoid of the pdx-1 gene product. 
Interestingly, pdx-1 gene transfer normalized the defect in glucose-stimulated gene 
expression. Also, MODY4 (maturity onset diabetes of the young, another form of diabetes) is 
caused by a mutation in PDX-1 (164). In addition, chronically elevated glucose levels in vitro 
impair insulin gene expression which is associated with diminished binding activity of PDX-1 
(38). Furthermore, recent studies suggest an important influence of post-translational 
modifications of PDX-1 in -cell function under diabetic conditions since oxidative stress 
(165) as well as the combination of palmitate and elevated glucose (166) induce nucleo-
cytoplasmic translocation of PDX-1. These findings emphasize the importance of the 
regulation of the unique transcriptional complexes in -cells which assures an appropriate 
insulin transcription in response to a variety of physiological stimuli such as nutrients 
(glucose, NEFAs) and hormonal stimuli (insulin, glucagon, leptin, glucagon like peptide-1). 
Despite all the signals that affect -cell function and survival, glucose is the most 
important fuel and regulator. Besides its well-known role as stimulator of insulin secretion, it 
also promotes translation to new protein and enhance posttranslational pro-insulin 
processing. In addition, it is believed to enhance insulin gene transcription and stabilize 
mature insulin mRNA (167-170), two aspects that have been difficult to investigate due to the 
very high abundance and long half-life of insulin mRNA. An elegant study by Evans-Molina et 
al. (171) evaluated the quantities and abundance of insulin mRNA and different species of 
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pre-mRNAs as well as their changes in response to glucose. They found that only the intron-
2 containing pre-mRNA species have a short-enough half-life and a low-enough abundance 
to reflect acute glucose-induced changes in insulin gene transcription. Already after 30 
minutes, they observed glucose-induced increase in H4 acetylation and RNA polymerase II 
recruitment. Measurable increases of the intron-2 containing pre-mRNAs were delayed by 60 
minutes and a rise of mature mRNA levels was not detected before 48 hours. These data 
further elucidated insulin gene transcription in human islets and emphasizes the necessity of 
measuring pre-mRNA species to detect acute changes of insulin transcription. 
Downstream in glucose-activated pathways, the mitogen-activated protein kinases 
(MAPKs) ERK1/2 have been implicated as crucial steps in signal transduction that integrate 
short- as well as long-term nutrient sensing information (172). ERK1/2-activity has been 
found to correlate with the secretory demand on -cells as well as insulin secretion. 
However, the mode of activation is complex and depends specifically on the individual 
ligands, leading to a precise output signal that incorporates the different stimuli. ERK1/2 
action has been shown to regulate different aspects of -cell function, the most prominent of 
which is insulin gene transcription. The insulin promoter is positively and negatively regulated 
by glucose (153) and both require ERK1/2-activity. Acute glucose stimulates insulin gene 
expression which is dependent on ERK1/2 as demonstrated by inhibition of this effect by the 
MEK1/2-inhibitors PD098059 or U0126 (173; 174). There are several substrates whose 
DNA-binding to the insulin promoter requires ERK1/2-activity, including BETA2, MafA and 
PDX-1. In addition, ERK1/2 might also mediate the deleterious long-term effects of glucose 
by modulating transcription factors such as NFAT (nuclear factor of activated T-cells) or 
C/EBP- (CCAAT/enhancer binding protein-) that leads to repression of the insulin 
promoter (174). Moreover, prolonged high glucose-induced impaired function and apoptosis 
were prevented by inhibiting chronic ERK1/2-activation (175).  
The second project in this work aimed to investigate the effects of hyperglycemia on 
ERK1/2 in regard to their response to an acute glucose challenge. We tested the hypothesis 
that insulin secretion correlates with ERK1/2 phosphorylation and that both events are 
diminished after chronic incubations in elevated glucose. Furthermore, we propose that 
inducing -cell rest during the chronic period by either inhibiting insulin secretion or ERK1/2-
activity restores acute -cell function and therefore might be a therapeutic strategy to 
preserve -cell function in diabetes. 
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4.  THE POTENT ROLE OF IL-1RA TO PREVENT DIET-
INDUCED DIABETES 
 
The first part of this study (Figure 1-7) has been published: 
Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K:  
The anti-inflammatory cytokine IL-1Ra protects from high-fat diet induced hyperglycemia. 
Endocrinology 2008 May;149(5):2208-18. Epub 2008 Jan 31. 
The second part will be submitted for publication. 
 
4.1  SUMMARY 
 
Sub-clinical inflammation is a recently discovered phenomenon in type 2 diabetes (T2DM). 
Elevated cytokines impair -cell function and survival. A recent clinical trial shows that 
blocking Interleukin-1 (IL-1) signaling by Interleukin-1 Receptor Antagonist (IL-1Ra) 
improves -cell secretory function in patients with T2DM. In the present study we provide 
further mechanisms of the protective role of IL-1Ra on the -cell. 
IL-1Ra improved glucose tolerance and insulin secretion in vivo in C57BL/6J mice fed 
a high fat/ high sucrose diet (HFD) for 12 weeks. High fat diet treatment increased serum 
levels of free fatty acids, triglycerides and cholesterol and of the adipokines resistin and 
leptin, all of which were reduced by IL-1Ra. In addition, IL-1Ra counteracted the high fat diet 
induced decrease in adiponectin.  
Studies on isolated islets revealed that IL-1Ra specifically acted on the -cell. IL-1Ra 
protected from -cell apoptosis, induced -cell proliferation and improved glucose-stimulated 
insulin secretion. Insulin mRNA was reduced in islets from mice fed a HFD, but normalized in 
the IL-1Ra group whereas PDX-1 mRNA levels were oppositely regulated, increased by HFD 
and normalized by IL-1Ra treatment. PDX-1 protein was localized in the cytosol in pancretic 
sections of HFD animals, but remained in the nucleus in islets when HFD mice were treated 
with IL-1Ra. Importantly, IL-1Ra counteracted glucose-induced PDX-1 nuclear export in 
isolated human islets. We found the JNK-pathway as a possible link in the downstream 
signaling from IL-1Ra to PDX-1. In addition to the diet-induced model of diabetes, we 
investigated the effect of IL-1Ra in another model of genetically induced T2DM, the db/db 
mouse. Also in this system, IL-1Ra was found to have a protective role as it was able to 
delay the onset of diabetes. 
Our results show that IL-1Ra improves -cell survival and function and support the potential 
role for IL-1Ra in the treatment of diabetes. 
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4.2  INTRODUCTION 
 
Obesity is a risk factor for insulin resistance and type 2 diabetes (T2DM). Most obese 
individuals are insulin resistant but compensate by increasing insulin secretion to maintain 
normoglycemia. The factors determining the amount of insulin that can be secreted are -cell 
function as well as -cell mass. T2DM manifests when the -cell fails to adaptively increase 
insulin secretion as a result of impaired -cell function (2-5), as well as decreased -cell 
mass (6-8). The decrease in -cell mass in both type 1 diabetes (T1DM) and T2DM can be 
attributed to the increase in frequency of -cell apoptosis (6; 9; 10). Once hyperglycemia is 
present, the loss of -cells accelerates, accompanied by further impairment of -cell 
secretory function, both factors in the development of T2DM (11). 
The mechanisms of -cell destruction in a diabetic milieu are complex. Studies on 
isolated islets show the interplay of glucotoxicity and lipotoxicity (12). Additionally, the -cells 
are particularly prone to oxidative stress due to their low expression of antioxidant molecules. 
Reactive oxygen species cause direct cellular damage in the -cell by oxidizing nucleic acids 
and proteins (13) and inactivating genes that are involved in cellular defense (14; 15). 
Furthermore, the -cell is especially sensitive to inflammatory attack and in vitro studies have 
shown that pro-inflammatory cytokines induce -cell apoptosis and impair function (16). 
In human islets, we have provided evidence that glucose-induced -cell apoptosis 
and dysfunction are partly mediated by -cell production and secretion of the pro-
inflammatory cytokine Interleukin-1 (IL-1) (17). After chronic exposure to high glucose, the 
-cell itself produces IL-1, followed by NF-κB activation, Fas up-regulation, DNA-
fragmentation and impaired -cell function (17). IL-1 has been shown to contribute to -cell 
destruction in T1DM (reviewed in (18; 19)) as well as in T2DM (reviewed in (11)). Also in 
three animal models, the Psammomys obesus (17), the GK rat (20) and the human islet 
amyloid polypeptide transgenic rat (21), (Peter Butler, personal communication), pancreatic 
-cell expression of IL-1 under hyperglycemic conditions has been observed. IL-1 signal 
transduction is initiated by ligand binding to type 1 IL-1 receptor (IL-1R1), allowing docking of 
the IL-1R accessory protein (IL-1AcP) (reviewed in (22)). This activates downstream 
effectors, which regulate -cell survival and function (reviewed in (19; 23)). A promising 
target to block these deleterious effects of IL-1 (24; 25) as well as of elevated glucose levels 
(17) is the use of IL-1Ra. IL-1Ra is an anti-inflammatory cytokine and naturally occurring 
antagonist of IL-1α and  (26-28). Four forms of IL-1Ra have been described, three of them 
are intracellular proteins (icIL-1Ra I, II and III) and one is secreted (sIL-1Ra) (29). Similarly to 
IL-1, IL-1Ra binds to type 1 and 2 IL-1 receptor but lacks a second binding domain. 
Therefore, IL-1Ra does not recruit IL-1AcP, the second component of the receptor complex. 
Endogenous production and secretion of sIL-1Ra has been shown to limit inflammation and 
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tissue damage, but the biological effects of icIL-1Ra remain unclear. Exogenous sIL-1Ra has 
been reported to protect against IL-1 induced -cell damage (24; 25), and to counteract 
both low dose streptozotocin induced diabetes (30) and autoimmune diabetes (31) as well as 
promoting graft survival (31-33). Also, IL-1Ra protected from glucose as well as IL-1 
induced apoptosis in human islets (17). Therefore, the balance of IL-1 and IL-1Ra may play 
a crucial role in the pathogenesis of diabetes. We have recently shown that IL-1Ra is 
secreted from -cells and is expressed in -cell granules (34). Inhibition of endogenous IL-
1Ra by culturing the islets with small interfering RNAs to IL-1Ra, or with leptin for the long 
term, leads to -cell apoptosis and impaired function, providing a link from obesity to 
diabetes (34). The possible crucial role of inflammatory cytokines in the pathogenesis of 
T2DM is underscored by several recent studies (35). Spranger et al. observed that 
individuals with elevated levels of IL-1 and IL-6 have a significantly increased risk to 
develop T2DM (36), pointing to a possible role for IL-1Ra in the treatment of diabetes. 
Results from a recent clinical study in patients with T2DM showed that IL-1Ra improved 
glycaemic control and -cell function (37). In the present study we show that IL-1Ra is able to 
protect from diabetes progression induced by a high fat diet.  
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4.3  EXPERIMENTAL PROCEDURES 
 
Animals. For IL-1Ra- or vehicle injections, C57BL/6J wildtype mice were obtained from 
Jackson Laboratories (Bar Harbor, ME) at 4 weeks of age. One of the 4 following treatments 
was initiated in mice at 5 weeks of age: Two groups were kept under normal diet (ND, Harlan 
Teklad Rodent Diet 8604, containing 12.2, 57.6 and 30.2% calories from fat, carbohydrate 
and protein, respectively). Another two groups were fed a high fat/ high sucrose diet (HFD, 
“Surwit” Research Diets, New Brunswick, NJ, containing 58, 26 and 16% calories from fat, 
carbohydrate and protein, respectively (38)). Half of the animals from each diet group were 
daily treated with IL-1Ra (ND + IL-1Ra and HFD + IL-1Ra; Kineret, Amgen, Thousand 
Oaks, CA, i.p. injection at a dose of 10 mg/kg body weight) or with vehicle as control (control 
ND and control HFD). Throughout the study period of 12 weeks, food consumption and body 
weight were measured weekly. Four independent experiments with a total of 16 mice (four 
mice/ cage) in each group were performed. 
Transgenic mice overexpressing IL-1Ra (IL-1Ra-OE) were kindly provided by Dr. 
Emmet Hirsch (Northwestern University, Evanston, IL, USA, (39)). Beginning at 5 weeks of 
age and continuing for 16 weeks, transgenic animals as well as their wildtype littermates 
were fed a normal diet (WT ND and IL-1Ra-OE ND) or a high fat/ high sucrose diet (WT HFD 
and IL-1Ra-OE HFD) as described above. Body weight and food intake was measured 
weekly. Four independent experiments with a total of 16 mice per group, respectively, were 
performed.  
Heterozygous leptin receptor deficient mice on the C57BLKS/J background (Leprdb/+ , 
db/+) were purchased from Jackson Laboratory. By crossbreeding these mice to C57BL/6J-
IL-1Ra-overexpressing mice (OE), we obtained diabetic Leprdb/db (db/db) as well as non-
diabetic Lepr +/+ (WT) with endogenous overexpression of IL-1Ra (OE-db/db and OE) as well 
as littermates without IL-1Ra as appropriate negativ controls (db/db and WT) with the same 
mixed background.  
All animals were housed in a temperature-controlled room with a 12-hour light/dark cycle and 
were allowed free access to food and water according to the protocol approved by the UCLA 
Chancellor's Animal Research Committee in agreement to NIH animal care guidelines. 
 
Intra-peritoneal glucose and insulin tolerance tests. After 4, 8 and 12 weeks of diet and 
IL-1Ra treatment, all animals underwent in vivo studies. For intraperitoneal glucose tolerance 
tests (IPGTT), mice were fasted 12 hours overnight and injected intraperitoneally with 
glucose (40%, Phoenix Pharmaceuticals Inc., St. Josephs, MO) at a dose of 2 g/kg body 
weight. Blood samples were obtained at time-points 0, 15, 30, 60, 90 and 120 min. for 
glucose measurements using a Glucometer (Freestyle, TheraSense Inc, Alameda, CA) and 
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at time-points 0 and 30 min. for measurement of serum insulin levels. For intraperitoneal 
insulin tolerance tests (IPITT), mice were injected intraperitoneally with 0.75 U/kg body 
weight recombinant human insulin (Novolin, Novo Nordisk) after 5 hour fasting and glucose 
concentration was determined with the Glucometer.  
 
Islet isolation and culture. After 12 weeks of diet and treatment, mice were sacrificed, 
blood was taken by cardiac puncture and serum stored at -80°C until further analysis. 
Thereafter, islets from all groups were isolated as described previously (40). In brief, 
pancreata were perifused with a collagenase solution (Collagenase type 4, Worthington, 
Lakewood, NJ, according to the manufacturer’s instructions) and digested in the same 
solution at 37°C followed by washing and handpicking. The islets were then cultured in 
RPMI-1640 medium containing 11.1 mM glucose, 100 U/ml penicillin, 100 µg/ml streptomycin 
and 10% FCS (Invitrogen). Human islets were isolated from pancreata of healthy organ 
donors at the University of Illinois at Chicago as described previously (41) and cultured in 
CMRL-1066 medium containing 5.5 mM glucose 100 U/ml penicillin, 100 µg/ml streptomycin 
and 10% FCS. All islets were kept in a humid environment containing 5% CO2 at 37 ºC. Islets 
were kept for 24 hours in culture medium in suspension dishes prior to treatment start or to 
harvesting for islet sections or RNA extraction. For treatment of human and mouse islets, 
medium was changed to the respective culture medium containing 5.5, 11.1, 22.2 or 33.3 
mM glucose or 5.5 mM plus 2 ng/ml recombinant human IL-1 (R&D Systems, Minneapolis, 
MN), with or without 500 ng/ml recombinant human IL-1Ra (R&D) or 10 µM JNKi (kindly 
provided by Xigen S.A., Lausanne, Switzerland) for 72 hours. 
 
Glucose stimulated insulin secretion. Islets used to perform glucose-stimulated insulin 
secretion experiments were kept in culture medium on matrix-coated plates derived from 
bovine corneal endothelial cells (Novamed Ltd., Jerusalem, Israel) for 4 days, allowing the 
cells to attach to the dishes and spread (42). These experimental conditions allowed direct 
comparison to our previous studies in human islets pre-treated with IL-1Ra in vitro (17). For 
acute insulin release in response to glucose, islets were washed and pre-incubated (30 min) 
in Kreb’s Ringer bicarbonate buffer (KRB) containing 2.8 mM glucose and 0.5% BSA. KRB 
was then replaced by KRB 2.8 mM glucose for 1 h (basal), followed by an additional 1 h in 
KRB 16.7 mM glucose (stimulated). Islets were extracted with 0.18 N HCl in 70% ethanol for 
determination of insulin content. Islet insulin was determined using mouse insulin ELISA 
(ALPCO, Salem, NH). 
 
Serum analysis. Serum obtained by cardiac puncture at the time of sacrifice was analyzed 
for serum lipids by the UCLA Lipid and Lipoprotein Laboratory as described (43). All lipid 
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assays were performed in triplicate determinations. An external control sample with known 
analyte concentration was run for each assay to assure accuracy. Free plasma glycerol 
concentrations were also determined and used to correct the triglyceride values. Leptin and 
resistin were measured using a mouse serum adipokine panel (LINCOplex, LINCO). Serum 
adiponectin and insulin concentrations were determined using mouse adiponectin and insulin 
ultrasensitive ELISA (ALPCO). Serum IL-1Ra levels were evaluated using mouse IL-1Ra 
Quantikine ELISA (R & D, Minneapolis, MN, USA).  
 
Pancreatic insulin and glucagon content. To determine the total pancreatic insulin and 
glucagon content, ~30 mg of pancreatic tissue from eight mice/ treatment group, respectively 
was homogenized in 1 ml 0.18 N HCl in 70% ethanol and incubated overnight at 4°C. After 
centrifugation, supernatants were collected and stored at -80°C. Insulin concentrations were 
measured using mouse insulin ELISA (ALPCO) and glucagon levels were determined by 
glucagon EIA (ALPCO) and values were normalized to tissue weight. 
 
Adipocyte size. Epididymal fat pads were dissected and fixed overnight at 4°C in 4% 
paraformaldehyde, followed by washing in 30% sucrose/ PBS for 12 hours at 4°C. After 30 
minutes incubation in a 1:1 mixture of 30% sucrose and OCT (Tissue Tek, Sakura Finetek, 
CA), the tissue was placed in 100% OCT for 30 minutes, embedded in plastic molds and 
frozen on dry ice before sectioning. To determine adipocyte size, sections were stained with 
hematoxylin and eosin. Cross-sectional adipocyte area was measured by manual tracing of 
300 or more cells per mouse and 6 animals per treatment group using an Olympus IX70 
inverted system microscope (Olympus America, Melville, NY) and Image-Pro Plus software 
(Media Cybernetics, Silver Springs, MD). 
 
-cell mass and histochemical analyses. After 12 weeks of diet and treatment, pancreata 
were weighed and fixed overnight in 4% paraformaldehyde at 4°C under continuous shaking 
followed by paraffin embedding, orienting pancreata such that sections were cut along the 
head-tail axis. To obtain sections from isolated mouse or human islets, islets were washed 
with PBS, fixed in Bouin’s solution for 15 minutes and resuspended in 2% melted agarose in 
PBS, followed by short centrifugation and paraffin embedding. To determine - and α-cell 
mass, ten sections (spanning the width of the pancreas) were deparaffinized, rehydrated and 
incubated overnight at 4°C with guinea-pig anti-insulin antibody (Dako, Carpinteria, CA), 
followed by detection with a fluorescein-conjugated donkey anti-guinea pig antibody (Dako). 
Subsequently, the specimens were labeled for glucagon with rabbit anti-glucagon (Dako), 
followed by detection with donkey anti-rabbit Cy3-conjugated antibody (Dako). An image of 
each slide was captured using Openlab and ImageJ software (Improvision Inc., Lexington, 
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MA). Tissue areas were determined by marking the image for total tissue and for -cells 
(fluorescein-labeled) or α-cells (Cy3-labeled), respectively. - and α-cell mass was analyzed 
using Openlab software. The relative area of -cells (green fluorescence) or α-cells (red 
fluorescence) was determined by quantification of the cross-sectional - or α-cell area 
divided by the cross-sectional area of total tissue, respectively. The cell mass per pancreas 
was estimated as the product of the relative cross-sectional area of -cells or α-cells per total 
tissue and the weight of the pancreas. For analysis of -cell proliferation, mouse pancreas 
sections were deparaffinized, rehydrated and incubated overnight at 4°C with rat anti-mouse 
Ki67 (Dako), followed by detection with donkey-anti-rat Cy3-conjugated antibody (Dako). For 
detection of -cell apoptosis, sections were incubated with 20 g/ml proteinase K (Roche 
Diagnostics, Indianapolis, IN) for 15 minutes at 37°C and apoptosis was analyzed by the 
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) technique 
according to the manufacturer’s instructions (In Situ Cell Death Detection Kit, TMR red; 
Roche). For PDX-1 localization studies, sections were incubated overnight at 4°C with rabbit 
anti-PDX-1 (kindly provided by Christopher Wright, Vanderbilt University Medical Center, 
Nashville, TN) followed by detection with donkey anti-rabbit Cy3-conjugated antibody (Dako). 
Subsequently, all sections were double-stained for insulin as described above. Same 
staining was performed on sections of isolated islets. Fluorescent slides were analyzed using 
Leica DM6000 microscope or Leica DMIRE2 confocal microscope and images aquired using 
Openlab software. 
 
RNA extraction and quantitative RT-PCR analysis. Total RNA of isolated islets was 
extracted after overnight culture as described previously (44). Total RNA from epididymal fat 
pads was isolated using RNeasy Lipid Tissue Kit (Qiagen, Valencia, CA, USA). For 
quantitative analysis, we used the LightCycler Quantitative PCR System (Roche) with a 
commercial kit (LightCycler FastStart DNA Master plus SYBR Green I, Roche). Mouse 
primers used were: 5’-ttcttctacacaccca-3’ and 5’-ctagttgcagtagttct-3’ (insulin); 5’-
gtccatgccatcactgccac-3’ and 5’-cagcaccagtggatgcaggg-3’ (GAPDH); 5’-
gttggccaggctggtgtccag-3’ and 5’-ctgtgatgagctgctcagggtgg-3’ (tubulin); 5’-
ctttggctatgggcttccagtc-3’ and 5’-gcaaggaggacagagtttatcgtg-3’ (F4/80); 5’-
ctggatagcctttcttctgctg-3’ and 5’- gcacactgtgtccgaactc-3’ (CD11c); 5’-acggcatggatctcaaagac-3’ 
and 5’-agatagcaaatcggctgacg-3’ (TNFα), 5’-gaccttccaggatgaggaca-3’ and 5’-
agctcatatgggtccgacag-3’ (IL-1); 5’-ccagctcattgctgggtact-3’ and 5’-cagctgactcaaagctggtg-3’ 
(IL-1Ra); 5’-gaggacccgtactgcctaca-3’ and 5’-cggggtcccgctactacgtt-3’ (PDX-1). 
 
Western Blot analysis. At the end of the incubation periods, islets were washed in ice-cold 
PBS and lysed for 40 minutes on ice in 40 µl lysis buffer containing 20 mM Tris acetate, 0.27 
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M sucrose, 1 mM EDTA, 1 mM EGTA, 50mM NaF, 1% Triton X-100, 5 mM sodium 
pyrophosphate and 10 mM -glycerophosphate. Prior to use, the lysis buffer was 
supplemented with Protease- and Phosphatase-inhibitors (Pierce, Rockford, IL, USA). 
Equivalent amounts of protein from each treatment group were run on a NuPAGE 4-12% Bis-
Tris gel (Invitrogen) and electrically transferred onto PVDF membranes. Membranes were 
incubated with rabbit anti-phospho JNK (Thr183/Tyr185) or rabbit anti--actin (Cell Signaling 
Technology) antibodies, followed by horseradish-peroxidase-linked anti-rabbit IgG. 
 
Statistical analysis. Samples were evaluated in a randomized manner by a single 
investigator (N.S.S.) who was blinded to the treatment conditions. Data are presented as 
means +/- SE and were analyzed by paired, Student’s t test or by analysis of variance with a 
Bonferroni correction for multiple group comparisons. 
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4.4  RESULTS 
 
4.4.1  IL-1Ra Prevents Diet-Induced Diabetes 
 
IL-1Ra has no impact on weight gain or food intake in mice. 
To assess the effect of IL-1Ra on diet-induced diabetes, we injected C57BL/6J mice daily 
with IL-1Ra or with vehicle for 12 weeks. Mice were fed a normal (ND) or a high fat/ high 
sucrose diet (HFD). Mice fed the HFD gained more weight than the ND control group; this 
was not influenced by IL-1Ra treatment. From one week of diet and treatment onward, body 
weight was significantly increased in mice fed the HFD. After 12 weeks, body weight of 
control mice was 35.6 ± 1.7 g at HFD compared to 24.1 ± 0.5 g at ND, p<0.001, and of IL-
1Ra-treated mice 34.3 ± 1.3 g at HFD compared to 25.4 ± 0.5 g at ND, p<0.001 (Fig.1A). 
Average weekly food intake was stable throughout the study in both ND- and HFD-groups 
and was not changed by IL-1Ra-treatment (Fig.1B). Similar results were obtained from 
transgenic mice overexpressing IL-1Ra (IL-1Ra-OE, data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-1Ra protects from diet-induced hyperglycemia and improves glucose tolerance in 
mice. 
Before and throughout the treatment period, we measured fasting and fed blood glucose 
every 4 weeks. Average fasted glucose levels before beginning the study in 5-week-old mice 
were 4 mM glucose and insulin levels 0.4 ug/l insulin, similar as measured in control ND mice 
throughout the study. As shown in Figure 2, neither fasting (Fig. 2A) nor fed (Fig. 2B) blood 
Figure 1: IL-1Ra has no impact on weight gain or food intake in mice. 
C57BL/6J wildtype mice were fed a normal (ND) or a high fat/ high sucrose diet (HFD) for 12 weeks. Mice were 
daily i.p. injected with 10 mg/kg body weight recombinant IL-1Ra (ND + IL-1Ra or HFD + IL-1Ra) or with vehicle 
(ND or HFD). Body weight (A) and food intake (B) per cage of four mice was measured weekly. Data show results 
from a total of 16 animals per group, performed in four separate experiments ± SE. *p<0.01 HFD compared to ND 
same treatment from 1 week on. 
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glucose concentrations changed during the 12 weeks of the study in both control and IL-1Ra-
treated mice under the normal diet. After 4 weeks of treatment, no differences in glucose 
levels were observed in all four treatment groups (Fig.2 A,B). After 8 weeks, fasting glucose 
was 1.9-fold increased in the HFD-group compared to the ND-group. This increase was 
prevented in animals from the HFD-group that received IL-1Ra (Fig.2A). After 12 weeks, high 
fat feeding increased both fasting and fed glucose levels (1.7-fold and 1.5-fold increase in 
fasting and fed glucose levels, respectively, in the HFD-group, compared to ND, Fig.2 A,B, 
p<0.001), whereas in the IL-1Ra-treated HFD-group, glucose levels were significantly lower 
than in the vehicle HFD-group (1.2-fold reduction compared to the untreated HFD-group in all 
conditions, p<0.05). In parallel, glucose tolerance was impaired in the HFD-group already 
after 4 weeks (data not shown) and was further declined during the experiment. Fig. 2C 
shows the response to an intraperitoneal glucose challenge after 12 weeks of diet and 
treatment. High fat feeding resulted in significantly higher glucose levels before (0 min) and 
30, 60, 90 and 120 min after glucose injection (p<0.05). IL-1Ra administration protected the 
HFD-mice from this effect, resulting in blood glucose levels that were significantly lower 
compared to controls at all time points during the IPGTT (p<0.05). Moreover, IL-1Ra 
treatment led to decreased peak glucose levels in the normal diet group compared to control 
animals, which reached significance at 15 min (1.3-fold reduction, p<0.001, Fig.2C).  
Fig. 1D shows serum insulin levels during an IPGTT after 12 weeks of diet and 
treatment. As previously described (45), high fat feeding resulted in hyperglycemia 
(Fig.2B,C) as well as hyperinsulinemia (Fig.2D) compared to control diet mice. Compared to 
ND counterparts, fasted insulin levels were 2.9-fold higher in HF fed mice (p<0.01). These 
mice also failed to further increase their insulin levels in response to a glucose challenge. 
HFD-mice under IL-1Ra treatment exhibited significantly lower fasting insulin levels (1.7-fold, 
p<0.01) and increased serum insulin concentrations during the IPGTT 2.5-fold. Under the 
normal diet, IL1-Ra treatment resulted in a higher stimulatory index compared to untreated 
animals (1.9- vs. 4.2-fold, p<0.05).  
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Figure 2: IL-1Ra protects from diet-induced hyperglycemia and improves glucose tolerance. 
(A,B) Blood glucose levels were measured after 4, 8 and 12 weeks of diet and IL-1Ra treatment after overnight 
fasting (A) or without fasting (B). Blood glucose (C) and plasma insulin (D) levels following i.p. injection of 2 g/kg 
body weight glucose in mice after 12 weeks of treatment. (E) Blood glucose concentrations of mice after 12 weeks 
of treatment, undergoing an insulin tolerance test. Insulin was injected i.p. at a concentration of 0.75 U/kg body 
weight. (F) Blood glucose levels during IPGTT experiment as described above in IL-1Ra-overexpressing (IL-1Ra-
OE) animals and their wildtype (WT) littermates after 16 weeks of normal or high fat diet. Data show mean ± SE. 
*p<0.05 HFD compared to ND, +p<0.05 IL-1Ra or IL-1Ra-OE compared to vehicle or wildtype same diet, 
respectively, #p<0.05 stimulated compared to basal insulin secretion. Data were collected from 16 animals per 
group, performed in four separate experiments. 
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To determine insulin sensitivity, we performed an insulin tolerance test by measuring glucose 
concentrations after intraperitoneal insulin injection of 0.75 U/kg of body weight. No 
significant difference in insulin sensitivity was found among the animals of the normal diet 
group (Fig.2E). As previously described, untreated HFD-mice displayed impaired insulin 
sensitivity compared to ND-mice. Animals that received IL-1Ra injections were protected 
against this high fat diet-induced insulin resistance (Fig.2E).  
Similar results were obtained from IL-1Ra-OE mice. After 16 weeks of HFD, glucose 
tolerance was impaired showing increased glucose levels at all time-points during the IPGTT 
as well as increased fasting glucose levels in the wildtype mice, compared to ND (p<0.05, 
Fig.2F). This was prevented in IL-1Ra-OE mice under the HFD, showing significantly 
reduced fasting glucose levels and improved glucose tolerance at all time-points during the 
IPGTT (p<0.05, Fig.2F). Also, IL-1Ra overexpression led to decreased peak glucose levels in 
the ND-group compared to wildtype mice, which reached significance at 30 min (1.2-fold 
reduction, p<0.001, Fig.2F). 
 
 
IL-1Ra treatment has no effect on -cell or -cell mass. 
Pancreatic weight per body weight remained unchanged by diet and treatment (data not 
shown). Immunohistochemical evaluation of pancreata of all four treatment groups after 12 
weeks of diet and treatment revealed a normal islet structure (Fig. 3B). Islet -cell mass was 
dramatically increased by high fat feeding in vehicle- and in IL-1Ra-injected animals 
compared to normal diet (2.3-fold increase in the control and 2.6-fold increase in the IL-1Ra-
treated HFD-group compared to ND, respectively, p<0.001; Fig. 3C). High fat feeding also 
resulted in increased α-cell mass (2.1 fold and 1.8-fold increase in the control and the IL-
1Ra-treated HFD-group compared to ND, respectively, p<0.05, Fig. 3D). IL-1Ra-treatment 
did not affect -cell mass nor α-cell mass in both ND and HFD groups. Consistent with an 
increase in -cell mass, the pancreas of control and IL-1Ra-treated high fat diet-mice 
contained 2.6-fold and 3.1-fold more insulin as compared to their normal diet counterparts 
(p<0.01, Fig. 3E). In addition, pancreatic glucagon content also increased by high fat feeding 
(3.3-fold and 2.6-fold increase in the control and the IL-1Ra-treated HFD-group compared to 
the respective ND-group, p<0.05, Fig. 3F). In consistency with the increase in -cell mass, 
we also observed larger islets from both HFD treated groups compared to ND during islet 
isolation. 
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Figure 3: IL-1Ra treatment has no effect on -cell mass or -cell mass. 
(A) Pancreatic weight per body weight was measured at the end of the study and is expressed relative to control normal diet 
conditions. (B) Double immunostaining for insulin in green and glucagon in red (Magnification x125), (C) -cell mass and (D) α-
cell mass in tissue sections spanning the width of the whole pancreas of vehicle-treated control mice or IL-1Ra-injected mice fed 
a normal or high fat diet for 12 weeks (n=4 mice for each group). The - and α-cell mass per pancreas was estimated as the 
product of the relative cross-sectional area of - or α-cells (determined by quantification of the cross-sectional area occupied by 
- or α-cells divided by the cross-sectional area of total tissue) and the weight of the pancreas. Pancreatic insulin (E) and 
glucagon (F) content in ng per mg pancreas of normal and high fat fed mice injected with vehicle or IL-1Ra for 12 weeks. 
*p<0.05 HFD compared to ND same treatment, +p<0.05 IL-1Ra-treated compared to vehicle same diet. 
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IL-1Ra induces proliferation after 12 weeks in mice under the normal diet. 
In cultured human islets, IL-1Ra increased basal -cell proliferation (46) and protected from 
hyperglycemia induced -cell apoptosis (17). Therefore, we investigated -cell turnover in 
islets from all four groups after 12 weeks of diet and treatment. Staining of pancreatic 
sections for the replication marker Ki67 revealed that IL-1Ra-injections increased -cell 
proliferation 2.0-fold (Fig. 4A;B p<0.05) in the ND-mice. In contrast, high fat feeding reduced 
proliferation 2.2-fold in vehicle-treated animals compared to the control ND-group (Fig. 4A,B), 
whereas IL-1Ra-treated mice on the HFD were protected against this decrease in 
proliferation. Same results were obtained from isolated islets. Proliferation was 2.0-fold 
increased (p<0.05) in vitro in islets from IL-1Ra-injected ND-mice. In the HFD-group, islets 
from IL-1Ra-injected mice were protected against the decreased proliferation observed in 
control HFD-mice. 
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Figure 4: IL-1Ra increases -cell proliferation in animals under the ND. 
(A,B) Triple staining for proliferation by Ki67-antibody in red, insulin in green and DAPI in blue was performed on fixed, paraffin 
embedded mouse pancreas sections (Magnification x250). (B) Results are expressed as percentage of Ki67-positive β-cells ± SE 
normalised to control ND islets (100%, in absolute values: 0.3 ± 0.1 % Ki67-positive cells in isolated islets from vehicle-treated 
mice under the normal diet). The mean number of -cells scored was 4599 ± 643 for each treatment condition in four independent 
experiments. *p<0.05 HFD compared to ND same treatment, +p<0.05 IL-1Ra-treated compared to vehicle same diet. 
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IL-1Ra protects from -cell apoptosis in cultured isolated islets. 
In addition to proliferation, we investigated -cell apoptosis in pancreatic sections. Staining 
revealed no TUNEL-positive -cells in sections from both ND-groups and from the IL-1Ra-
treated HFD-group. We detected 0.016% TUNEL-positive -cells/ islet in sections from the 
vehicle treated HFD-group (1 TUNEL-positive -cell was found in 61 islets analyzed). Due to 
this low frequency of positive -cells in pancreatic sections, we analyzed the occurrence of -
cell apoptosis in isolated islets (Fig. 5A). We found a 3.2-fold increase in -cell apoptosis in 
islets derived from the high fat diet group. Islets from high fat fed-mice that were treated with 
IL-1Ra showed a rate of -cell apoptosis similar to islets from the normal diet group (Fig 5B). 
 
 
 
IL-1Ra treatment preserves -cell function in high fat fed-mice. 
Since we observed a protective effect of IL-1Ra on blood glucose levels, glucose tolerance 
as well as insulin secretion during the glucose tolerance test, we investigated if this effect 
can be explained by improved -cell function. Islets were isolated from all four treatment 
groups and insulin secretion into the culture medium was measured. Acute glucose-
stimulated insulin secretion was completely abolished in islets derived from animals fed a 
high fat diet (Fig. 5C). We found that islets from high fat fed animals, which were treated with 
IL-1Ra, showed a significant response to a glucose challenge and a stimulatory index 
comparable to normal diet animals (Fig. 5D). In parallel, high fat feeding induced a decrease 
in insulin mRNA in isolated islets, which was prevented by IL-1Ra administration (Fig. 5E).  
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Figure 5: IL-1Ra protects from -cell apoptosis and preserves -cell function in cultured isolated islets of HFD-mice. 
Islets were isolated after 12 weeks of diet and treatment. (A) Triple staining for TUNEL in red, insulin in green and DAPI in blue 
was performed on fixed, paraffin embedded islet sections (Magnification x750). (B) Results are expressed as percentage of 
TUNEL-positive β-cells ± SE normalised to control ND islets (100%, in absolute values: 1.02 ± 0.19 % TUNEL-positive -cells in 
isolated islets from vehicle-treated mice under the normal diet). The mean number of -cells scored was 2169 ± 894 for each 
treatment condition from six individual mice. (C,D) For glucose-stimulated insulin secretion (GSIS) experiments, islets were 
cultured on extracellular matrix-coated dishes. (C) Glucose-stimulated insulin secretion of islets. Basal and stimulated insulin 
secretion during successive 1-hour incubations at 2.8 mM (basal) and 16.7 mM (stimulated) glucose. (D) Stimulatory index 
denotes the ratio between stimulated and basal values of insulin secretion. Assay was performed in triplicate from four individual 
mice. (E) Quantitative RT-PCR analysis of insulin expression relative to control normal diet conditions. In the LightCycler System 
the levels of insulin expression were normalized to GAPDH and tubulin with the same result. mRNA levels were evaluated from 6 
individual mice per treatment group. Data are shown as mean ± SE. *p<0.05 HFD compared to ND same treatment, +p<0.05 IL-
1Ra-treated compared to vehicle same diet, #p<0.05 stimulated compared to basal insulin secretion.  
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IL-1Ra prevents HFD-induced changes in serum adipokine and lipid levels. 
Epididymal fat pad mass was significantly increased in both HFD-groups (3.7-fold in the 
control and 3.8-fold in the IL-1Ra-treated HFD-group, compared to ND-group, respectively, 
p<0.01, Fig. 6A). IL-1Ra-injections did not affect epididymal fat mass in both diet groups.  
At the end of the study, we measured serum adipokines, lipids and cytokines known to affect 
insulin action and secretion. IL-1Ra levels are unchanged by the HFD. IL-1Ra concentrations 
in IL-1Ra-injected mice were increased under both diets (Fig. 6B, p<0.05).  
High fat diet treatment has been shown to increase serum levels of lipids and of the 
adipokines resistin and leptin (47). To test the hypothesis that IL-1Ra is able to prevent those 
changes despite the increase in fat mass, we analyzed serum from all mice for these 
adipokines.  
Levels of leptin and resistin were raised 22-fold and 1.8-fold in the vehicle-treated HFD-group 
compared to ND, respectively (Fig. 6C;D p<0.05). IL-1Ra treatment led to a 3.9-fold and 1.6-
fold reduction in leptin and resistin levels in the HFD-group, respectively (p<0.05). 
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Figure 6: IL-1Ra treatment prevents HFD-induced changes in serum adipokine levels. 
(A) Epididymal fat pad weight per body weight was measured at the end of the study and is expressed relative to control normal diet 
conditions. Serum levels of IL-1Ra (B), leptin (C) and resistin (D) in mice after 12 weeks of diet and treatment. Data show mean 
results from 8 mice per treatment group from four independent experiments ± SE. *p<0.05 HFD compared to ND, +p<0.05 IL-1Ra-
treated HFD compared to vehicle HFD.  
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IL-1Ra prevents HFD-induced changes in serum lipid levels. 
Free fatty acid (FFA) levels were increased by 21% in vehicle-treated HFD-animals 
compared to ND (p<0.05, data not shown). In contrast, animals under the HFD that were 
given IL-1Ra did not show any significant rise in FFA levels compared to their ND-fed 
counterparts. High fat feeding also significantly increased triglyceride (TG) and cholesterol 
(Chol) levels (TG: 1.4-fold increase, Chol: 2.1-fold increase, p<0.05). IL-1Ra-administration 
to HFD-mice had the tendency to reduce triglyceride and cholesterol levels compared to 
vehicle-treated animals, however, this reduction did not reach statistical significance (data 
not shown). Mice under the high fat diet, which endogenously overexpress IL-1Ra (IL-1Ra-
OE), showed significantly reduced levels of FFA as well as triglyceride and cholesterol (Fig. 
7A-C, p<0.05). Additionally, circulating adiponectin levels were reduced by 20% in the HFD 
mice compared to ND-mice (p<0.05, Fig. 7D). HFD-induced reduction in adiponectin levels 
was prevented in mice overexpressing IL-1Ra (p<0.01, compared to wildtype HFD-mice). In 
the ND-groups, neither IL-1Ra-injections nor overexpression affected lipid or adipokine 
levels. Since IL-1Ra-induced changes of adipokine and lipid levels in the HFD-group 
occurred without changes in fat mass, we investigated the size of adipocytes in hematoxylin- 
and eosin-stained sections of epididymal fat pads. Measuring the cross-sectional area by 
manual tracing revealed an over 3-fold high fat diet-induced increase in adipocyte size in 
both wildtype and IL-1Ra-OE mice compared to their ND counterparts (p<0.005, Fig. 7E). IL-
1Ra overexpression did not affect adipocyte size in either diet group. To further elucidate the 
underlying mechanisms of the observed changes in serum adipokines and lipids, we isolated 
RNA from epididymal fat tissue and assessed expression of inflammatory genes by 
quantitative RT-PCR. While in wildtype mice high fat diet increased adipose tissue 
expression of IL-1, F4/80, CD11c and TNFα (p<0.05), this induction was attenuated in IL-
1Ra-OE mice (p<0.05, Fig. 7F). IL-1Ra-expression in adipocytes was increased by HFD in 
wildtype animals. In IL-1Ra-OE mice, we confirmed increased IL-1Ra mRNA in adipocytes 
(6.9-fold increase in IL-1Ra mRNA in ND and 2.7-fold increase in HFD, compared to wildtype 
mice, p<0.05, Fig.7F). 
 
 
 
 
 
 
 
 
 
The Potent Role of IL-1Ra to Prevent Diet-Induced Diabetes 53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
E 
Adiponectin 
Normal diet High fat diet 
40
50
60
70
Se
ru
m
 
le
v
el
 
µµ µµg
/m
l 
* 
+ 
WT IL-1Ra- 
OE 
WT IL-1Ra- 
OE 
Normal diet High fat diet 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
* 
* 
Ad
ip
o
cy
te
 
s
iz
e 
µm
2 
WT IL-1Ra- 
OE 
WT IL-1Ra- 
OE 
F 
Free Fatty Acids A 
Normal diet High fat diet 
0
20
40
60
Se
ru
m
 
le
v
e
l 
m
g/
dl
 
* 
+ 
WT IL-1Ra- 
OE 
WT IL-1Ra- 
OE 
Total Cholesterol C 
Normal diet High fat diet 
0
50
100
150
200
250
300
Se
ru
m
 
le
v
el
 
m
g/
dl
 
* 
+ 
WT IL-1Ra- 
OE 
WT IL-1Ra- 
OE 
Triglyceride B 
Normal diet High fat diet 
0
20
40
60
80
Se
ru
m
 
le
v
e
l 
m
g/
dl
 
* 
+ 
WT IL-1Ra- 
OE 
WT IL-1Ra- 
OE 
Adipose tissue 
0
100
200
300
400
500
600
700 WT ND
IL-1Ra-OE ND
WT HFD
IL-1Ra-OE HFD
0
500
1000
1500
2000
2500
3000
Re
la
tiv
e 
ge
n
e 
e
x
pr
e
ss
io
n
 
/ t
u
bu
lin
 
R
elativ
e
 IL1
-R
a
 e
xp
re
s
sio
n
 
/
 tub
ulin
 
F4/80 CD11c TNFα IL-1β IL-1Ra 
* 
+ 
+ 
+ 
+ 
* 
+ 
* 
* 
+ 
+ 
* 
+ 
Figure 7: IL-1Ra prevents HFD-induced changes in serum lipid levels. 
(A-D) Serum levels of triglycerides, cholesterol, free fatty acids and adiponectin in IL-1Ra-overexpressing (IL-1Ra-OE) mice and their 
wildtype littermates (WT), fed a normal or high fat diet for 16 weeks (n=8). (E) Size of adipocytes in epididymal fat tissue of IL-1Ra-OE 
mice or WT littermates under ND or HFD. Sections were stained with hematoxylin and eosin followed by measuring cross-sectional area 
by manual tracing (n=6). (F) Quantitative RT-PCR of inflammatory gene expression in epididymal fat pads. Total RNA was isolated after 
16 weeks of normal or high fat diet and gene expression was evaluated in the LightCycler System after normalization to tubulin. Results 
are expressed relative to mRNA levels in wildtype mice under normal diet (n=7). All data are shown as mean ± SE. *p<0.05 HFD 
compared to ND, +p<0.05 IL-1Ra-OE mice compared to WT same diet. Analyses were performed in four independent experiments. 
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4.4.2  IL-1Ra Maintains PDX-1 Nuclear Localization 
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Figure 8: IL-1Ra treatment prevents PDX-1 translocation to the cytoplasm in mouse and human islets 
(A) Quantitative RT-PCR analysis of PDX-1 expression relative to control ND conditions was performed in mouse islets isolated from the 
four treatment groups. PDX-1 levels were normalized to GAPDH and tubulin with the same result. Islets were isolated from 4 mice per 
treatment. Data are shown as mean ± SE, *p<0.05 HFD vs. ND vehicle. (B) Double immunostaining for insulin (green, panel A, C, E and 
G) and PDX-1 (red, panel B, D, F and H) in mouse pancreatic tissue sections from all four treatment groups, staining was performed from 
four different pancreases per treatment group (magnification x250, insert x2000). (C) Human isolated islets were treated for 72 hours with 
5.5 mM glucose (control), 33.3 mM glucose or 2 ng/ml IL-1 with or without 500 ng/ml recombinant human IL-1Ra. Fixed and paraffin 
embedded islets sections were double-stained for insulin (green, panel A, C, E, G, I, K) and PDX-1 (red, panel B, D, F, H, J, L) and 
analyzed under the confocal microscope (magnification x1000, insert x4000). Islets were isolated from three different donors. 
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IL-1Ra treatment prevents PDX-1 translocation to the cytoplasm in mouse and human 
islets. 
The molecular mechanism behind insulin gene regulation was studied by performing RT-
PCR for the insulin transcription factor pancreatic duodenal homeobox-1 (PDX-1). While 
insulin mRNA in islets from high fat diet animals was decreased to 27% of control islets (Fig. 
5E), PDX-1 levels were increased (Fig. 8A). IL-1Ra inhibited such increase. Since it has 
been reported that PDX-1 activity is primarily regulated by its sub-cellular localization (48; 
49), we stained pancreatic tissue sections for PDX-1 and insulin. Sections from both normal 
diet groups showed PDX-1 immunoreactivity predominantly in the nucleus of -cells (Fig. 
8B). In contrast, islets under the high fat diet expressed PDX-1 exclusively in the cytoplasm. 
IL-1Ra treatment inhibited this translocation to the cytoplasm and the islets showed more 
prominent staining in the nucleus. To investigate whether our results on the mouse HFD 
model can be translated into mechanisms in human cells, we analyzed the effect of IL-1Ra 
on PDX-1 localization in human islets (Fig. 8C). Isolated human islets were treated with 
increasing glucose concentrations (5.5, 11.1 and 33.3 mM glucose) or 5.5 mM glucose plus 2 
ng/ml IL-1 for 72 hours. As reported in many publications and in our previous studies (46; 
50) (data not shown), under conditions of elevated glucose levels or IL-1 treatment -cells 
failed to adequately increase insulin secretion in response to a glucose challenge. As shown 
in Fig. 8C, upper panel, in control conditions at 5.5 mM glucose, PDX-1 is localized in the 
nucleus in the insulin positive -cells. Co-exposure of the islets to IL-1Ra did not change 
PDX-1 localization. Increasing glucose concentrations to 11.1 (data not shown) or 33.3 mM 
(Fig. 8C, middle panel) or addition of IL-1 (Fig. 8C, lower panel) shifted the PDX-1 signal 
almost exclusively to the cytoplasm, resulting in co-localization of PDX-1 with insulin (yellow 
merged color), whereas co-incubation with IL-1Ra protected from such PDX-1 shift; PDX-1 
remained in the nucleus in the IL-1Ra treated islets (Fig. 8C right panel). 
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Figure 9: IL-1Ra prevents glucose- and IL-1
induced prolonged JNK-activation in human islets. 
Isolated human islets were cultured in suspension for 72 
hours in 5.5mM glucose (control), 33.3mM glucose or 
2ng/ml IL-1 with or without the addition of 500ng/ml 
recombinant human IL-1Ra. Immunoblotting of 
phosporylated JNK and -actin (loading control). The 
antibodies were blotted on the same membrane. One 
representative blot of three experiments from three 
donors is shown. 
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IL-1Ra prevents prolonged glucose- and IL-1-induced JNK-activation. 
It has been shown that PDX-1 nuclear export is induced by oxidative stress through a 
signaling pathway that involves c-Jun N-terminal kinase (JNK) and forkhead transcription 
factor (Foxo) activity (1; 51; 52). Therefore, we investigated whether these cellular 
components also mediate glucose- and IL-1-induced effects on PDX-1 localization by first 
evaluating whether IL-1Ra regulates JNK-activation. In isolated human islets, phosphorylated 
JNK-levels were increased by a 3-day culture in 33.3mM glucose or in the present of IL-1 
(Fig. 9, upper blot) compared to control cultured at 5.5mM glucose. In both cases, this 
increase was inhibited when IL-1Ra was added to the culture medium. We confirmed these 
findings in isolated mouse islets. JNK remains in its activated state over a 3-day period in the 
presence of elevated glucose concentrations (Fig. 10, left panel, upper blot). In islets from 
mice that endogenously overexpress IL-1Ra (IL-1Ra-OE), glucose induces transient JNK 
phosphorylation after 1 day of culture, whereas after 3 days, JNK activation decreases (Fig. 
10, right panel, upper blot). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JNK-inhibition prevents glucose- and IL-1-induced nuclear export of PDX-1. 
Since we postulate that glucose-induced JNK-activation leads to PDX-1 export, JNK-
inhibition would prevent shuttling despite the presence of elevated glucose or IL-1. To test 
this hypothesis, we treated human islets with 33.3 mM glucose or with 2 ng/ml IL-1, with or 
without the addition of JNKi, a small peptide that inhibits JNK-activity. We again observed 
glucose- and cytokine-mediated PDX-1 translocation (Fig. 11, panels D,F). We not only 
found cells that co-express insulin and PDX-1 in the cytoplasm, there are also cells that show 
cytoplasmic PDX-1 with almost no detectable insulin anymore (Fig. 11, arrow panel C,D and 
merge). In addition, some cells display PDX-1 in the nuclear periphery, which has been 
Figure 10: IL-1Ra-overexpression prevents glucose-induced prolonged JNK-activation in isolated mouse islets. 
Isolated islets from mice overexpressing IL-1Ra (IL-1Ra-OE) and wildtype littermates were treated for 1 or 3 days with 
11.1mM glucose (control) or 33.3mM glucose. Immunoblotting for phosphorylated JNK and -actin (loading control). The 
antibodies were blotted on the same membrane. One representative experiment of three is shown. 
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previously observed in cell lines kept at low glucose concentrations ((53), Fig. 11, arrow 
panel F). JNK-inhibition prevented glucose- and IL-1-induced PDX-1 translocation and kept 
the transcription factor in the nucleus in most cells, indicating that the JNK-pathway is 
involved in regulating PDX-1 localization.  
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Figure 11: JNK-inhibition prevents PDX-1 translocation to the cytoplasm in human islets. 
Human isolated islets were treated for 72 hours with 5.5 mM glucose (control), 33.3 mM glucose or 2 ng/ml IL-1 with or without 500 
ng/ml recombinant human IL-1Ra. Fixed and paraffin embedded islets sections were double-stained for insulin (green, panel A, C, 
E, G, I, K) and PDX-1 (red, panel B, D, F, H, J, L) and analyzed under the confocal microscope. (magnification x1000, insert x4000). 
Islets were isolated from three different donors and experiments were performed in three independent experiments. 
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4.4.3  IL-1Ra Delays the Onset of Diabetes in the db/db-Mouse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL-1Ra overexpression delays the onset of diabetes in db/db-mice. 
To investigate the ability of IL-1Ra to protect from diabetes in another mouse model, we 
examined the effects of IL-1Ra in Leprdb/db mice (db/db). Homozygous mice on the 
C57BLKS/J background with this depletion in the leptin receptor become obese, 
hyperglycemic and hyperinsulinemic within the first month of age. It has been shown in these 
mice that IL-1-mediated innate immunity is augmented which results from a diabetes-
associated loss of IL-1 counteregulation (54). To test the hypothesis that IL-1Ra would 
prevent diabetes progression in this model of type 2 diabetes, we injected db/db-mice daily 
with IL-1Ra or with vehicle from 4 weeks of age on. Db/db mice which received IL-1Ra 
showed improved glucose tolerance during IPGTT experiments after 2 weeks of treatment as 
compared to their vehicle-treated littermates (p<0.05 at time points 30 and 60 minutes, data 
not shown). From 3 weeks of treatment on, we did not observe any differences in glucose 
levels among the two groups anymore. Considering the short half life of IL-1Ra (6 to 8 hours) 
and the 10- to 100-fold excess that is needed to block IL-1-mediated effects (24), we tested 
whether constitutiv endogenous overexpression of IL-1Ra would improve the outcome of 
elevated IL-1Ra levels in db/db-mice. By crossbreeding mice which endogenously 
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Figure 12: IL-1Ra overexpression delays the onset of diabetes in db/db-mice. 
Blood glucose levels during IPGTT experiments in mice of 6 (A) and 8 (B) weeks of age. Glucose was i.p. injected at a 
concentration of 1 g/kg body weight. Data show mean ± SE. *p<0.05 db/db compared to OE-db/db. Data were collected from 
8 animals per group, respectively. 
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overexpress IL-1Ra (OE) to C57BLKS-Leprdb we obtained four groups of mice: IL-1Ra-OE-
Leprdb/db (OE-db/db) and IL-1Ra-OE-Lepr+/+  (OE) as well as their littermates without IL-1Ra-
overexpression, Leprdb/db (db/db) and Lepr+/+  (WT). As shown in Figure 12, IL-1Ra-
overexpression delayed the onset of diabetes in db/db mice as their glucose tolerance is 
improved up to 6 weeks of age compared to db/db mice without IL-1Ra overexpression (Fig. 
12A). As observed in mice injected with IL-1Ra, this protection is a transient state as at 8 
weeks of age, there is no difference in glucose tolerance despite the constitutiv 
overexpression of IL-1Ra (Fig. 12B).  
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4.5  DISCUSSION 
 
Elevated glucose concentrations impair -cell function and induce apoptosis and thus are 
implicated in accelerating the progression of diabetes. Strategies to block these deleterious 
effects on the -cell are needed for a successful diabetes therapy. Interleukin-1 Receptor 
Antagonist has been shown to inhibit the deleterious effects of glucose on -cells by blocking 
pro-inflammatory IL-1 signaling in vitro (17). Here we show that IL-1Ra improved glucose 
tolerance, insulin secretion, and insulin sensitivity in C57BL/6J mice fed a high fat/ high 
sucrose diet (Surwit), serving as an animal model of T2DM. Twelve weeks of high fat feeding 
resulted in hyperglycemia accompanied by impaired glucose-stimulated insulin secretion. 
Interestingly, the changes induced by the high fat feeding strongly correlated with the 
individual weight gain of the mice. For instance, a mouse with a 1.15-fold higher body weight 
in our study (46 g vs. 40 g) also had 1.12-fold higher glucose levels at all time-points during 
the IPGTT (p<0.05, data not shown). This strong association of glucose tolerance and body 
weight may explain the relatively large variation we observed throughout the study, which 
has been reported before in a similar diet-induced obesity model (55).  
Long-term high fat diet in C57BL/6J mice is associated with an adaptive increase in -
cell number but an early functional abnormality (56). In the present study, -cell mass 
increased over 2-fold during the twelve weeks of high fat/ high sucrose diet. Despite this 
increase in -cell mass, -cell turnover was already impaired at that time point. We assume 
that the combination of high fat and high sucrose in the diet results relatively early in an 
impairment of -cell turnover together with loss of function. In line with this, massive 
reduction in -cell replication after long-term high fat/ high carbohydrate diet (decreased to 
one third of the control group) has been observed in mice before a significant decrease in -
cell mass (57). Consistent with our present study, ~0.3% proliferating -cell were observed in 
the control mice (57) and low numbers as 0.025% proliferating -cells were reported from 
human pancreatic sections from autopsy (6). Proliferation in adult -cells is a rare event, but 
small changes in -cell proliferation or apoptosis over the years can result in marked 
changes in -cell mass and diabetes progression (6; 57). 
Previous studies observed that glucose induces increased proliferation in short-term 
culture, but decreases proliferation after long-term exposure of isolated islets (58). We 
hypothesize that in our model, a transient rise in diet-induced proliferation occurred earlier in 
the study, mediated by mildly elevated glucose levels, proceeding to decreased proliferation 
measured at 12 weeks, when severe hyperglycemia was present. IL-1Ra-treated mice were 
protected from this HFD-induced decrease in proliferation. Under the normal diet, IL-1Ra-
injections resulted in increased -cell proliferation after 12 weeks, consistent with in vitro data 
on isolated human islets (46). We measured only very few apoptotic -cells in vivo, and could 
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not quantify significant changes among the four treatment groups. It is noteworthy that 
isolated islets derived from the HFD-group displayed a 3-fold induction of -cell apoptosis 
compared to islets from the ND-group. This suggests that high fat feeding renders -cells 
more susceptible to apoptosis induced by isolation procedures and/ or culture. This 
increased sensitivity was not observed in islets from IL-1Ra-treated HFD-mice. 
The effect of IL-1Ra on improving glucose tolerance is probably a result of both improved 
function of the -cell and insulin action. Especially, the effects of IL-1Ra serum lipids, 
adipokines and cytokines would in turn improve -cell function as well as insulin sensitivity. 
Free fatty acids have been shown to directly activate pro-inflammatory signaling through 
TLR4 in adipose cells and macrophages (59). Also, free fatty acids (40) and triglycerides (60) 
induce -cell dysfunction and apoptosis. 
Several adipocytokines, e.g. leptin, resistin and adiponectin play a central role in the 
regulation of insulin resistance, as well as of inflammation, immunity and -cell function (47; 
61). In line with this we show pro-inflammatory leptin and resistin induced by the HFD, 
whereas adiponectin, which is known to prevent inflammation (61), was decreased by the 
HFD. All of these adipokines were normalized by IL-1Ra. Interestingly, adiponectin can 
directly inhibit IL-6 and TNF- production and induce production of IL-1Ra by human 
monocytes, macrophages and dendritic cells (61). To analyze systemic levels of 
inflammatory cytokines in the mice, we measured IL-1 and IL-6 serum concentrations. 
Unfortunately, no ultra-sensitive assays for such measurements are available and therefore 
most of the values were under the detection levels of the assays. We detected positive IL-1 
and IL-6 readings in some but not all samples from the HFD control mice. However, data 
analysis and statistics were not possible. On the other hand, serum IL-1Ra levels were 
unchanged by the HFD after 12 weeks. Therefore, we hypothesize that the ratio of IL-1/IL-
1Ra plays an important role in maintaining glucose homeostasis.  
Amounts of secreted leptin and free fatty acids are dependent on fat mass (62), but 
also on the direct effect of IL-1 on the adipocytes (63). The fact that we do observe changes 
in leptin and FFA secretion in IL-1Ra-treated HFD-mice without changes in fat mass and 
adipocyte size supports an IL-1 dependent effect. TNF- and IL-1 expression in epidydimal 
fat pads could trigger HFD-induced insulin resistance (64) and also negatively act on the -
cell (65; 66). Here we show mRNA levels of the inflammatory cytokines IL-1 and TNF-, the 
macrophage marker F4/80 and the pro-inflammatory macrophage marker CD11c are 
increased by the HFD in wildtype mice but reduced by IL-1Ra overexpression. A HFD-
induced pro-inflammatory state of adipocytes may be the reason for the increased leptin, 
FFA, cholesterol and triglyceride production in the HFD control mice. Even though IL-1Ra 
mRNA in adipocytes was 7.4-fold increased by the HFD, this could likely not counteract the 
2.7-fold HFD-induced increase of IL-1, since an excess of 10- to 1000-fold of IL-1Ra is 
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needed to inhibit IL-1 effects, dependent on the exposure time (17; 24). In contrast, in IL-
1Ra-OE mice of both diet groups, IL-1 mRNA levels were significantly lowered, whereas IL-
1Ra mRNA was increased. Our study provides more evidence for an existing link between 
inflammation, -cell function and survival and insulin resistance. Undoubtedly, the effect of 
IL-1Ra on adipocyte-derived factors participated in the protective role of IL-1Ra on the level 
of the -cell. 
Increased IL-1Ra serum levels correlate with obesity and insulin resistance in 
humans (67), suggesting that IL-1Ra induces rather than protects from insulin resistance. 
Moreover, a negative correlation of elevated IL-1Ra and whole body glucose uptake has 
been shown in offspring of T2DM subjects. In addition, injecting rats with IL-1Ra for 5 
consecutive days leads to decreased whole body glucose disposal due to a selective 
decrease in glucose uptake in the muscle (68). In our study, we have not assessed the short-
term effects of IL-1Ra administration in mice. We had no indication that 12-week 
administration of IL-1Ra negatively influences insulin sensitivity. IL-1Ra treated ND mice 
showed similar insulin levels and insulin tolerance as the vehicle-treated controls. Moreover, 
under the high fat diet, IL-1Ra-mice had lower insulin levels than the control mice and 
improved insulin sensitivity. Possibly, the increased IL-1Ra serum levels in obese patients 
could be secondary in response to insulin resistance. 
Investigating the underlying mechanisms of IL-1Ra-mediated improved glucose-
stimulated insulin secretion in islets from the HFD-group, we found that IL-1Ra counteracted 
high fat diet-induced diminished insulin mRNA levels. Unexpectedly, PDX-1 mRNA levels 
were oppositely regulated to insulin levels, with increased PDX-1 levels induced by high fat 
feeding which were normalized in the IL-1Ra-treated HFD-group. The pancreatic duodenal 
homeobox PDX-1 is an important islet transcription factor, which controls the physiological 
expression of the insulin gene (69) and mediates the effects of glucose on insulin gene 
transcription (70; 71) as well as -cell survival (72). Our results are in contrast to previous 
data showing PDX-1 downregulation in response to hyperglycemia in -cells in culture (73) 
as well as in type 2 diabetic animal models, e.g. in ZDF rats (74), in psammomys obesus 
(75) and in partially pancreatectomized rats (76). However, studies with isolated islets from 
patients with T2DM have shown a similar opposite regulation, with reduced insulin mRNA in 
parallel to increased PDX-1 mRNA levels, compared to islets isolated from non-diabetic 
controls (77). Possibly, -cell functional compensation can occur through increased PDX-1 
mRNA. On the other hand, posttranslational changes, which define PDX-1 localization, rather 
than mRNA expression levels, may play a more important role under diabetic conditions (78). 
Upon acute exposure of -cells to glucose, PDX-1 translocates from the cytoplasm/nuclear 
periphery to the nucleoplasm, leading to insulin gene transcription (53). In contrast, oxidative 
stress induces PDX-1 shuttling from the nucleus to the cytosol, and thus causes severe 
The Potent Role of IL-1Ra to Prevent Diet-Induced Diabetes 63 
reduction of PDX-1 activity (52). In our study, we detected PDX-1 predominantly expressed 
in the cytosol of the HFD-group. In both control groups (ND, ND+IL-1Ra) as well as in the IL-
1Ra-treated HFD-group, PDX-1 was mostly localized in the nucleus. Since IL-1Ra protected 
from the pro-diabetic effect of the high fat diet, we propose that this is partly the result of 
maintaining PDX-1 functionally in the nucleus.  
We show that, besides oxidative stress (52) and the combination of palmitic acid and 
elevated glucose (79), chronic hyperglycemia as well as the cytokine IL-1 induce PDX-1 
nuclear export. In both conditions, IL-1Ra preserved nuclear PDX-1, in parallel to previously 
observed protection from -cell failure (17). In this study, we identify JNK as cellular 
component involved in glucose- and IL-1-regulated PDX-1 localization. In wildtype islets, 
JNK is phosphorylated after short-term (30min (data not shown) and 1 day) as well long-term 
(3 days) incubations with elevated glucose. Therefore, it seems that acute JNK-activation is 
beneficial for -cell function, whereas chronic activation correlates with glucotoxicity. 
However, IL-1Ra protected islets from prolonged JNK-activation. 
JNK-activity has previously been linked to PDX-1 shuttling under conditions of 
oxidative stress (52), together with Foxo1 as keyplayer (1). Foxo1 cellular localization 
determines PDX-1 localization, which is opposite to each other. Foxo1 itself is regulated by 
JNK and AKT-activity, JNK induces Foxo1 nuclear import, which leads to PDX-1 export, 
whereas AKT-mediated Foxo1 phosporylation results in Foxo1 cytoplasmic and PDX-1 
nuclear localization. Our findings suggest the JNK-PDX-1 pathway as critical signaling 
network which transduces short-term as well as long-term glucose stimulation and therefore 
might partly mediate the dual effect of glucose on -cells function and survival (Fig. 13).
 
The fact that IL-1Ra potentially prevented hyperglycemia and improved -cell function is in 
favor for the critical role of IL-1 signaling in the -cell not only in type 1 but also type 2 
diabetic environments. Our data provide new insights into mechanisms of the protective 
effect of IL-1Ra on -cell function and turnover and support IL-1Ra as a potential therapy of 
diabetes. 
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Figure 13: Model of IL-1Ra-regulated PDX-1 shuttling. 
Extracellular signals lead to JNK phosphorylation and activation. As a consequence, pFoxo gets dephosphorylated and 
translocates into the nucleus. This results in export of PDX-1 from the nucleus to the cytoplasm. Foxo and PDX-1 are 
hypothesized to always be localized opposite to eachother, by a mechanism that might include direct protein-protein 
interactions (1). PDX-1 is a transcription factor that activates expression of genes such as insulin, glucokinase and 
glucosetransporter 2. It has also been shown to regulate its own expression. 
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5.  INHIBITION OF ERK1/2-ACTIVATION IS RESPONSIBLE 
FOR GLUCOSE - DESENSITIZATION OF HUMAN 
PANCREATIC ISLETS 
 
A manuscript of this study will be submitted for publication. 
 
5.1 SUMMARY 
 
In type 2 diabetes, chronic overstimulation due to hyperglycemia is suggested to be 
detrimental to pancreatic -cell-function and survival, leading to the concepts of -cell 
desensitization and glucotoxicity. It has been shown that the mitogen-activated protein-
kinases ERK1/2 are activated by increased concentrations of glucose and that their 
activation is crucial for -cell function via activation of the insulin promoter. However, it is not 
known if chronic hyperglycemia affects ERK1/2 signaling in the -cell. The aim of the present 
study was to determine if glucose-induced -cell desensitization is associated with loss of 
ERK1/2 activity in order to find a target to protect from the deleterious effects of glucose on 
-cell function. 
Human islets were maintained in suspension culture for 3 days at 5.5, 11.1 or 33.3 
mM glucose with or without the addition of Diazoxide, Somatostatin or PD98059. After the 
incubation period, the islets were challenged with an additional short-term (30 minutes) 
glucose-incubation at 5.5 mM or 33.3 mM, respectively, to address their glucose 
responsiveness. ERK1/2-activation was measured using antibodies that selectively 
recognize the phosphorylated forms of the kinases. In parallel, insulin secretion into the 
culture medium was evaluated to assess -cell function. 
Human islets, maintained in culture at 5.5 mM glucose, showed a 3-fold glucose-
stimulated insulin secretion as well as a 5-fold stimulation of ERK1/2-phosphorylation. In 
contrast, islets cultured for three days at 11.1 or 33.3 mM glucose showed a competely 
abolished stimulatory index, together with a decrease in ERK-activation in response to a 
glucose challenge compared to control islets cultured at 5.5 mM glucose.  
We tested the hypothesis that inhibiting overstimulation would induce -cell rest and 
restore its function. Therefore, we co-incubated the islets with diazoxide or somatostatin 
during the three-day culture period, which almost completely inhibited insulin secretion. 
Subsequently, short-term glucose challenge for 30 minutes induced insulin secretion and 
western blot analysis showed that glucose was able to upregulate ERK1/2-phosphorylation. 
Finally, and in support of our results, we demonstrated that co-incubation of the islets 
with the ERK1/2 inhibitor PD98059 also prevented decreased ERK1/2-activation as well as 
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impaired stimulated insulin release after the additional glucose challenge, indicating that 
PD98059 induces -cell rest similar to Diazoxide.  
We conclude that chronic exposure of human islets to elevated glucose levels 
desensitizes the -cell to further glucose stimulation and inhibits ERK1/2-activation. Inhibition 
of -cell overstimulation, by blocking either insulin secretion or ERK1/2 phosphorylation 
during the chronic culture, restores glucose induced ERK1/2 activation together with -cell 
function. Our data provide a new mechanism of glucose desensitization.
 
 
 
 
5.2  INTRODUCTION 
 
Glucose is a key modulator of -cell function and survival that regulates an array of cellular 
signaling networks. In the short-term, glucose metabolism in the -cell itself generates a rise 
in the ATP to ADP ratio that results in closure of ATP-dependent potassium channels, 
followed by membrane depolarization and opening of voltage-operated Ca2+ channels. The 
consequent Ca2+-influx triggers insulin release by exocytosis of insulin-containing secretory 
granules. Despite this well-recognized mechanism, calcium entry has been reported to also 
activate various kinases in the -cells, including the extracellular signal-regulated protein 
kinases 1 and 2 (ERK1/2) (1; 2). In isolated islets, increasing glucose concentration markedly 
increases the levels of the phosphorylated forms of ERK1/2 (3). ERK1/2 are ubiquitous 
enzymes with many substrates that are involved in a variety of cellular events such as 
proliferation, differentiation and survival (4). Besides the calcium-dependent activation of 
ERK1/2 by glucose, insulin and growth factors regulate ERK1/2 in -cells in a largely 
calcium-independent manner (5). It has been shown that insulin transcription is dependent 
on ERK1/2 as blockade of ERK1/2-activity inhibited basal as well as glucose-stimulated 
insulin promoter activity (6). In addition to an involvement of ERK1/2 on glucose-stimulated 
insulin transcription, the kinases have also been implicated in the process of insulin 
secretion. Longuet et al. (7) showed that glucose-induced activated ERK1/2 remains to a 
large part in the cytoplasm. Therefore, phosphorylated ERK1/2 seems to exert other 
functions beside gene regulation in the nucleus. Indeed, blocking activation of ERK1/2 
resulted in partial inhibition of glucose-induced insulin release. Furthermore, cytoplasmic 
pERK1/2 interacts with synapsin I. Synapsin I phosphorylation by protein-kinase A (PKA) and 
calmodulin kinase II (CAMKII) has been linked to mediate glucose-induced insulin release (8; 
9). This interaction only occurred between synapsin I and the phosphorylated, active form of 
ERK1/2 and resulted in serine phosphorylation of synapsin I, implicating a participation of 
ERK1/2 in acute glucose-stimulated insulin secretion. 
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In contrast to short-term effects, chronically elevated glucose can lead to -cell 
desensitization. Desensitization is a temporary physiological state of cellular refractoriness to 
glucose stimulation that, in contrast to glucotoxicity, can be reversed after restoration of 
normal glucose concentrations. Parts of the toxic effects of hyperglycemia are thought to be 
due to chronically elevated intracellular Ca2+-concentrations. Inducing ‘-cell rest’ by 
potassium channel openers or calcium channel antagonist might therefore preserve -cell 
function in the presence of prolonged high glucose. Already in 1976, there was evidence that 
KATP channel openers may have protective effects on -cells since diabetic patients which 
received the KATP channel opener diazoxide for 7 days showed imroved insulin secretion 
(10). These findings were confirmed in more recent studies with type 1 (11) and type 2 (12) 
diabetic patients. Moreover, diazoxide also protected -cells in vitro from the deleterious 
effects of high glucose as well as IL-1 (13). Addition of diazoxide to the chronic culture 
medium prevented glucose- and IL-1-induced impaired function and apoptosis. 
Interestingly, blocking ERK1/2-activation by PD098059 also inhibited diminished function and 
increased -cell death. However, it is not known whether glucose desensitization after 
chronic hyperglycemia also affects the responsiveness of ERK1/2 to a short-term glucose 
challenge and whether restoration of -cell function after normalization of glucose 
concentrations also involves a recovered ability to phosphorylate and activate ERK1/2 in 
response to glucose. Therefore, we investigated basal and glucose-stimulated pERK1/2 
levels as well as insulin secretion into the supernatant of islets after chronic incubation in 
control and elevated glucose conditions with or without the addition of agents that inhibit 
insulin secretion or ERK1/2-activity.  
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5.3  EXPERIMENTAL PROCEDURES 
 
Islet isolation and culture. Human islets were isolated at the University of Illinois at 
Chicago as previously described (14). The islet purity was >95% as judged by dithizone 
staining. When this degree of purity was not primarly achieved by routine isolation, islets 
were handpicked. In all experiments, islets were pre-cultured for 24 hours after receiving the 
islets and before starting experiments. Groups of 100 human islets were cultured in 
suspension culture dishes in CMRL-1066 medium containing 5.5 mM glucose supplemented 
with 100 U/ml penicillin, 100µg/ml streptomycin and 10 % FCS (Invitrogen Ltd., Carlsbad, 
CA, USA), hereafter referred to as culture medium. After the preincubation time, the medium 
was changed to culture medium containing 5.5, 11.1 or 33.3 mM glucose with or without the 
addition of 100 µM Diazoxide (Sigma-Aldrich, St. Louis, MO, USA), 1 µM PD098059 
(Calbiochem, San Diego, CA, USA) or 50nM Somatostatin (Bachem, Torrance, CA, USA) for 
72 hours. For recovery experiments, medium was again changed to culture medium 
containing 5.5 mM glucose for an additional two days. 
 
Acute insulin release and ERK1/2 phosphorylation. For acute insulin release in response 
to glucose, islets were washed in Kreb’s Ringer bicarbonate buffer (KRB) containing 5.5 mM 
glucose and 0.5% BSA. KRB was then replaced by KRB 5.5 mM glucose (basal) or by KRB 
33.3 mM glucose (stimulated) for 30 minutes with or without the addition of 100 nM 
somatostatin (to investigate the influence of secreted insulin on ERK1/2 activation). Acute 
supernatants were collected and stored at –80°C until analysis for insulin concentration by 
human insulin ELISA (Dako, Carpinteria, CA, USA). Islet pellets were harvested for Luminex 
assays, Western blotting or RT-PCR quantification. 
 
Detection of Phosphoproteins. After the respective chronic and acute incubation periods, 
phosphoprotein levels in the islets were measured using Bio-Plex Luminex technology (Bio-
Rad Laboratories, Hercules, CA, USA), accoring to the manufacturer’s instructions. The 
premixed multiplex assays were designed to detect levels of phosphorylated GSK, ATF2, 
JNK, p38, ERK1/2, STAT3, IB, AKT. 
 
Western blot analysis. At the end of the chronic and acute incubation periods, islets were 
washed in ice-cold PBS and lysed for 40 minutes on ice in 40 µl lysis buffer containing 20 
mM Tris acetate, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50mM NaF, 1% Triton X-100, 5 
mM sodium pyrophosphate and 10 mM -glycerophosphate. Prior to use, the lysis buffer was 
supplemented with Protease- and Phosphatase-inhibitors (Pierce, Rockford, IL, USA). Equal 
amounts of protein of each treatment group were run on NuPAGE 4-12% Bis-Tris gels. 
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Proteins were electrically transferred to PVDF membranes. Blocking of non-specific protein 
binding was achieved by incubating the filter membrane in blocking buffer (1xTBS, 0.1% 
Tween-20, 5% BSA). After washing in 1xTBS, 0.1% Tween-20 (TBS-T), membranes were 
incubated with rabbit anti-phospho p44/42 MAP-kinase (Thr202/Tyr204) antibody overnight 
at 4°C followed by incubation with horseradish-peroxidase-linked anti-rabbit IgG. 
 
RNA extraction and quantitative RT-PCR analysis. Total RNA of isolated islets was 
extracted after overnight culture as described previously (15). For quantitative analysis, we 
used the LightCycler Quantitative PCR System (Roche) with a commercial kit (LightCycler 
FastStart DNA Master plus SYBR Green I, Roche). Human primers used were 
5’CTACCTAGTGTGCGGGGAAC3’ and 5’GCTGGTAGAGGGAGCAGATG3’ (Insulin) and 
compared to the house keeping gene 5’AGAGTCGCGCTGTAAGAAGC3’ and 
5’TGGTCTTGTCACTTGGCATC3’ (α-Tubulin). 
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5.4  RESULTS 
 
Chronically elevated glucose levels lead to loss of acute glucose-stimulated 
phosphorylation of ATF2 and ERK1/2. 
To investigate which proteins are affected by chronically elevated glucose levels, we cultured 
isolated human islets at 5.5 mM (control) or 33.3 mM glucose for 3 days. To address their 
glucose responsiveness after this incubation time, they were exposed to an additional short-
term glucose challenge for 30 minutes at basal (5.5 mM) or stimulated (33.3 mM) conditions, 
immediately followed by protein extraction. We then performed bead-based multiplex assays 
for several phosphoproteins. We found 3 proteins whose acute glucose-induced 
phosphorylation was diminished when islets were previously exposed to chronically high 
glucose: the transcription factor ATF2 (Fig.1A) and the kinases ERK1/2 (Fig.1B) and AKT 
(data not shown). Short-term glucose (30 minutes at 33.3 mM glucose) after 3-day culture 
under control conditions enhanced phosphorylation status of these proteins significantly 
compared to basal. There was no acute glucose-stimulated activation when islets were kept 
in elevated glucose concentrations of 33.3 mM for 72 hours. 
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Figure 1: Chronic hyperglycemia diminishes acute glucose-stimulated phosphorylation. 
Human islets were cultured in suspension dishes for 72 hours in 5.5 mM or 33.3 mM glucose, followed by an acute glucose 
incubation for 30 minutes at basal (5.5 mM) or stimulated (33.3 mM) conditions. Islet proteins were extracted and evaluated for 
phosphorylation levels of (A) ATF2 and (B) ERK1/2 using Luminex technology. Data show mean ± SE. *p<0.05 stimulated 
compared to basal phosphorylation. Analysis was performed in three experiments from three organ donors. 
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We confirmed these findings by Western blotting with a phospho-specific antibody that only 
recognizes ERK1/2-proteins that are phosphorylated at positions 202 (Thr) and 204 (Tyr). As 
seen in Fig. 2, following culture at 5.5 mM glucose, islets respond to a 30min glucose 
challenge with upregulating phospho-ERK1/2 levels (left panel), whereas chronic 
hyperglycemia (middle and right panel) abolishes acute ERK1/2-activation. 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibition of insulin secretion and ERK1/2-activity during chronic incubation restores 
acute ERK1/2-activation. 
To test the hypothesis that inhibiting overstimulation would induce -cell rest and protect 
function, we added diazoxide to the culture medium during the chronic period which inhibited 
insulin secretion. Subsequently, short-term high glucose was able to enhance ERK1/2-
phosphorylation compared to basal (Fig.3 second panel). Co-incubation with PD098059 
during the 3 days, an inhibitor of MEK1/2, also prevented decreased acute ERK1/2-
activation, indicating that ERK1/2 inhibition induces -cell rest comparable to Diazoxide 
(Fig.3, third panel).  
 
Acute ERK1/2-activation does not depend on secreted insulin. 
It has been shown that ERK1/2 can be activated by glucose and by insulin but through 
different pathways (reviewed in (5)). Hence we investigated whether pERK1/2-upregulation is 
a direct result of glucose-stimulation and or whether it depends on secreted insulin. In 
consequence, we added somatostatin to the islets during the chronic as well as during the 
acute period. In that, insulin secretion was prevented for the long-term culture and for the 30 
minutes stimulation time. Inhibiting insulin secretion had no effect on ERK1/2-activation 
(Fig.3, lowest panel). In islets cultured at 5.5 mM glucose, there is a still strong acute 
glucose-induced pERK1/2 signal despite abolished insulin secretion. In addition, in cells 
pERK1/2 
3 day culture 
Glucose (mM): 5.5mM 11.1mM 33.3mM 
30’ stimulation 
Glucose (mM): 5.5 5.5 5.5 33.3 33.3 33.3 
Figure 2: Chronically elevated glucose levels lead to loss of ERK1/2-activation after glucose challenge. 
Western blot analysis of pERK1/2. Human islets were cultured in suspensiond dishes for 72 hours at 5.5, 11.1 or 33.3 mM 
glucose, followed by acute 30 minutes stimulation with 5.5 or 33.3 mM glucose in KRB. One representative blot out of six 
experiments from six organ donors is shown. 
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treated with 11.1 mM glucose, we observed restoration of glucose-stimulated ERK1/2-activity 
showing independece between ERK-phosphorylation and secreted insulin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Desensitized islets cultured at 11.1mM glucose can regain acute glucose-stimulated 
ERK1/2 phosphorylation after recovery.  
Since glucose desensitization is a temporary state that can be reversed upon restoration of 
normoglycemia, we postulated that in parallel to glucose sensing, islets would also regain the 
ability to respond to glucose by activating ERK1/2. To test this hypothesis, after chronic 
incubation at 5.5, 11.1 or 33.3 mM glucose for 3 days, islets were cultured for another 2 days 
at 5.5 mM glucose to allow them to recover from chronic hyperglycemia before acute 
glucose-stimulation. 2 days under normal glucose concentrations restored acute ERK1/2 
phosphorylation in islets that were previously treated with 11.1 mM glucose for 3 days (Fig.4, 
middle panel). However, 2 days of recovery following chronic incubations at 33.3 mM was 
not able to reverse the adverse effects of glucose, as the islet cells did not upregulate active 
ERK1/2 in response to the glucose challenge (Fig.4, right panel).  
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Figure 3: Prevention of hyperglycemia-induced loss of acute ERK1/2-phosphorylation. 
Isolated human islets were cultured for 72 hours in suspension dishes at 5.5 or 11.1 mM glucose with or without the 
addition of 100 µM Diazoxide, 1 µM PD098059 or 50 nM somatostatin. Chronic incubation was followed by 30 minutes 
acute stimulation in KRB containing 5.5 mM or 33.3 mM glucose. For experiments investigating the influence of secreted 
insulin, somatostatin at a concentration of 100 nM was also added to the acute stimulation with KRB. Islet protein was 
extracted and equal amounts were analyzed by Western blotting for pERK1/2 levels. One representative experiment of four 
experiments from four organ donors is shown. 
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Glucose-stimulated acute ERK1/2-activation correlates with insulin secretion. 
We postulated that prevention of decreased glucose-stimulated ERK1/2 phosphorylation by 
inducing -cell rest would in parallel restore insulin secretion. To test this hypothesis, we 
measured secreted insulin in the supernatants of the above-described experiments (Figures 
2-4). As shown in Figure 5, human islets cultured in control conditions (5.5 mM glucose) 
increased their insulin secretion 2-3 fold in response to a glucose challenge. This increase 
was completely abolished when the islets were kept at 11.1 mM glucose for 72 hours. 
Addition of diazoxide or the ERK1/2-inhibitor PD098059 to the chronic culture medium 
containing 11.1 mM glucose, counteracted this effect as seen by a restored stimulation of 
insulin release induced by glucose which is consistent to restored ERK1/2 phosphorylation. 
As a control and as expected, adding somatostatin to the acute stimulation completely 
inhibited insulin secretion. Nevertheless, as shown by western blot (Fig.3), this does not 
affect glucose-induced ERK1/2-activation. In addition, recovery from 11.1 mM glucose not 
only resensitizes the islets for acute glucose-stimulated pERK upregulation (Fig.4) but also 
for stimulation of insulin secretion. 
 
Acute effects of glucose do not result in increased mature insulin RNA levels. 
Since it has been shown that acute glucose stimulates insulin transcription in a ERK1/2-
dependent manner (3; 6), we investigated mature insulin RNA levels in our experimental 
settings. Total RNA was isolated from human islets incubated at 5.5 mM or 11.1 mM glucose 
for 3 days, followed by stimulation at 5.5 (basal) or 11.1 (stimulated) mM glucose for 1 hour. 
RT-PCR revealed that there is no detectable change in insulin mRNA concentrations in 
response to glucose stimulation in islets previously cultured at 5.5 or 11.1 mM glucose. 
3-day culture 
Glucose (mM): 5.5 11.1 
30’ stimulation 
Glucose (mM): 5.5 33.3 
33.3 
5.5 33.3 5.5 33.3 
+ 2-day recovery 
at 5.5 mM 
Figure 4: Recovery of glucose-desensitized islets. 
Human islets were cultured in suspension dishes for 72 hours at 5.5, 11.1 or 33.3 mM glucose. Following this chronic 
incubation, islets were allowed to recover for an additional 2 days at 5.5 mM glucose before assessing acute glucose 
responsivness for 30 minutes at 5.5 or 33.3 mM glucose in KRB. Islet protein was extracted and analyzed by Western 
blotting for pERK1/2 levels. One representative blot from 3 experiments from 3 organ donors is shown. 
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Figure 5: Prevention of hyperglycemia-induced impaired GSIS. 
Human islets were cultured for 72 hours at 5.5 or 11.1 mM glucose with or without the addition of 100 µM Diazoxide, 1 µM 
PD098059 or 50 nM Somatostatin. This chronic incubation was followed by 30 minutes acute stimulation at 5.5 mM (basal) 
or 33.3 mM (stimulated) glucose with or without the addition of 100 nM somatostatin. Secreted insulin in the supernatant was 
measured using human insulin ELISA. Data show mean ± SE. *p<0.05 compared to control stimulated, +p<0.05 compared to    
stimulated levels after 3-day glucose treatment. 
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Figure 6: 1-hour glucose stimulation does not result in increased mature insulin mRNA expression. 
Total RNA was isolated from human islets that were cultured for 72 hours in 5.5 or 11.1 mM glucose, followed by a 1-hour 
glucose challenge at 5.5 (basal) or 33.3 mM (stimulated) glucose. In the LightCycler system, quantitative RT-PCR was 
performed for stimulated insulin gene expression relative to basal gene expression and insulin levels were normalized to 
tubulin. Data show mean ± SE of four experiments from four organ donors. 
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5.5  DISCUSSION 
 
The adverse effects that chronic hyperglycemia might have on -cells have been well 
described in regard to function and mass. In the present study, we idenfity the MAP-kinases 
ERK1/2 as keyplayer in the process of glucose desensitization. Supporting the concept that 
the ERK1/2 cascade is a significant regulator of glucose-dependent events, we demonstrate 
that -cell responsiveness correlates with the ability of glucose to upregulate pERK1/2. After 
prolonged elevated glucose concentrations, human islets do not respond to an acute glucose 
challenge as observed by abolished stimulated insulin secretion in parallel to inhibited 
ERK1/2-activation. 
The potent role of potassium channel openers to protect from high glucose-induced 
impaired function and apoptosis have been addressed in vitro and in vivo in diabetic patients 
(10-13). Our data confirm these findings as addition of Diazoxide during the chronic 
incubation period counteracted glucose-induced -cell dysfunction. We demonstrate that 
impaired function paralles diminished glucose-induced ERK1/2 activation, both of which are 
restored by Diazoxide. In addition, we found that ERK1/2 also mediates the adverse effects 
of prolonged elevated glucose levels, as ERK1/2-inhibition by PD098059 during the chronic 
period blocked these effects which resulted in restored stimulated insulin secretion together 
with acute ERK1/2-activation. The similarities of the effects of Diazoxide and PD098059 
suggest that ERK1/2-inhibition induces -cell rest comparable to Diazoxide. By adding 
somatostatin to the chronic as well as to the acute medium, we confirmed our hypothesis that 
the observed effects are due to glucose directly affecting -cells and therefore independent 
of secreted insulin.  
Glucose desensitization is a temporary state of cellular refractoriness (16) that can be 
reversed upon restoration of normoglycemia, which stands in contrast to glucotoxicity where 
-cell damage is potentially irreversible. In our experimental settings, we found that elevated 
glucose levels of 11.1 mM for 3 days induces glucose desensitization of human islets, since 
an additional 2 days at control conditions of 5.5 mM led to their recovery as assessed by 
restored glucose-stimulated insulin secretion together with ERK1/2-activation. However, 
rising glucose concentrations to supraphysiological 33.3 mM during the chronic period seems 
to result in glucotoxicity as the islets did not recover ERK1/2-upregulation, showing that, 
besides culture time, glucose concentrations also play a crucial role in the outcome.  
The fact that we did not observe any acute, detectable changes in insulin mRNA 
levels is in line with a recent study by Evans-Molina et al. (17). The authors investigated the 
abundance and half-lives of insulin mRNA and pre-mRNAs and found that only pre-mRNA 
species that contain intron-2 reflect acute changes since they are relatively rare compared to 
the others and have a short half-life of ∼ 60 minutes. Increase in mature (total) mRNA did not 
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occur before 48 hours. This seems to be controversial to the findings that acute glucose 
stimulates insulin gene transcription in an ERK1/2-dependent manner (3; 6). However, these 
studies were done using an insulin-promoter-luciferase construct. In addition, Evans-Molina 
et al. confirmed that glucose does rapidly increase insulin gene transcritption as they 
observed increased H4 acetylation and RNA polymerase II recruitment 30 minutes after 
glucose stimulation. Nonetheless, measurable increases in pre-mRNA are delayed by 60 
minutes and mature mRNA by 48 hours. 
In conclusion, these data suggest that glucose-mediated adverse effects are 
dependent on ERK1/2-activity and imply ERK1/2 as mediator of -cell responses to short- as 
well as long-term incubations with elevated glucose. ERK1/2 might therefore be a promising 
novel therapeutic target to preserve -cell function in diabetes. 
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6.  CONCLUSION 
 
Increasing evidence indicates that there is a progressive deterioration in -cell function and 
mass underlying the development of type 2 diabetes. Research with isolated islets over the 
past decade identified glucose itself as key physiological regulator of -cells. It is not only the 
main stimulus of insulin secretion but it also modulates -cell turnover in order to adapt to the 
body’s insulin demand. However, it has also been recognized as one of the main contributors 
leading to -cell failure and death. Specifically, chronic stimulation due to prolonged elevated 
glucose levels are detrimental for -cell survival and insulin release. These deleterious 
effects are described with the term ‘glucotoxicity’ and have important consequences in 
regard to the occurrence of hyperglycemia in type 2 diabetic patients as well as individuals at 
risk to develop the disease. It suggests that even slightly elevated blood glucose levels or 
transient postprandial glycemic excursions might have a negative impact on -cells. 
Understanding mechanisms and identifying components involved in glucose-induced -cell 
destruction have been a focus in the search for a therapy for diabetes and have also been 
investigated in the course of this work. 
Low levels of circulating inflammatory mediators secreted by the adipose tissue have 
been associated with obesity and type 2 diabetes, indicating that the immune system is 
involved in the pathogenesis of this disease. The pro-inflammatory cytokine IL-1 has been 
characterized as contributer to the steady loss of -cells as its expression has been detected 
in pancreata from type 2 diabetic patients but not in control subjects. Indeed, this local 
upregulation in islets is a result of high glucose-induced production and secretion of IL-1 by 
-cell themselves which in turn leads to a decline in mass and function, thereby further 
disturbing glycemic control and fueling a vivicious cycle. The anti-inflammatory cytokine IL-
1Ra has been studied in vitro and in vivo in regard to its effectivness to inhibit IL-1-mediated 
effects. IL-1Ra is a naturally occuring antagonist to IL-1 that competitively binds to the same 
receptor without activating a signaling cascade. It protects human and rodent islets from 
glucose- and IL-1-induced functional impairment and apoptosis and improves glycemic 
control in patients with type 2 diabetes. Our study aimed to investigate the ability of IL-1Ra to 
prevent diet-induced diabetes and elucidate underlying mechanisms. 12 weeks of high fat/ 
high surcrose diet (HFD) in wildtype C57BL/6J-mice significantly raised fasting and fed blood 
glucose levels, a development that was prevented by concomitant, daily IL-1Ra-
administration. Intraperitoneal glucose tolerance tests revealed that IL-1Ra also counteracted 
HFD-induced impairement of glucose clearance. Our data demonstrate that this is a result of 
the combination of enhanced insulin secretion together with improved insulin action. 
Examining pancreatic sections and isolated islets from all four treatment groups showed that 
IL-1Ra induced proliferation in animals under the normal diet group and prevented HFD-
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induced apoptosis in cultured islets. Decreased -cell function as a result of high fat feeding 
correlated with decreased insulin mRNA levels, both of which were inhibited in the IL-1Ra-
treated HFD-group. We found that reduced insulin gene transcription might be due to HFD-
induced nuclear export of the insulin transcription factor PDX-1. Improved -cell function in 
animals from the HFD-group that received IL-1Ra is associated with nuclear PDX-1 
localization comparable to ND-animals. Importantly, our study confirmed a glucose-/ IL-1-
mediated regulation of PDX-1 shuttling in human islets that is counteracted by IL-1Ra, and 
identified JNK as intermediate factor, providing new insights into how hyperglycemia may 
directly affect -cell function. Besides the immediate effects of IL-1Ra on -cells, we provide 
evidence that treatment partly prevents sub-clinical systemic inflammation which in turn 
might contribute to the benefical outcome in regard to -cell function. IL-1Ra inhibited HFD-
induced increased serum levels of the adipokines leptin and resistin as well as of free fatty 
acids, triglycerides and cholesterol. Analysis of adipose tissue revealed decreased 
macrophage infiltration and activation as compared to untreated HFD-animals. Our data 
support the findings that IL-1 plays a critical role in the development of type 2 diabetes and 
further examines the potency of IL-1Ra as therapy for this disease. 
Research has revealed several extra- and intracellular factors that mediate the dual 
role of glucose on -cell function and survival and whose precise and directed modulation 
might switch a toxic signal into a benefical outcome. Among these factors are the protein-
kinases ERK1/2. Acute glucose-induced activation leads to insulin gene transcription and 
insulin secretion, both processes that are partly abolished when ERK1/2-activity is blocked. 
In contrast, prolonged ERK1/2 phosphorylation is responsible for adverse effects including 
impaired function and apoptosis. The results of the second project demonstrate that 
hyperglycemia-induced impaired glucose-stimulated insulin secretion correlates with 
diminished phospho-ERK1/2 upregulation. Inhibiting overstimulation during chronic 
incubations restores glucose-induced ERK1/2-activation together with -cell function. 
Interestingly, -cell rest can thereby be achieved by preventing insulin secretion as well as by 
inhibiting prolonged ERK1/2-activity. Hence, ERK1/2 function as mediators of -cell 
responses to short- as well as long-term stimulation with glucose and constitutes a possible 
target for therapeutic interventions that would switch a toxic into a benefical outcome. 
Hyperglycemia, which is the biochemical hallmark of type 2 diabetes, mainly results 
from a defect in the appropriateness of insulin secretion that occurs together with insulin 
resistance. Increasing evidence suggests that an impairement of -cell function precedes 
diabetes by several years. The progressive decline in -cell performance in turn may partly 
be attributed to prevailing elevated blood glucose concentrations. Hence, therapeutic 
interventions, which are designed to prevent hyperglycemia-induced alterations in -cells, 
are desired since they are considered to have a high impact on the survival of functional -
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cells. The findings of the present work underscore the importance of two factors, IL-1Ra and 
ERK1/2, by elucidating their role in mediating and modulating the adverse effects of glucose 
and by characterizing their potential as therapeutic targets.  
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7.1.3  TCF7L2 Regulates -Cell Survival and Function in Human Pancreatic 
Islets. 
Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Butler PC, Oberholzer J, Maedler 
K. 
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7.1.4  IP-10 is Produced by Human Pancreatic Islets in Type 2 Diabetes and 
Impairs -Cell Function and Viability through TLR4 Signaling. 
Schulthess FT, Sauter NS, Ribaux P, Haataja L, Strieter RM, Rizza RA, Oberholzer 
J, King CC, Maedler K. 
Manuscript submitted 
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Summary 
 
In both, type 1 (T1DM) and type 2 diabetes (T2DM), β-cell destruction by apoptosis results in 
decreased β−cell mass and progression of the disease. We hypothesize that pro-
inflammatory cytokines and chemokines contribute to the etiology. In the present study, we 
found that the Interferon-gamma-inducible Protein-10 (IP-10/CXCL10) plays a role in the 
progression of diabetes triggering impaired β-cell function and destruction. 
Islets isolated from patients with T2DM secreted IP-10 and contained 33.5-fold more IP-10 
mRNA than islets from control patients. Pancreatic sections from patients with T2DM and 
T1DM were found to express IP-10 in the β-cells. 
Treatment of isolated human islets with recombinant human IP-10 induced β-cell 
proliferation and increased beta-cell apoptosis. Quantitatively, this resulted in a decrease in 
beta-cell viability. IP-10 induced changes in beta-cell turnover were accompanied by 
impaired glucose stimulated insulin secretion (GSIS) and decreased insulin mRNA. IP-10 
induced rapid and sustained activation of Akt and JNK and downstream cleavage of p21-
activated protein kinase 2 (PAK-2), switching Akt signals from proliferation to apoptosis. This 
was mediated through TLR4 signaling. Our data suggest that secretion of IP-10 by the β-cell 
in diabetes causes impaired β-cell function and survival. 
 
Introduction 
 
The ability of the β-cells to secrete adequate amounts of insulin to maintain normoglycemia 
depends on their function and mass. In both, type 1 and type 2 diabetes, the major 
mechanism leading to the decreased -cell mass is increased -cell apoptosis (1-3). In type 
1 diabetes (T1DM), -cell destruction occurs through immune mediated processes; 
mononuclear cell infiltration in the pancreatic islets and interaction between antigen 
presenting cells and T-cells leads to high local concentrations of inflammatory cytokines, 
chemokines, reactive oxygen species (ROS) and other inflammatory products (4; 5). 
Type 2 diabetes (T2DM) occurs when β-cells fail to compensate adequately to increased 
insulin demand, most commonly as a consequence of obesity (6). The decline in -cell 
function is accompanied by a deficit in -cell mass. Several mechanisms have been 
postulated to contribute to increased -cell apoptosis in T2DM. These include endoplasmic 
reticulum (ER) stress, hyperglycemia, hyperlipidemia, oxidative stress, islet amyloid 
polypeptide (IAPP) oligomers and activation of pro-inflammatory cytokines (7-10). 
The role of inflammation in the pathogenesis of T2DM is supported by several recent 
prospective studies. Inflammatory markers are found in obesity, insulin resistance and 
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diabetes and link the pathology of the metabolic diseases (11). Low-grade inflammation and 
activation of the innate immune system can lead to -cell failure in T2DM (12). Although the 
markers of immune activation are below the levels of acute inflammation, there are 
increases in acute phase proteins such as CRP and factors associated with endothelial 
activation including ICAM, VCAM and t-PA, cytokines (IL-1β, IL-6, TNFα) and chemokines, 
e.g. RANTES, MCP-1, IL-8 and IP-10 (13-15). Elevated cytokine levels lead to impaired -
cell survival and function, shown in numerous publications (16; 17).  
Interferon-γ-inducible protein IP-10, also known as chemokine (C-X-C motif) ligand 10 
(CXCL10), is a 10-kDa secreted protein produced in a variety of cells including endothelial 
cells, monocytes, fibroblasts and keratinocytes (18). 
Increased levels of IP-10 have been detected in the serum of patients with T1DM (19; 20) 
and in patients with high risk for developing T1DM (19) as well as T2DM (13; 15). A recent 
report also found elevated IP-10 levels in serum of patients with T2DM (21). In animal 
models, β-cells secrete IP-10 during insulitis (22-25) and isolated human islets produce IP-
10 in response to IFN-γ  (25). Inhibition of IP-10 delayed immune mediated diabetes by 
suppression of insulitis and permitting β-cell proliferation (22). Furthermore, in mice deficient 
for the IP-10 receptor CXCR3, T-cell mediated diabetes is substantially delayed (24). 
Collectively these studies imply that IP-10 is important in mediation of -cell apoptosis in 
T1DM and a potential candidate in T2DM. In order to address this possibility we first posed 
the question, is IP-10 expression increased in the islet in T1DM and T2DM? Having affirmed 
that postulate we investigated, if increased IP-10 expression in the islet in T2DM is 
secondary to most common metabolic milieu in T2DM, specifically increased glucose or fatty 
acid concentrations. Since the answer is negative, we further postulate that the expression 
of IP-10 may be a primary event in the evolution of -cell dysfunction in T2DM. We therefore 
finally examined the effects of IP-10 on -cell function and viability in human islets and the 
underlying mechanisms. 
 
Materials and Methods 
 
Animals. Ethical approval for mouse studies was granted by the UCLA Chancellor's Animal 
Research Committee in agreement to NIH animal care guidelines. C57BL/6J wild-type mice 
and TLR4 knockout mice (C57BL/10ScCr) were obtained from Jackson Laboratory (Bar 
Harbor, ME). Homozygous CXCR3 on a C57BL/6J background, produced by gene targeting 
as described previously (26), were kindly provided by Dr. Craig Gerard, Perlmutter 
Laboratory, Children’s Hospital and Harvard Medical School, Boston, were. Animals were 
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housed at 22°C with a 12-h light-dark cycle (lights on at 07:00) and allowed free access to 
water and chow. 
Islet isolation and culture. Human islets were isolated from pancreata of eleven healthy 
organ donors and three with T2DM at the University of Illinois at Chicago, the University 
Hospital of Zurich and the Diabetes Institute for Immunology and Transplantation, University 
of Minnesota as described previously (27). The islet purity was >95%, as judged by dithizone 
staining. When this degree of purity was not primarily achieved by routine isolation, islets 
were handpicked. To include only functional human islets for the study, islet quality was 
assessed by performing glucose stimulated insulin secretion and double staining of islets for 
apoptosis by the TUNEL assay and insulin after overnight incubation. Human islets from 
three isolations were purified into single -cells and cultured as described (28). Mouse islets 
were isolated by bile duct perfusion and collagenase digestion as described (29). In all 
experiments, islets were pre-cultured for 24 hours after the isolation before the experiment. 
The islets were cultured on matrix-coated plates derived from bovine corneal endothelial 
cells (Novamed Ltd., Jerusalem, Israel), allowing the cells to attach to the dishes and spread 
(30) or in suspension culture dishes. Human islets were cultured in CMRL 1066 medium 
containing 5.5 mM glucose and mouse islets in RPMI 1640 medium containing 11.1 mM 
glucose, both supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin and 10% FCS 
(Invitrogen Ltd., Carlsbad, CA), hereafter referred to as culture medium. Two days after 
plating, when most islets were attached and began to flatten, the medium was changed to 
culture medium containing 5.5 or 33.3 mM glucose with or without 0.1 ng/ml or 50 ng/ml 
recombinant human or mouse IP-10, 0.1 ng/ml or 50 ng/ml recombinant I-TAC, 50 ng/ml or 
500 ng/ml Mig, 2 ng/ml recombinant human IL-1β, 1,000 U/ml recombinant IFN-γ, 100 U/ml 
TNF- (all R&D Systems Inc., Minneapolis, MN), 100 nM Wortmannin, 50 µM LY294002 
(Cell signaling, Beverly, MA), adenoviruses for dominant negative MyD88m (100 MOI, kindly 
provided by Professor Brian Foxwell, Imperial College, London, UK) or , 100 MOI of 
luciferase-control viruses (kindly provided by Dr Alan Karlson, Novo Nordisc), 5, 20 or 40 µM 
human islet amyloid polypeptide (h-IAPP, as described previously (31)), 100 ng/ml LPS or 
fatty acids (Sigma Chemical, St. Louis, MO; 0.5 mM palmitate or 0.5 mM palmitate plus 0.5 
mM oleate). Fatty acids were dissolved at 10 mM in culture medium containing 11% fatty 
acid–free BSA (Sigma) under N2-atmosphere, shaken overnight at 37°C, sonicated 15 
minutes, and sterile-filtrated (stock solution) (32). For control experiments, BSA in the 
absence of fatty acids was prepared, as described above. Male Wistar rat islets were 
isolated and -cells were sorted as described previously (33). -cells were allowed to spread 
for 24h on 804G-extracellular matrix (34) and treated with or without 50 ng/ml of IP-10 for 
24h. 
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CXCR3 neutralization. Isolated mouse islets were pre-cultured 1 hour prior to IP-10 
treatment (0.1 ng/ml recombinant mouse IP-10) with an antagonistic goat anti-mouse 
CXCR3 antibody (10 µg/ml), which has been previously demonstrated a specific neutralizing 
capacity against mouse IP-10 (35). Control islets were treated with goat serum at the same 
concentration. 
Neutralization of human IP-10.
 The recombinant hIP-10 neutralizing antibody (R&D 
Systems Inc., Minneapolis, MN) was used at 2 µg/ml. 50 ng/ml recombinant hIP-10 was 
incubated with the antibody for 30 minutes at room temperature. Following this pre-
incubation period, the cytokine-antibody solution was added to isolated human islets and 
incubated for 4 days. Control islets were incubated with the antibody only. 
Measurement of IP-10 release. IP-10 secretion into culture media of isolated islets from 
healthy and organ donors with T2DM was assessed with a Human Cytokine/Chemokine 
LINCOplex Kit (Linco Research, Inc., St. Charles, MO) according to the manufacturer’s 
instructions. 
Measurement of changes in intracellular Ca2+ concentration.
 INS-1 cells were seeded on 
Fluoro-dishes with Cover glass bottom (WPI, Sarasota, FL) and cultured overnight in RPMI 
1640 medium containing 3 mM glucose without FCS. Cells were then loaded with 2.5 µM 
Fluo-3 AM by incubation for 30 min. in Krebs-Ringer bicarbonate buffer (KRB) buffer. After 
washing, intracellular Ca2+ was assayed after single stimulation with I-TAC or Mig. or 20 mM 
glucose (+control) in a perfusion chamber (370C, supplied with 95% air and 5% CO2) onto 
the stage of a laser confocal microscope (DMIRE2; Leica, Dearfield, IL). Fluo-3 was excited 
with 488 nm light supplied by an argon. The images with 630x magnification were acquired 
using a CCD camera (Hamamatsu Photonics, Hamamatsu City, Japan) and Volocity 
software (McBain Instruments, Chatsworth, CA). 
β-cell apoptosis and replication. After washing with PBS, islets were fixed with 4% 
paraformaldehyde followed by permeabilisation with 0.5% Triton X-100. To quantify 
apoptosis, the free 3’-OH strand breaks resulting from DNA degradation were detected by 
the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) 
technique according to the manufacturer’s instructions (In Situ Cell Death Detection Kit, AP; 
Roche Diagnostics, Indianapolis, IN). For -cell proliferation studies, a monoclonal antibody 
against the human Ki-67 antigen was used (Zymed, San Francisco, CA), followed by 
detection using the streptavidin-biotin-peroxidase complex. Subsequently, islets were 
incubated for 40 minutes at 37°C with a guinea pig anti-insulin antibody (Dako, Carpinteria, 
CA), followed by detection using either the fluorescein-conjugated rabbit anti-guinea pig 
antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) or the streptavidin-
biotin-peroxidase complex. 
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MTT assay.
 The MTT colometric assay (In Vitro Toxicology Assay Kit, Sigma, St Louis, MO) 
was performed to assess cell viability according to manufacturer’s instructions. Rat 
insulinoma (RIN) cells, were seeded on a 96-well plate at 2.0 x 104 cells/well. The next day, 
the medium was replaced with fresh medium containing recombinant human IP-10 (0.1 and 
50 ng/ml) or vehicle. Four days later, the cells were incubated for three hours in the 
presence of 1 mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) in 
RPMI culture media without phenol red. Mitochondrial dehyrogenase activity reduced the 
yellow MTT dye to a purple formazan, which was then solubilized with acidified isopropanol 
and absorbance was read at 570 nm with an ELISA plate reader. (Spectramax 250; 
Molecular Devices, Sunnyvale, CA). The background wavelength at 690 nm was substracted 
from the 570-nm measurement. 
Immunohistochemistry. Islets were cultured in suspension and washed with PBS. Islets 
were fixed in Bouin’s solution for 15 minutes and resuspended in 2% melted agarose in 
PBS, followed by short centrifugation and paraffin embedding. Human pancreatic tissue was 
obtained at autopsy from nondiabetic subjects (all with fasting plasma glucose <110 mg/dl, 
age 65±13, BMI 25±6), from patients with T2DM (poorly controlled type 2 diabetic patients, 
all with documented fasting plasma glucose >145 mg/dl, age 72±10, BMI 27±2). Autopsies 
were taken within 12 hours of death. Patients had no chronic glucocorticoid treatment, no 
signs of autolysis or pancreatitis were detected in the pancreas. A pancreas biopsy was 
obtained from an 89-year old newly T1DM diagnosed patient (with random blood glucose of 
349 mg/dl, details were described recently (36)). 
Islet and pancreatic sections were deparafinized in toluene, rehydrated in grades of alcohol, 
and washed in H20. Slides were exposed to antigen-retrieval using antigen unmasking buffer 
according to the manufacturer’s instructions (Vector Laboratories, Inc. Burlingame, CA). 
After antigen unmasking, the sections were cooled to room temperature, permabilized in 
0.4% Triton X-100/TBS for 30 minutes, and blocked with 0.2% Tween 20/3% IgG-free 
BSA/2% Triton X-100/TBS. Primary antibodies were diluted in the blocking solution and the 
following dilutions: mouse anti-IP-10, 1:50; mouse anti-CXCR3, 1:100 (R&D Systems Inc.); 
guinea pig anti-insulin, 1:100 (Dako, Carpinteria, CA); rabbit anti-glucagon, 1:500 
(Immunostar Inc., Hudson, WI); rabbit anti-somatostatin, 1:100; rabbit anti-CD3, 1:100 
(Dako, Carpinteria, CA); rabbit anti-caspase-3, 1:50 (cleaved, Biocare medical, Concord, 
CA); rabbit anti-synaptophysin, 1:200; rabbit anti-chromogranin A, 1:250 (Chemicon, 
Temecula, CA). Donkey anti-mouse, anti-guinea pig or anti-rabbit derived secondary 
Antibodies conjugated to FITC or Cy3 were used at dilutions of 1:100 (Jackson 
ImmunoResearch Laboratories Inc.). Sections and cells were embedded in glycerol gelatin 
(Sigma) or Vectashield mounting media (Vector Laboratories, Inc. Burlingame, CA), which 
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visualized all cells by DAPI staining. Fluorescent slides were analyzed using a Leica DM600 
microscope and images acquired using Openlab software. 
Western blot analysis. Islets were maintained in culture in suspension in non-adherent 
plastic dishes in supplemented CMRL 1066 medium as described above. Two days after 
plating, medium was changed and groups of 150 islets were incubated in culture medium. At 
the end of the incubation, islets were washed in PBS and lysed for 40 minutes on ice in 40 µl 
lysis buffer containing 20 mM Tris acetate, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50 
mM NaF, 1% Triton X-100, 5 mM sodium pyrophosphate and 10 mM β-glycerophosphate. 
Prior to use, the lysis buffer was supplemented with Protease - and Phosphatase – Inhibitors 
(Pierce, Rockford, IL). Equal amounts of protein of each treatment group were run on 
NuPAGE 4-12% Bis-Tris gels. Proteins were electrically transferred to PVDF filters and 
incubated with rabbit anti-phospho-Akt Ser473 (#9271), rabbit anti-Akt (#9272), rabbit anti-
caspase-3 (#9961), rabbit anti-phospho-JNK Thr183/Tyr185, rabbit anti- JNK (#9252), rabbit 
anti-actin (#4967) (all from Cell signaling, Beverly, MA), rabbit anti-αPAK-2 (C-19, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) followed by incubation with horseradish-
peroxidase-linked anti-rabbit IgG peroxidase. The emitted light was captured on X-ray film 
after adding Immun-Star HRP Substrate (Bio-rad Laboratories, Inc.). As a positive control for 
cleaved PAK-2, we used Hamster Ovary Cells (CHO), cultured for 45 min at 44°C as 
described previously (37). 
Protein Pull-down Assay.
 Dynabeads® M-270 Epoxy (Invitrogen) were coated with 
recombinant human IP-10 (R&D Systems Inc., Minneapolis, MN) for 20 hrs at 37°C with slow 
tilt rotation prior to incubation with the human islet cell lysates. After washing with PBS + 
0.2% BSA, human islet cell lysates were added to the beads and incubated with tilting and 
rotation for 1 hour. Bound proteins were eluted in Laemmli buffer for SDS-PAGE. Whole cell 
lysates from cultured islets, eluted samples as well as follow-throughs were electrically 
transferred to polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, Inc.) 
and incubated with rabbit anti-TLR-4 (H-80, Santa Cruz Biotechnology, Santa Cruz, CA), 
rabbit anti-CCR3 (H-52, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-CCR5 
(eBioscience, San Diego, CA), rabbit anti-GPR1 (MBL, Woburn, MA) and biotinylated anti-
IP-10 (R&D Systems Inc., Minneapolis, MN, to control for IP-10 binding to the beads) 
followed by incubation with horseradish-peroxidase-linked anti-rabbit or peroxidase-
conjugated Streptavidin.  
RNA extraction and quantitative reverse transcription-PCR (RT-PCR). Total RNA was 
isolated from the cultured islets as described previously (38). For quantitative analysis, we 
used the Light Cycler quantitative PCR system (Roche Diagnostics, Indianapolis, IN) with a 
commercial kit (Light Cycler-DNA Master SYBR Green I; Roche). Human primers used were 
Appendix: Published Studies  129 
5’CTTCCAAGGATGGACCACAC3’ and 5’AGCAGGGTCAGAACATCCAC3’ (IP-10), 
5’GCTTTGACCGCTACCTGAAC3’ and 5’ATGTGGGCATAGCAGTAGGC3’ (CXCR3), 
5’CTGGGAGTTGTTCACTGGGT3’ and 5’GGATGGGGTTCAAGCAACTA3’ (GPR1), 
5’TCCTTCTCTCTTCCTATCAATC3' and 5’GGCAATTTTCTGCATCTG3’ (CCR3), 
5’TTCATTACACCTGCAGCTCTCATTT3’ and 5’TCACAGCCCTGTGCCTCTTCT3’ (CCR5), 
5’AAGCCGAAAGGTGATTGTTG3’ and 5’CTGAGCAGGGTCTTCTCCAC3’ (TLR4), 
5’CTACCTAGTGTGCGGGGAAC3’ and 5’GCTGGTAGAGGGAGCAGATG3’ (Insulin) and 
compared to the house keeping gene 5’AGAGTCGCGCTGTAAGAAGC3’ and 
5’TGGTCTTGTCACTTGGCATC3’ (α-Tubulin) and 
5’TCACCCACACTGTGCCCATCTACGA3’ and 5'CAGCGGAACCGCTCATTGCCA 
ATGG3’ (β-actin). 
Small interfering RNA.
 A knock down of TLR4 protein levels was carried out using the 
small interfering RNA (siRNA) technique. SiRNA-Lipofectamine2000 complexes were 
prepared according to the manufacturer’s instructions (Liptofectamine2000; invitrogen) using 
50 nM siRNA to TLR4 (RNAs of 25 nucleotides, designed to target human TLR4; Stealth 
SelectTM RNAi, invitrogen) and scramble siRNA (Ambion, Austin, TE). After 8 h overnight 
incubation, the transfection medium was aspirated and replaced by fresh culture medium 
with or without IP-10. To monitor transfection efficiency of siRNA into the islets, we 
transfected fluorescein labeled non-targeted siRNA (Cell signaling, Beverly, MA) and 
analyzed transfection under the fluorescent microscope during for 4 days of culture. 
Glucose-stimulated insulin secretion (GSIS). For acute insulin release in response to 
glucose, islets were washed and preincubated (30 min) in KRB containing 2.8 mM glucose. 
The KRB was then replaced by KRB containing 2.8 mM glucose for 1 h (basal), followed by 
additional 1 h incubation in KRB containing 16.7 mM glucose. Islets were extracted with 0.18 
N HCI in 70% ethanol for determination of insulin content. Insulin was determined using a 
human insulin ELISA kit (Dako, Carpinteria, CA) or a mouse insulin ELISA kit (Alpco, 
Windham, NH). 
Statistical analysis.
 Samples were evaluated in a randomized manner by a single 
investigator (F.T.S.) who was blinded to the treatment conditions. Data are presented as 
means +/- SE and were analyzed by paired, Student’s t test or by analysis of variance with a 
Bonferroni correction for multiple group comparisons. 
 
 
 
 
 
130 Appendix: Published Studies 
Results 
 
IP-10 is expressed and secreted in isolated pancreatic islets from organ donors with 
T2DM 
Healthy human islets neither secreted nor expressed IP-10 (Fig. 1A, 1B panel 1). In contrast, 
human isolated islets from organ donors with T2DM secreted 65.62 ± 14.6 pg/ml/20 islets 
within 24 hours, which was accumulated after 96 hours (196 ± 58 pg/ml/20 islets; Fig. 1A, 
p<0.001 vs. control islets). As a positive control for IP-10 secretion we incubated healthy 
islets in the presence of the cytokine IFN- (1000 U/ml). These islets secreted 999.1 ± 127.2 
pg/ml IP-10/20 islets into the culture medium during the 24-hour culture period. 
The expression of IP-10 mRNA by T2DM islets was confirmed by quantitative RT-PCR 
demonstrating a 33.5-fold increase compared to healthy controls (p<0.05, Fig. 1C). We also 
investigated the islet cellular localization of IP-10 in pancreatic sections obtained at autopsy 
from eight poorly controlled type 2 diabetic patients, all with documented fasting plasma 
glucose >145 mg/dl as well as from one pancreas biopsy obtained from a patient newly 
diagnosed with T1DM. Double immunostaining for IP-10 in red (Fig.1B panel 1,3,5) and 
insulin in green (Fig.1B panel 2,4,6) revealed the presence of IP-10 localized in the β-cells in 
human pancreatic sections from patients with T2DM (Fig.1B panel 3,4) and T1DM (Fig.1B 
panel 5,6), but not in non-diabetic controls (Fig.1B panel 1,2). The duration of T2DM in the 
different patients ranged from 1-26 years (table 1), and we did not detect differences in IP-10 
expression among them. IP-10 was absent in α and δ cells, as assessed by double 
immunostaining with anti-IP-10 and anti-glucagon or anti-somatostatin antibodies, 
respectively in controls, T1DM or T2DM (data not shown). IP-10 was also undetectable in 
exocrine tissue. Isolated human islets exposed to IFN-γ stained positive for IP-10 (data not 
shown). 
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Figure 1-1. IP-10 is increased in islets from patients with T2DM. 
(A) IP-10 secretion from isolated human pancreatic islets from five healthy control donors and three donors with 
T2DM cultured on extra- cellular matrix-coated dishes for 24 or 96 hours at 5.5 mM glucose (left) with or without 
addition of 1000 U/ml IFN- (right). (B) Double/ triple immunostaining for IP-10 in red (1,3,5) and insulin in green 
(2,4,6) and DAPI in blue in pancreatic tissue sections from a representative non-diabetic control (1,2) and from a 
patient with T2DM (3,4) or T1DM (5,6). (magnification x200). (C) RT-PCR quantification of IP-10 mRNA 
expression in human islets. The levels of IP-10 expression were normalized against tubulin. Results represent 
means ± SE from four non-diabetic controls and three organ donors with T2DM.  
0
50
100
150
200
250
300
IP
-
10
 
(p
g/
m
l)
control T2DM
*
*
culture       24/96h 24h           96h                                         24h   
T2DM
control
IP-10 Insulin
1 2
3 4
5 6
T1DM,
newly 
diagnosed
Merge
DAPI 0
100
200
300
400
500
600
700
IP
-
10
/T
u
bu
lin
control T2DM 
* 
0
200
400
600
800
1000
1200
1400
IP
-
10
 
(p
g/
m
l)
control                IFN-γ  
*
24h           96h                                         24h   24h        
132 Appendix: Published Studies 
To investigate the processes that mediate IP-10 expression in vitro, human islets from non-
diabetic organ donors were exposed for 48 hours to a diabetic milieu (0.5 mM palmitate, 0.5 
mM palmitate plus 0.5 mM oleate, 2 ng/ml IL-1 1,000 U/ml IFN-γ at 5.5 or 33.3 mM glucose 
(Fig. 1D left panel), the combination of the three cytokines 2 ng/ml IL-1 plus 1,000 U/ml IFN-
γ plus 100 U/ml TNF-α (Fig. 1D middle panel) or for 24 hours to 20 or 40 µM h-IAPP or 100 
U/ml TNF-α alone (Fig. 1D right panel). Western blot analysis revealed that IP-10 expression 
was independent of glucolipotoxicity or h-IAPP. IP-10 expression was induced by TNF-α and by 
IFN-γ (Fig.1D), confirming our RT-PCR and immunostaining results (not shown) and by the 
cytokine mixture IFN-γ plus IL-1β (Fig. 1D middle). Addition of TNF-α potentiated IP-10 
expression induced by IFN-γ plus IL-1. In contrast, elevated glucose levels did not further 
induce IFN-γ induced IP-10 expression (Fig. 1D lower panel). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. IP-10 is increased in islets from patients with T2DM. 
(D) Human islets were cultured at 5.5 or 33.3 mM glucose for 48 hours with or without 0.5 mM palmitate, a mixture of 
0.5 mM palmitate and 0.5 mM oleate, 1000 U/ml IFN- (left), with2 ng/ml IL-1 plus 1000 U/ml IFN- alone or with 
100 U/ml TNF- (middle), with 1000 U/ml IFN-  at 5.5 and 33.3 mM glucose (lower panel) or for 24 hours with 20 or 
40 M h-IAPP or TNF- alone (right). Representative Western Blots out of six experiments from six healthy organ 
donors are shown. Actin was used as a loading control. The same membranes were incubated with IP-10 and actin 
antibodies after stripping. *p < 0.05 vs. healthy untreated control islets. 
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IP-10 induces β-cell death and proliferation and impaired β-cell function 
To investigate the consequence of IP-10 expression in human type 2 diabetic islets, we added 
exogenous human recombinant IP-10 to cultured islets from healthy organ donors. We used 0.1 
ng/ml IP-10, a concentration we measured from islets from donors with T2DM, as well as 50 
ng/ml, the ED50 for the ability of IP-10 to chemo-attract T-lymphocytes cultured in the presence 
of IL-2 (39). Both 0.1 and 50 ng/ml IP-10 increased β-cell apoptosis by 1.6 ± 0.3-fold (n.s.) and 
2.0 ± 0.4-fold (p<0.01) after 1 day (not shown) and 2.8 ± 0.5-fold and 2.9 ± 0.4-fold (p<0.01), 
respectively after 4 days of culture compared to untreated control islets at 5.5 mM glucose 
(Fig.2A,C). After 1 day of culture, IP-10 showed tendency to induced β-cell proliferation (n.s., 
data not shown) which was significant after 4 day-treatment (1.5-fold with 0.1 ng/ml and 2.7-fold 
with 50 ng/ml, p<0.05) compared to controls (Fig. 2B,D).  
To verify a specific IP-10 mediated effect, human recombinant IP-10 was pre-incubated for 30 
min with a neutralizing IP-10 antibody and then exposed to the islets. Treatment with anti-IP-10 
Ab significantly inhibited IP-10 induced β-cell apoptosis after 4 days (1.5 fold, p<0.05) 
compared to IP-10 treated cells alone (Fig. 2E).  
To confirm that IP-10`s actions were mediated by apoptosis and to investigate a matrix 
independent effect, we quantified cleavage of caspase-3. Human islets were cultured in 
suspension with or without IP-10. After the 48-hour treatment period, islets were Bouin’s fixed, 
paraffin embedded and islet sections were double stained for cleaved caspase-3 and insulin. 
IP-10 induced a 2.6- (p<0.05) and 3-fold (p<0.001) increase in caspase-3 positive -cells at 0.1 
and 50 ng/ml IP-10 respectively (Fig. 2F). In order to quantify -cell number after IP-10 
exposure, we measured -cell viability in the -cell line RIN5m and detected an 18% and 25% 
decrease in viability by 0.1 and 50 ng/ml IP-10, respectively (p<0.01, Fig.2G). 
IP-10-induced a 1.9-fold decrease in GSIS after long-term culture with IP-10, compared to 
control (p<0.05, Fig. 2H,I). To determine the acute effect of IP-10 on GSIS we cultured the 
islets in the presence of IP-10 at low and high glucose for 1 hour. At low glucose IP-10 had no 
significant effect, however at high glucose IP-10 decreased GSIS 1.8-fold compared to control 
(p<0.05), suggesting that even in short term IP-10 inhibits -cell function (Fig.2J). Furthermore, 
insulin mRNA was 2.1 and 2.3–fold decreased after 1 day of culture by 0.1 and 50 ng/ml IP-10, 
respectively (p<0.05, Fig.2K).  
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Figure 2. IP-10 induces -cell death and impaired -cell function  
Human islets were cultured on ECM dishes for 4 days in 5.5 mM glucose alone or with increasing IP-10. Apoptosis 
was measured by the TUNEL assay (A,C,E) and stained in black (alkaline phosphate, A1-3) and proliferation by the 
Ki-67 antibody (D). Islets were double-stained for insulin in red (here grey, A1-3). Black arrows point doublets of 
apoptotic -cells indicative of post-mitotic apoptosis (A3). Results are means ± SE of the percentage of TUNEL-
positive (C,E) or Ki-67 positive (D) -cells normalized to control incubations at 5.5 mM glucose alone (100%; in 
absolute value: 0.46% TUNEL-positive and 0.33% Ki-67-positive -cells) from four different experiments in triplicate 
from four different organ donors. (E) Human recombinant IP-10 was pre-incubated for 30 min with an antagonistic IP-
10 antibody and then incubated with the islets. (F) Caspase-3 activation was analyzed in Bouin’s-fixed paraffin 
embedded sections from human islets cultured in suspension for 48 hours with or without IP-10. Results are means ± 
SE of the percentage of cleaved caspase-3-positive cells. Each experiment was repeated three times from three 
organ donors. *p < 0.05 to untreated control. (G) MTT assay was performed on RIN cells exposed for 4 days to IP-
10. Each bar represents the mean of three separate experiments ± SE. (H-J) GSIS from islets exposed to IP-10. (G) 
Basal and stimulated insulin secretion indicate the amount secreted during 1-hour incubations at 2.8 (basal) and 16.7 
mM (stimulated) glucose following the 6-day culture period, normalized to insulin content and expressed as percent 
change from basal secretion. (I) Stimulatory index, which denotes the amount of stimulated divided by the amount of 
basal insulin secretion. (J) Acute basal and stimulated insulin secretion with or without IP-10 at low and high glucose 
for 1 hour, normalized to insulin content and expressed as percent change from basal secretion. (K) Quantitative RT-
PCR analysis of insulin expression. The level of insulin mRNA expression was normalized against -actin. Results 
were expressed as mRNA levels relative to control incubations. Data represent results of three different experiments 
from three different organ donors. Results are means ± SE of untreated controls at 5.5 mM glucose, *p<0.05 to 
untreated control. 
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We then examined the effects of two other ligands of CXCR3; IFN-γ inducible chemokines I-
TAC (CXCL11) and Mig (CXCL9) on -cell turnover in human isolated islets. In contrast to IP-
10, neither I-TAC nor Mig at comparable concentrations based on their activity affected -cell 
apoptosis and -cell proliferation (Fig.3A) after 4 days of culture. To investigate a functional 
response induced by I-TAC and Mig, the mobilization of intracellular calcium was assessed by 
Fluo-3 in INS-1 cells after addition of the two chemokines. Both I-TAC and Mig induced the 
mobilization of [Ca2+]i in the cells, which confirms their activity (Fig.3B). As positive control for 
[Ca2+]i influx in the -cells we used 20 mM glucose, which also resulted in Fluo-3 uptake. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Distinct effects of other CXCR3 ligands 
(A) Relative number of TUNEL-positive and Ki-67-positive -cells after 4-days of culture in control conditions (5.5 
mM glucose) with or without I-TAC (0.1-50 ng/ml) and Mig (50-500 ng/ml). Data are expressed as % of control 
conditions (100%; in absolute value: 0.10% TUNEL-positive or 0.16% Ki-67 positive -cells) from three different 
experiments in triplicates from three different organ donors. (B) Fluo-3-uptake in the -cell line INS-1 before and 
during 10 min of addition of Mig (full diamonds) or I-TAC (open diamonds), analyzed by on-line confocal microscopy 
(Leica). Data show relative fluorescence from one representative analysis from three independent experiments. 
 
IP-10 mediated PAK-2 cleavage switches Akt signaling into apoptosis 
Next we examined the molecular mechanism of the deleterious effects of IP-10 on cultured 
human islets. Since exposure to IP-10 led to both increased apoptosis and β-cell proliferation, 
we hypothesized, that IP-10 acts to drive -cells into cell cycle, but these cells are then driven 
to apoptosis. By western blot analysis, we detected increased Akt phosphorylation within 30 
minutes of culture with IP-10, which was sustained through the entire 24-hour culture period 
(Fig. 4A,B). The PI3K inhibitor Wortmannin (100 nM) blocked this Akt phosphorylation in the 
presence of IP-10, confirming PI3K signaling was involved (Fig.4A). Furthermore, PI3K 
inhibition fully blocked IP-10 induced β-cell death (Fig. 4C). Here, we show for the first time, that 
sustained Akt activation can trigger apoptosis in the -cell. One of the direct downstream 
effectors of Akt is the p21-activated kinase 2 (PAK-2). Akt-mediated phosphorylation of PAK-2 
mediates cell survival, however if PAK-2 is proteolytically cleaved, apoptosis is induced (40). 
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We found full length PAK-2 constitutively expressed in human islets and rat -cells. However, 
upon IP-10 induced caspase-3 cleavage (Fig.2E for human islets & 4E for rat -cells), we 
detected increased levels of the cleaved C-terminal fragment of PAK-2 (PAK-2p34) in human 
islets and in purified rat β-cells (Fig. 4D, E). Heat-shocked Hamster Ovary Cells (CHO), were 
used as positive control for PAK-2 cleavage (37). Besides caspase-3 and PAK-2 activation, IP-
10 also triggered JNK activation, a pathway, which is activated by inflammatory cytokines and 
free fatty acids in the -cell leading to -cell apoptosis (41). After 5 minutes of exposure, IP-10 
induced JNK activation that still persisted after 1 day of culture (Fig. 4F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Activation of the PI3K/Akt pathway by IP-10 subsequently leads to PAK-2 cleavage and apoptosis  
(A) Western blot analysis of p-Akt in human islets exposed for 30 min or 1 day to IP-10 without Wortmannin (100 nM) 
and (B) shows a time course experiment from 0 to 24 h after IP-10 treatment. Akt and Actin were used as loading 
controls. This Western blot is representative of four experiments from four different organ donors. (C) Human islets 
were cultured for 4 days in 5.5 mM glucose alone (control) or in the presence of IP-10 with or without addition of 100 
nM Wortmannin. Results are mean ± SE of the percentage of TUNEL- positive -cells normalized to control. *p< 0.05 
relative to islets cultured at 5.5 mM glucose alone, +p< 0.05 relative to islets in the absence of Wortmannin at the 
same IP-10 concentration. (D) Western blot analysis of full length PAK-2, cleaved PAK-2p34 and actin from human 
isolated and (E) of full length PAK-2, cleaved PAK-2p34 and activated caspase-3 from purified rat -cells. Human 
islets and purified rat -cells were cultured for 1 day in with or without IP-10. Heat shock (Hs) treated CHO cells were 
used as a positive control for cleaved PAK-2p34. Hs treatment was performed at 44°C for 45 min, followed by a 2h 
incubation at 37°C. Antibodies were incubated with the same membrane after stripping. (F) Human islets were 
stimulated with IP-10 for 5 min. to 24 hours. Total JNK was used as a loading control. One representative Western 
blot is shown out of four experiments from four different organ donors (D,F) or three different -cell isolations (E). 
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The effect of IP-10 on -cells is independent of the CXCR3 receptor 
IP-10 is the ligand for the receptor CXCR3. To further study the mechanisms of IP-10 induced 
-cell destruction, we investigated the role of its receptor CXCR3. We exposed islets isolated 
from CXCR3 knockout mice to IP-10. Similar to our observations in human islets, IP-10 induced 
-cell apoptosis in islets from wildtype C57Bl/6J mice (Fig. 5E). Furthermore, we did not detect 
alterations of IP-10 induced increase in -cell death (Fig. 5A,B) and insulin secretion (Fig. 
5C,D) in islets isolated from CXCR3 knockout mice (0.1 and 50 ng/ ml IP-10 increased -cell 
apoptosis 2.7-fold and 2.0-fold, respectively (p<0.05) and stimulatory index was 3-fold 
decreased by 0.1 ng/ml IP-10 compared to control (p<0.05). Furthermore, we pre-cultured 
isolated pancreatic islets from C57Bl/6J mice with goat anti-mouse CXCR3, an antagonistic 
antibody to CXCR3, which has been shown previously to block IP-10 mediated effects (42). 
After 1 hour pre-culture, IP-10 was added to the islets for the 3-day culture period. IP-10 
increased apoptosis 2.4-fold without and 2.6-fold with CXCR3 neutralization, compared to 
serum treated control (Fig. 5E, p<0.05). In parallel, proliferation was 1.7-fold increased without 
and 1.6-fold increased with CXCR3 neutralization, compared to serum treated control (Fig. 5F, 
p<0.05). There were no differences between the treatment groups with or without the 
neutralizing antibody. 
Since IP-10 exhibits similar effects in the presence and absence of CXCR3, we assume that its 
effect is CXCR3-independent in pancreatic -cells. 
Subsequently, we analyzed CXCR3 gene expression in human islets. CXCR3 mRNA was 
detected in islets as well as in purified -cells (Fig.5G). Sequence analysis of the PCR products 
confirmed CXCR3 expression according to published sequences. By fluorescent 
immunocytochemistry we found CXCR3 expression in human islets (1.08 ± 0.16 positive 
cells/islet). We observed CXCR3 positive -cells (Fig.5H panel 1,2), but most CXCR3 positive 
cells were negative for insulin. No CXCR3 staining was observed in α and δ cells, as assessed 
by double immunostaining with anti-glucagon or anti-somatostatin antibodies, respectively 
(Fig.5H panels 3-6). Synaptophysin and chromogranin A (alternative markers for endocrine 
cells) only partially colocalized with CXCR3 (data not shown). Since CXCR3 is expressed in 
activated T-cells, we performed triple staining for insulin (Fig.5H panel 7), CXCR3 (Fig.5H panel 
8) and a T-cell marker CD3 (Fig.5H panel 9) and found CXCR3 positive T-cells in human islets. 
However, we detected large variation in the number of these CXCR3 positive - and T-cells in 
the six different human islet isolations studied. The expression levels of CXCR3 in the islets 
was similar in untreated and cells treated with IP-10 or IL-1β and IFN-γ (data not shown). 
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Figure 5. The effects of IP-10 are CXCR3 independent 
 (A-D) Analysis of -cell apoptosis and function in CXCR3-/- mice. Mouse islets were cultured on extracellular matrix-
coated dishes for 4 days in 5.5 mM glucose alone or in the presence of IP-10. (A,B) Islets were stained for TUNEL 
(black) and insulin (grey). Results are means ± SE of the percentage of TUNEL-positive -cells versus control 
incubations at 5.5 mM glucose alone (100%; in absolute value: 1.12% TUNEL-positive -cells). (C) Basal and 
stimulated insulin secretion during 1-hr incubation at 2.8 (basal) and 16.7 mM (stimulated) glucose following a 4-day 
culture period with or without IP-10, normalized to insulin content and expressed as percent change from basal 
secretion. (D) Stimulatory index. (E,F) Isolated islets from C57BL/6J mice were pre-cultured for 1 hr with goat serum 
(control) or with goat anti-mouse CXCR3 neutralizing antibody prior to addition of 0.1 ng/ml recombinant mouse IP-
10. Results are means ± SE of the percentage of TUNEL-positive (E) and Ki-67-positive (F) -cells versus control at 
5.5 mM glucose. Results are means ± SE of two independent experiments in quadruplicates from six mice, 
respectively. *p < 0.05 to untreated control islets. (G) RT-PCR for CXCR3 was performed from purified human -cells 
and human islets cultured for 3 days in 5.5 mM glucose alone or with IP-10. One of two experiments from two organ 
donors is shown. (H) Immunohistochemical analysis for CXCR3 on sections from human islets. Double/triple 
immunostaining for CXCR3 (green, 2,4,6, black, 8) and insulin (red, 1,7), glucagon (red, 3), somatostatin (red, 5) and 
CD3 (green, 9). Magnification x200. 
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IP-10 binds to TLR4 in pancreatic -cells and mediates -cell apoptosis 
In the search for the specific receptor for the IP-10 mediated effects in -cells, we analyzed 
gene expression of a number of receptors in islets by PCR. Initially, we looked for GPR1 (which 
is an orphan receptor, and has sequence motifs shared by chemokine receptors (43)), CCR3 
(CXCR3 ligands were found to bind to CCR3 (44; 45), but exhibiting antagonistic effects), 
CCR5 which is highly up-regulated by TNF- and IFN-, together with up-regulation of IP-10 
(46), and TLR4, because upon its activation, IP-10 production is induced. Untreated human 
islets expressed all of the four receptors (Fig. 6A). To identify the binding capacity of IP-10 to 
these receptors beads were coated with IP-10 prior to incubation with human islet lysates. 
While CCR5 and GPR1 failed to bind IP-10 and CCR3 had a limited capacity to bind IP-10, we 
identified TLR4 as the receptor for IP-10 (Fig.6B). We next examined the ability of IP-10 to 
regulate TLR4 receptor expression. 0.1 ng/ml IP-10 caused a 2-fold induction of TLR4 mRNA 
(Fig.6C). Since TLR4 signaling results in up-regulation and secretion of IP-10 (47-49), we 
examined IP-10 production downstream of IP-10 signaling and measured a 4.5-fold and 33.3-
fold induction of IP-10 mRNA in human islets after treatment with 0.1 and 50 ng/ml IP-10, 
respectively (Fig.6D). To investigate whether IP-10 signaling is TLR4 dependent, we tested the 
effect of IP-10 on islets isolated from TLR4-KO (8–12 weeks old) and measured -cell 
apoptosis. We used lipopolysaccharide (LPS), the major ligand for TLR4 (50) as positive control 
to induce TLR4 dependent apoptosis. LPS induces -cell damage in vitro (51) and in vivo (52). 
In our study, LPS induced a 2.9-fold induction of -cell apoptosis, which was prevented in 
isolated islets from TLR4-KO mice (data not shown). IP-10 treatment induced a 2.2-fold 
induction of -cell apoptosis in the wildtype islets, but not in the TLR4-KO islets (Fig.6E). To 
further confirm the involvement of TLR4 in mediating the effects of IP-10, we exposed human 
islets to a TLR4 specific siRNA (siTLR4) or scrambled control siRNA (siScr). We achieved an 
average down-regulation of 48% TLR4 protein expression by the siRNA, shown by Western blo 
analysis (Fig.6G). After a 4-day culture period with 0.1 ng/ml IP-10, we analyzed -cell 
apoptosis. IP-10 treatment induced a 4-fold induction of -cell apoptosis in human islets pre-
treated with scramble control siRNA (siSCR). Pre-treatment with siTLR4 induced a 1.7-fold 
reduction of -cell apoptosis (p<0.05, Fig.6F). We next investigated if IP-10 mediated TLR4 
signaling is linked to the activation of the Akt/PAK-2/JNK pathway by Western blot analysis. 
Addition of a neutralizing antibody against CXCR3 neither changed IP-10 induced PAK-2 
cleavage nor activation of JNK. In contrast, inhibition of TLR4 signaling by addition of a 
dominant negative virus for myeloid differentiation primary-response protein 88 (Myd88), a key 
adaptor molecule in TLR4 signaling, prevented both IP-10 induced PAK-2 cleavage and 
activation of JNK (Fig. 6-2H,I). Also, blocking Akt activation by two different PI3K inhibitors 
(Wortmannin and LY294002) blocked PAK-2 cleavage as well as JNK activation, which suggest 
that Akt might be upstream of PAK and JNK and confirms their interaction.
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Figure 6-1. IP-10 binds to TLR4 in pancreatic -cells and mediates apoptosis 
(A) PCR-analysis of GPR1, CCR3, CCR5 and TLR4 in isolated human islets. (B) Pull down assay in human 
islets. IP-10 was bound to magnetic beads and incubated with human islet lysates. After magnetic separation, the 
bead fraction, supernatants (output) together with the original islet fraction before the pull down (input) were 
transferred to lysate buffers and western blot analysis was performed for TLR4, CCR3, CCR5, GPR1 and IP-10. 
The analysis was done in triplicate from 3 different islet donors. (C,D) Quantitative RT-PCR was performed in 
human islets exposed to IP-10 for 3 days, the increase in TLR4 (C) and IP-10 (D) mRNA expression are 
expressed as relative change from untreated control and represents the mean of four experiments from four islet 
donors. (E) Analysis of -cell apoptosis in  WT and TLR4-/- mice. Mouse islets were cultured on ECM dishes for 4 
days in 5.5 mM glucose alone or in the presence of 0.1 ng/ml IP-10. (F) Human islets were cultured on ECM and 
exposed to 50 nM scrambled control siRNA (siScr) or siRNA to TLR4 (siTLR4). One day after transfection, IP-10 
was added and apoptosis was measured by double-staining for TUNEL and insulin after a 4-day culture period. 
Results are means ± SE of the percentage of TUNEL-positive -cells normalized to control (siScr) at 5.5 mM 
glucose. (G) Western blot analysis of TLR4 shows 48% downregulation in the siTLR4 treated islets. (H,I) Western 
blot analysis of full length PAK-2, cleaved PAK-2p34  (H) or p-JNK (I) from human islets after 24 h exposure to 
0.1 ng/ml IP-10 with or without pre-incubation with an antagonistic CXCR3 antibody, 100 nM Wortmannin, 50 M 
LY294002 or a dominant negative virus for Myd88 as indicated. Actin was used as a loading control. Western 
blots are representative of three independent experiments from three different organ donors. *p<0.05 to untreated 
control, **p<0.05 to IP-10 treated control islets. 
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Discussion 
 
Cytokines and chemokines produced and secreted by activated macrophages, adipocytes 
and also by pancreatic β-cells have been suggested to initiate β-cell apoptosis in T1DM and 
T2DM (53). Understanding the mechanisms of secretion and function of these pro-
inflammatory factors is important for treatment of diabetes. 
One potential pathway involves secretion and production of pro-inflammatory signals within 
the islets as well as in the circulation (9; 53). Part of this pro-inflammatory cascade in the -
cell is mediated by elevated glucose concentrations. Once hyperglycemia is present, the rate 
of -cell apoptosis is accelerated. When -cells are exposed to chronic high glucose levels in 
vitro, or in response to viral infection (54), they produce and secrete the pro-inflammatory 
cytokine interleukin-1 (IL-1) (55). Inhibition of IL-1 by its naturally occurring antagonist, 
the interleukin-1 receptor antagonist (IL-1Ra), blocked apoptosis and induced -cell 
proliferation (55). 
In the present study, we report that the chemokine IP-10 is produced and secreted by 
cultured human islets of patients with T2DM. Importantly, in these islets IP-10 was 
predominantly localized in -cells. A diabetic milieu (high glucose, free fatty acids or h-IAPP) 
did not induce IP-10 synthesis in human islets in vitro indicating that IP-10 secretion is 
independent of glucolipotoxicity or IAPP oligomer toxicity. 
In the non-obese diabetic (NOD) mouse model, IP-10 is produced in pancreatic islets before 
detectable insulitis (25; 56). In a model of LCMV-induced diabetes, IP-10 has been shown to 
be among the first chemoattractant factors expressed in the pancreas (57). 
In the present study, we detected IP-10 positive -cells in a newly diagnosed patient with 
T1DM. Furthermore, in a large study with humans, IP-10 serum levels were increased in 
patients with newly diagnosed T1DM (19) and in patients at risk of developing T2DM (21). 
These data suggest that up-regulated IP-10 synthesis takes place in either a pre- or in an 
early phase of the disease. 
In confirmation with previous data (25), -cell IP-10 expression in vitro was induced by IFN- 
alone or in a mixture with IL-1 and/ or TNF-. Here we show that also TNF- alone can 
induce IP-10 expression. TNF- has been shown to be up-regulated under conditions of 
insulin resistance and T2DM (15), and thus provides a mechanism for IP-10 up-regulation in 
T2DM.  
Macrophages producing these cytokines could be the possible paracrine inducers of IP-10 
expression, since resident macrophages are present in all islets and increased in islets in 
T2DM (58). Another possibility is, that IP-10 up-regulates its own expression in islets as 
shown by RT-PCR (Fig.6D), since in T1 as well as in T2DM, IP-10 serum levels are elevated 
and could trigger IP-10 expression in pancreatic islets. 
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In our current study, we assessed consequences of such elevated IP-10 concentrations on 
-cell turnover and function. Culture of human islets with IP-10 increased -cell apoptosis as 
well as proliferation, with the net number of -cells being decreased. We frequently observed 
doublets of apoptotic -cells, indicative of post-mitotic apoptosis, supporting the concept that 
replicating -cells are more vulnerable to apoptotic stimuli (59). While the IP-10 effect on -
cell function, proliferation and apoptosis occurred after chronic incubation, acute glucose 
stimulated insulin secretion was already impaired in the presence of IP-10 after 1h. A 
possible explanation for that early IP-10 effect on acute insulin secretion, which was only 
present at the stimulatory glucose concentration of 16.7 mM, could be that the combination 
of high glucose and IP-10 has rapid deleterious effects. IP-10 induced a ~3-fold induction of 
-apoptosis in all human and mouse islet isolations, which correlates with the induction of 
apoptosis observed in vivo in pancreatic sections from autopsy from patients with T2DM (1) 
as well as with T1DM (3). 
A critical regulator of -cell proliferation and survival is Akt (also known as protein kinase B 
(PKB)), which is activated downstream of PI3K (60; 61). In previous reports, blocking Akt 
phosphorylation by the PI3K inhibitor Wortmannin or other Akt inhibitors renders islets more 
susceptible to -cell apoptosis (reviewed in (62)). Moreover, transgenic mice expressing a 
constitutively active Akt specifically in -cells have increased -cell size (61), whereas mice 
lacking Akt have a decrease in -cell mass (63). Insulin, acting in an autocrine manner, 
promotes Akt phosphorylation in -cells in culture (64). Here we show, that IP-10 mediates 
its effects through Akt activation independent of insulin secretion (at physiological glucose 
conditions, insulin levels were unchanged in control and IP-10 treated islets). Upon chronic 
chemokine stimulation, this leads to impaired function and -cell death rather than survival. 
This is reminiscent of downstream signaling of pro-inflammatory cytokines. IFN- as well as 
TNF- activate PI3K upon receptor binding, which phosphorylates Akt and induces increased 
surface expression of the Fas receptor, leading to apoptosis in vascular smooth muscle cells 
(65; 66). TNF- or IFN- alone or in combination with IL-1 induces Fas expression in the -
cells and apoptosis (67; 68), and it is doubtless, that Fas is a major pathway of -cell 
destruction in T1DM (69) and T2DM (70; 71) as well as of regulation of insulin secretion (72). 
PI3K/Akt signaling leads to the transcriptional activation of IP-10 (73). Since IFN-γ induces 
IP-10 expression, IP-10 might induce a vicious cycle in -cells, with IFN-γ induced Akt 
activation as a possible mediator of IP-10 up-regulation. 
Notably, in our study sustained Akt activation by IP-10 triggered apoptosis in the -cell. 
Administration of the PI3K inhibitor Wortmannin inhibited Akt phosphorylation as well as IP-
10 induced -cell death. A possible explanation for this is, that IP-10 induced Akt activation 
first leads to proliferation and survival, however at an event, when -cells are highly 
vulnerable to apoptosis, it is finally switched towards -cell death by Akt dependent 
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downstream signals. One of such downstream targets of Akt are p21-activated kinases 
(PAK; (74; 75)). PAKs are activated by a variety of GTPase dependent and independent 
mechanisms (76). Among them, PAK-1 and –2 regulate cell survival and apoptosis. PAK-1 
protects from apoptosis (74; 77), whereas PAK-2 has a unique dual function: activation of full 
length PAK-2 stimulates cell survival (78), whereas upon cleavage of PAK-2 into a 34-kDa 
activated form (PAK-2p34) directs apoptosis. PAK-2 is a substrate for caspases during 
apoptosis in various cell types (79-81). Here we show for the first time the presence of the 
cleaved fragment PAK-2p34 upon caspase-3 activation in human islets as well as in isolated 
rat -cells. Such proteolytic activation of PAK-2 correlated with activation of the c-Jun amino 
terminal kinase (JNK) in our study as well as in previous reports (75; 82). Similar to the 
pattern of Akt activation, we observed that stimulation of human islets with IP-10 elicits a 
prolonged activation of JNK. 
Inflammatory cytokines and free fatty acids activate JNK in several tissues including the -
cell, leading to -cell destruction and insulin resistance (see review (41)). The JNK pathway 
has been proposed as a candidate gene implicated in T2DM (83). JNK inhibition promoted -
cell survival (84) as well as insulin sensitivity in vitro and in vivo (85). Based on our results 
we therefore assume, that pro-apoptotic IP-10 signals involve PAK-2p34 and JNK activation. 
IP-10 exerts its biological activity through the G-protein-coupled receptor CXCR3, but also 
CXCR3 independent effects of IP-10 have been described (43; 86; 87). We detected specific 
CXCR3 expression within human islets in β-cells and T-cells. However, most CXCR3 positive 
islet cells could not be allocated to any particular endocrine cell type, and blocking CXCR3 
did not prevent IP-10 mediated apoptosis in the -cell. Our data support the hypothesis that 
the IP-10 effect on pancreatic islets is CXCR3-independent. Firstly, IP-10 exhibited similar 
effects on the -cells in the presence and absence/neutralization of CXCR3, and secondly, 
two other known CXCR3 binding chemokines I-TAC and Mig did not affect β-cell turnover. 
The possible mechanisms of such a CXCR3 independent IP-10 signaling would therefore be 
the presence of another IP-10 binding receptor. This is supported by the fact, that the low 
dose of IP-10 tested (0.1 ng/ml = ~ 10 pM) had full efficacy, but the dissociation constant (KD) 
of IP-10-binding to CXCR3 is typically in the nanomolar range (88). 
A novel functional receptor with unknown identity that binds IP-10 has been identified 
recently, with abundant levels in epithelial and endothelial cells (43). Unlike CXCR3, this 
receptor does not bind Mig or I-TAC, which would support our findings that Mig and I-TAC 
have no effect on the -cells in contrast to IP-10. Possible candidates were a variety of 
seven-transmembrane-spanning G-protein-coupled receptors without identified ligands, but 
with sequence motifs shared by chemokine receptors. Of these orphan receptors we have 
tested GPR1, which was highly expressed in islets but failed to bind IP-10. Another 
candidate, APJ (89), was only marginally present in human islets (data not shown). CCR3 is 
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the receptor for eotaxin and several other CC chemokines and characteristic for Th2 cells. 
CXCR 3 ligands have shown before to bind to CCR3 but lack agonistic effects (44; 45). 
CCR5 is highly up-regulated by TNF-α and IFN-γ, together with up-regulation of IP-10 (46). 
Both, CCR3 and CCR5 were expressed in islets. While CCR3 bound to IP-10 to a limited 
extend, CCR5 did not. 
Interestingly, we observed activation of IP-10 mRNA upon IP-10 exposure, and such IP-10 
up-regulation has been observed as a downstream event upon Toll like receptor 4 (TLR4) 
activation (47-49). TLR4 is the receptor for LPS and is responsible for the microbial defense 
mechanism. Stimulation of TLR4 activates pro-inflammatory pathways and induces cytokine 
expression in many cell types (90). TLR4 is highly expressed in pancreatic -cells (47; 91). 
After we confirmed TLR4 expression in human islets, we then tested its binding capacity to 
IP-10 and found IP-10 as another ligand for TLR4.  
Interestingly, the dose of 0.1 ng/ml IP-10 (~10 pM) already induced intracellular signaling, 
whereas the dissociation constant (KD) of LPS-binding to TLR4 is in the micromolar range 
(92). These data suggest that IP-10 has comparably high affinity to TLR4. 
Signal transduction downstream of TLR4 is another mechanism, which induces Akt 
activation, This has been shown by the ligands of TLR4; LPS (93) and lauric acid (94) and 
results in NFκB activation and inflammation. 
TLR4 depletion has been shown to prolong islet graft survival of pancreatic islets after 
transplantation (95). Importantly, non-endotoxine ligands of TLR4 have been identified 
recently. Shi et al show that free fatty acids induce TLR4 up-regulation and activation in 
adipocytes and macrophages to induce inflammation and trigger insulin resistance (96).  
Another recent study shows that a Loss-of-function mutation in TLR4 prevents diet-induced 
obesity and insulin resistance (97). Furthermore, a Toll-like receptor 4 gene polymorphism in 
humans is associated with reduced CRP levels and a decreased risk of coronary heart 
disease and diabetes (98). These earlier studies and our new observations suggest that 
TLR4 signaling plays an important role in diabetes and insulin resistance. 
The present study provides further evidence that chemokines, in addition to other pro-
inflammatory factors, directly trigger -cell destruction and contribute to the pathophysiology 
of T2DM. Moreover, we suggest a potential mechanism for the switch from proliferation into 
apoptosis in -cells. To prevent such a progression using anti-inflammatory targets of the 
TLR4 signaling pathway will be of high importance to rescue the -cell from inflammation 
induced self-destruction to preserve -cell function and mass. 
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7.2  ABBREVIATIONS 
 
 
ADP Adenosin diphosphate 
ATP Adenosin triphosphate 
BMI Body mass index 
Ca2+ Calcium 
Db/db Leptin-receptor deficient mouse model 
DD Death domain 
Dia Diazoxide 
DNA Deoxyribonucleic acid 
ER Endoplasmatic reticulum 
ERK1/2 Extracellular signal regulated kinases 1/2 
FasL Fas Ligand 
Foxo Forkhead box protein 
Glut2 Glucosetransporter 2 
IFG Impaired fasting glucose 
IGT   Impaired glucose tolerance 
IL-1Ra Interleukin-1 Receptor Antagonist 
IL-1RAcP IL-1R accessory protein 
IL-1RI Interleukin-1 type 1 receptor 
IL-1 Interleukin-1 
IPGTT Intraperitoneal glucose tolerance test 
IPITT Intraperitoneal insulin tolerance test 
IRS Insulin receptor substrate 
JNK c-Jun N-terminal Kinase 
JNKi Small inhibitory peptide for JNK 
K+  Potassium 
MAPK Mitogen-activated protein kinase 
mM Millimolar 
NEFAs Non-esterified fatty acids 
NGT Normal glucose tolerance 
PD PD098059 
PDX-1 Pancreatic duodenum homeobox-1 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT-PCR Reverse transcriptase polymerase chain reaction 
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Soma Somatostatin 
T1DM Type 1 Diabetes Mellitus 
T2DM Type 2 Diabetes Mellitus 
TNF- Tumor necrosis factor- 
TUNEL Terminal deoxynucleotidyl transferase-mediated  
dUTP nick-end labeling 
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